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PREFACE 
 
This Thesis examines the influence of plasma membrane lipid composition on 
insulin-insulin receptor interactions. Subject to time and resource constraints, every 
attempt was made to thoroughly investigate this topic, an area of research which is of 
direct relevance to diabetes research. The work was conducted in School of 
Pharmacy and Biomedical Sciences and Curtin Health Innovation Research Institute, 
Curtin University under the supervision of Associate Professor Cyril Mamotte and 
Adjunct Professor Erik Helmerhorst. All experimental work was solely conducted by 
me unless otherwise stated.  
  
  
4 
 
ACKNOWLEDGEMENTS 
Firstly, I would like to express my sincere thanks and gratitude to my supervisors 
Associate Professor Cyril Mamotte and Professor Erik Helmerhorst for their 
invaluable guidance throughout my PhD candidacy. The support and motivation 
from both of my supervisors was critical to overcoming the problems and hurdles 
that are inevitable in the course of a PhD.  Their extensive research experience, in-
depth scientific knowledge and insight were also of enormous benefit, and something 
I truly appreciated.  
I would like to also extend my sincere thanks and gratitude to Dr. Steven Bottomley 
who was also one of my supervisors, albeit for a shorter period of time. He too had 
helpful insights and suggestions that were helpful in context of numerous 
experimental aspects, even when no longer part of my official supervisory team.  
Special thanks and gratitude to Professor Arunasalam Dharmarajan for 
introducing me to Curtin University and my supervisors through an India-initiative 
scholarship.  
I also extend my thanks to Mrs. Gaewyn Ellison, who is my lab colleague and 
fellow PhD candidate. I am extremely thankful for the support, advice and care, both 
professionally and personally, I had from her throughout the course of my studies. 
Her energetic and vibrant personality was a big motivation for me. My sincere thanks 
and gratitude goes also to Mr. Abhishek Kumar Singh, Dr. Abhijeet Deshmukh, 
Dr. Himel Nahreen Khaleeque, Mr. Behin Sundararajan and Dr. Imran Khan 
for their invaluable time and support, both professionally and personally during this 
time. 
I would like to express my sincere thanks to friends in Perth outside Curtin 
University for their help on numerous occasions. Special thanks to Mr. Shadesh 
Ramachandran and Mr. Harish Prabhakaran for their invaluable support during 
some of the tougher times in my personal life during my studies-I am truly indebted 
to them for the help and support they provided during that time. 
I would also like to express my sincere thanks and gratitude to all CHIRI staff 
members for their invaluable support and a special thanks to Mr. Sam Siem, not just 
for his support as a Purchasing Officer but also for being a very good friend. 
  
5 
 
Last but not least, I would like to thank my wife, Anithamani for all her support and 
encouragement and being there for the many ups, but also the downs and the 
challenges over the 4 years of my candidacy. The biggest thanks also to my parents 
and to my sister for believing in me and supporting me during my PhD study as they 
have always done since the early days of my childhood. 
This wonderful journey of four years as a PhD candidate also includes the birth of 
my son, Kavin Thiru. He has brought a lot of joy and happiness to my life, which is 
motivating me to go forge ahead and challenge myself in life and I dedicate this 
Thesis to him. 
  
  
6 
 
Conference presentations done during this thesis 
 
Oral Presentations 
Thiruvarutchelvan Sabapathy, Erik Helmerhorst and Cyril Mamotte. “The 
interaction of insulin with the insulin receptor in a membrane environment” at 
Australian Society of Medical Research (ASMR) symposium held in Curtin 
University, Perth, WA on 30
th
 May 2015 and Mark Liveris Research student 
seminar program held in Curtin University, Perth WA on 3
rd
 September 2015. 
Thiruvarutchelvan Sabapathy, Erik Helmerhorst and Cyril Mamotte. “Alterations in 
plasma membrane cholesterol content impairs insulin binding in HepG2 cells” at 
Australian Society of Medical Research (ASMR) symposium held in Curtin 
University, Perth, WA on 2
nd
 June 2016. 
Poster Presentations 
Thiruvarutchelvan Sabapathy, Erik Helmerhorst and Cyril Mamotte. “The 
interaction of insulin with the insulin receptor in a membrane environment” at 
Combined Biological Sciences Meeting (CBSM) held in University of Western 
Australia (UWA), WA, Perth on 28
th
 August 2015. 
Thiruvarutchelvan Sabapathy, Erik Helmerhorst and Cyril Mamotte. “The influence 
of plasma membrane cholesterol on insulin binding and signalling in insulin-
sensitive cells” at Mark Liveris Research student seminar program held in Curtin 
University, Perth WA on 28
th
 September 2017. 
Thiruvarutchelvan Sabapathy, Erik Helmerhorst and Cyril Mamotte. “The 
interaction of insulin with the insulin receptor in a membrane environment” at 
Science on the Swan held in Perth from 5
th
 to 7
th
 June 2017. 
Thiruvarutchelvan Sabapathy, Erik Helmerhorst and Cyril Mamotte. “The 
interaction of insulin with the insulin receptor in a membrane environment” at ADS-
ADEA Annual Scientific Meeting held at Perth Convention Centre, WA from 28
th
 
September to 1
st
 August 2017.  
 
  
  
7 
 
Publications arising from this thesis 
 
Thiruvarutchelvan Sabapathy, Erik Helmerhorst, Steven Bottomley, Sharon Babaeff, 
Kylie Munyard, Philip Newsholme and Cyril Mamotte. “Use of virus-like particles 
(VLPs) as a native membrane model to study the interaction of insulin with the 
insulin receptor” Manuscript under review with Biochimica Biophysica Acta-
Biomembranes (BBAMEM-18-380).  
 
Thiruvarutchelvan Sabapathy, Erik Helmerhorst, Gaewyn Ellison and Cyril D 
Mamotte. “The influence of plasma membrane cholesterol composition on insulin 
sensitivity in target tissues” (manuscript under preparation).  
  
  
8 
 
TABLE OF CONTENTS 
DECLARATION ................................................................................................... 2 
PREFACE .............................................................................................................. 3 
ACKNOWLEDGEMENTS ................................................................................... 4 
Conference presentations done during this thesis ................................................ 6 
Publications arising from this thesis ..................................................................... 7 
LIST OF FIGURES ..............................................................................................10 
LIST OF TABLES ................................................................................................12 
ABSTRACT ..........................................................................................................13 
ABBREVIATIONS ...............................................................................................17 
1.0. LITERATURE REVIEW ..........................................................................19 
1.1. Pathophysiology of diabetes mellitus ........................................................19 
1.2. Structure and function of insulin and insulin receptor ................................19 
1.2.1. Insulin ...............................................................................................19 
1.2.2. The insulin receptor ...........................................................................20 
1.2.3. Insulin receptor synthesis and its isoforms .........................................22 
1.3. Insulin – Insulin receptor interaction .........................................................23 
1.4. Limitations of currently used membrane models .......................................25 
1.4.1. Virus-like particles ............................................................................25 
1.5. Insulin signalling ......................................................................................27 
1.6. The plasma membrane environment ..........................................................29 
1.6.1. Cell membrane phospholipid composition .........................................30 
1.6.2. Cholesterol – structure and membrane topology .................................30 
1.6.3. Interaction of cholesterol with membrane lipids and proteins .............32 
1.7. Cholesterol synthesis and distribution in cells ...........................................34 
1.8. Membrane cholesterol alterations by cyclodextrins ...................................37 
1.9. Statins .......................................................................................................39 
  
9 
 
1.9.1. Beneficial and adverse effects of statin therapy ..................................39 
1.10. Conclusion ............................................................................................41 
2.0. MATERIALS AND METHODS ...................................................................43 
2.1. Materials ......................................................................................................43 
2.2. Methods........................................................................................................44 
2.2.1. Cell based study .....................................................................................44 
2.2.2. Animal studies .......................................................................................53 
2.2.3. Model membrane - virus-like particles (VLPs) .......................................58 
3.0 RESULTS ........................................................................................................63 
3.1. Effect of cyclodextrins and statins on cholesterol content and insulin action in 
cultured cells .......................................................................................................63 
3.2. Effects of a high fat diet and atorvastatin treatment on cholesterol content and 
insulin action in mouse liver ................................................................................89 
3.3. Development and characterization of virus-like particles as a novel membrane 
model to study the influence of membrane cholesterol on insulin binding .......... 105 
4.0. DISCUSSION ............................................................................................... 120 
4.1. Effects of cyclodextrins and statins on cholesterol content and insulin action in 
cultured cells ..................................................................................................... 120 
4.2. Effects of a high fat diet and atorvastatin treatment on cholesterol content and 
insulin action in mouse liver .............................................................................. 128 
4.3. Development and characterization of virus-like particles as a novel membrane 
model to study the influence of membrane cholesterol on insulin binding .......... 133 
5.0. CONCLUSIONS AND FUTURE DIRECTIONS ....................................... 137 
6.0. REFERENCES ............................................................................................. 140 
 
  
  
10 
 
LIST OF FIGURES  
 
Figure 1. The generation of virus-like particles (VLPs) from cultured cells. ...........26 
Figure 2. The key metabolic aspects of the insulin signalling pathway ...................28 
Figure 3. Cholesterol biosynthetic pathway ............................................................35 
Figure 4. A schematic representation for plasma membrane isolation from mouse 
liver .................................................................................................................55 
Figure 5. Effect of MBCD or cMBCD treatment on cell viability.. .........................64 
Figure 6. Effect of atorvastatin treatment on cell viability.......................................65 
Figure 7. Effect of MBCD or cMBCD treatment on cholesterol content of cells in 
culture..............................................................................................................66 
Figure 8. Effect of atorvastatin treatment on cholesterol content of cells in culture..
 ........................................................................................................................67 
Figure 9. Effect of MBCD or cMBCD on 
125
I-insulin binding in cultured cells.. .....68 
Figure 10. Effect of MBCD or cMBCD treatment on the competitive binding of 
125
I-
insulin to CHO T10 and HepG2 cells.. .............................................................70 
Figure 11. Effect of MBCD or cMBCD treatment on cell surface insulin receptor 
density in CHO T10 and HepG2 cells. .............................................................72 
Figure 12. Normalization of cell cholesterol content by cultured cells following 
MBCD or cMBCD treatment.. .........................................................................74 
Figure 13. Normalization in 
125
I-insulin binding in cultured cells following MBCD 
or cMBCD treatment........................................................................................75 
Figure 14. Effect of sequential treatment with MBCD and cMBCD on cholesterol 
content and 
125
I- insulin binding.. .....................................................................76 
Figure 15. Effect of atorvastatin treatment on the competitive binding of 
125
I-insulin 
to CHO T10 and HepG2 cells. .........................................................................78 
Figure 16. Effect of MBCD and cMBCD treatments on insulin signalling in CHO 
T10 cells.. ........................................................................................................81 
Figure 17. Effect of MBCD and cMBCD treatments on insulin signalling in HepG2 
cells.. ...............................................................................................................82 
Figure 18. Effect of MBCD and cMBCD treatments on insulin signalling in 
differentiated myotubes....................................................................................83 
Figure 19. Effect of atorvastatin on insulin signalling in CHO T10 cells.. ...............85 
Figure 20. Effect of atorvastatin on insulin signalling in HepG2 cells. ....................86 
  
11 
 
Figure 21. Effect of atorvastatin on insulin signalling in differentiated myotubes.. .87 
Figure 22. Characterization of mouse liver fractions based on specific protein 
markers.. ..........................................................................................................90 
Figure 23. Specific binding of 
125
I-insulin in mouse liver fractions.. .......................91 
Figure 24. Effect of diet and atorvastatin treatment on cholesterol content per 
milligram of protein. ........................................................................................93 
Figure 25. Effect of diet and atorvastatin treatments on total cholesterol content per 
gram of liver tissue.. ........................................................................................94 
Figure 27. Effect of MBCD or cMBCD treatment on insulin binding to plasma 
membranes obtained from mouse liver.. ......................................................... 100 
Figure 28. Effect of diet and atorvastatin treatments in mice on membrane insulin 
receptor content and its phosphorylation status............................................... 101 
Figure 29. Effects of diet and statin treatment on Akt and glycogen synthase kinase 
3β (GSK3β) phosphorylation.. ....................................................................... 103 
Figure 30. Morphological characterization of VLPs.. ........................................... 107 
Figure 31. Influence of insulin pre-treatment of parental cells on insulin binding to 
generated VLPs.............................................................................................. 108 
Figure 32. Competitive binding of 
125
I-insulin to CHO K1 and CHO T10 cells..... 110 
Figure 33. Competitive binding of 
125
I-insulin to CHO K1and CHO T10 cells and 
the VLPs generated from both parental cell lines.. .......................................... 111 
Figure 34. Insulin receptor expression in CHO K1 and CHO T10 cells prior to VLP 
generation. ..................................................................................................... 113 
Figure 35. Insulin receptor expression in VLPs and remainder parental cells after 
VLP generation.. ............................................................................................ 114 
Figure 36. Effect of MBCD or cMBCD treatment on cholesterol content of CHO 
cells.. ............................................................................................................. 115 
Figure 37. Effect of MBCD or cMBCD treatment on insulin binding to CHO cells..
 ...................................................................................................................... 116 
Figure 38. Effect of MBCD or cMBCD treatment on cholesterol content of VLPs..
 ...................................................................................................................... 117 
Figure 39. Effect of MBCD or cMBCD treatment on insulin binding in VLPs 
derived from CHO cells.. ............................................................................... 118 
  
12 
 
LIST OF TABLES 
 
Table 1. List of protein targets and their respective antibodies used in Western blot 
analyses ...........................................................................................................52 
 
Table 2. The effect of MBCD and cMBCD treatments on membrane insulin receptor 
number and affinity in CHO T10 and HepG2 cells. ..........................................71 
 
Table 3. The effect of atorvastatin treatment on insulin receptor number and affinity 
in CHO T10 and HepG2 cells. .........................................................................79 
 
Table 4. A summary of the effects of MBCD, cMBCD and atorvastatin treatments 
on insulin binding and insulin receptor content in cultured cells. ......................80 
 
Table 5. A summary of the effects of MBCD, cMBCD and atorvastatin treatments 
on insulin signalling events in cultured cells. ...................................................88 
 
Table 6. Effect of diet and atorvastatin treatments on insulin binding parameters in 
plasma membrane isolated from mice liver tissue. ............................................98 
 
Table 7. Insulin receptor number and affinity estimates in parental cells and derived 
VLPs based on competitive binding analysis. ................................................. 112 
 
   
  
13 
 
ABSTRACT  
The first event in insulin action is the interaction of insulin with its cognate receptor. 
While there is a detailed understanding of the insulin signalling mechanism at the 
intracellular level, knowledge on how insulin interacts with its cognate binding sites 
on the insulin receptor and the influence of plasma membrane lipid composition on 
this interaction is not known. This Thesis examines the influence of cholesterol on 
insulin binding to the insulin receptor in a membrane environment using several 
experimental models, including cultured cells, purified liver cell membranes, and a 
novel cell membrane model known as virus-like particles.  
Cell culture studies were done on HepG2 cells, differentiated myotubes and CHO 
T10 cells, the latter a CHO cell line which overexpresses the insulin receptor (A 
isoform). The cholesterol content of the cells were either reduced or enriched by 
using methyl-β-cyclodextrin (MBCD) or cholesterol loaded- methyl-β-cyclodextrin 
(cMBCD), respectively. Interestingly, insulin binding decreased by about 2-fold as a 
function of cholesterol concentration irrespective of treatment with either 10 mM 
MBCD or 10 mM cMBCD. This suggests that there is an ideal concentration of 
cholesterol may be required to achieve optimal insulin binding. 
The decreased binding of insulin observed in cells that were either depleted of or 
loaded with cholesterol was not due to a change in the affinity of the insulin 
receptors for insulin but rather, in each case, was due to about a 2-fold decrease in 
the number of available insulin receptors that were determined from detailed 
competition binding analyses. This observation was confirmed by quantitating cell 
surface insulin receptor expression using flow cytometry with a monoclonal antibody 
(83-7) directed against the α-subunit of the insulin receptor. This decrease in insulin 
receptor availability for insulin binding coincided with decreases in the 
autophosphorylation of insulin receptors and phosphorylation of Akt and GSK3β in 
HepG2 cells and differentiated myotubes but not in CHO T10 cells. One possible 
reason for this disconnect in insulin binding and signalling in CHO T10 cells could 
be due to the overexpression of the A-isoform of the insulin receptor, which 
predominantly signals through the ERK/MAPK pathway.  
The impact of membrane cholesterol on insulin binding was confirmed ex vivo in 
plasma membrane purified from the livers of mice that were fed either a normal or 
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high-fat diet and treated with or without atorvastatin for 12 weeks. Remarkably, the 
cholesterol content of the purified plasma membranes decreased at least 5-fold in the 
mice fed the high-fat diet relative to those fed the normal diet. Concomitantly, insulin 
binding decreased about 3-fold in the liver plasma membranes of mice fed the high-
fat diet. This parallel decrease in insulin binding coincides with the findings in the 
cell culture study. The decrease in plasma membrane cholesterol content was almost 
entirely accounted for by an increase in the microsomal cholesterol content in the 
mice fed the high-fat diet. The mechanism underlying the cholesterol distribution 
induced by the high-fat diet is unclear and it requires further exploration. 
Total liver cholesterol was unaffected by either diet or atorvastatin treatment of the 
mice. However, the low cholesterol content of the plasma membrane associated with 
the high-fat diet was reversed by atorvastatin treatment to levels observed in mice fed 
the normal diet. This again coincided with an increased binding of insulin to the 
plasma membrane to the level that was observed in mice fed the normal diet. This 
correlated with the changes to the apparent number of available insulin receptors in 
the plasma membrane as determined from both detailed binding analyses and 
Western blots of the insulin receptor in the liver plasma membrane of the mice. 
These observations collectively reiterate the strong association between membrane 
cholesterol on insulin binding observed in the cell culture study.  
Whilst the concomitant changes in plasma membrane cholesterol and insulin binding 
correlated with the decrease in the apparent number of available insulin receptors, it 
is difficult to explain how or why the availability of the receptors changes. This 
availability of the receptor cannot be explained by the downregulation of receptors 
because changes in cholesterol and insulin binding were also observed in purified 
plasma membranes or in VLPs, which were derived from the plasma membrane of 
cells in culture. Cholesterol is integral to lipid-raft structures in the membrane and 
altering cholesterol levels in the plasma membrane disrupts these structures. This in 
turn may influence the localization of insulin receptors in various membrane micro-
domains or potentially lead to the clustering of receptors and thus, affect insulin 
binding. The mechanisms describing the apparent availability of insulin receptors 
remain a mystery but should form a focus for future research.  
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Studies were also conducted on a novel membrane model known as virus-like 
particles (VLPs) generated from expression of lenti-viral Gag protein in CHO T10 
(overexpressing insulin receptor) and wild type CHO cells (CHO K1). Insulin 
receptor bearing VLPs derived from CHO T10 cells were highly uniform in size 
distribution with an average diameter of about 150 nM as estimated by dynamic light 
scattering analysis and scanning electron microscopy. Insulin receptors in VLPs 
generated from CHO K1 and CHO T10 cells bound insulin with a similar affinity to 
that observed with their corresponding parental cell lines as described by competition 
binding analyses. The changes in membrane cholesterol following MBCD or 
cMBCD treatment and its effects on insulin binding in VLPs followed a similar 
pattern to that observed in their corresponding parental cell lines.  
Almost all of the insulin receptors in CHO K1 cells (about 98%) were recovered in 
the VLPs generated in this particular cell line. Interestingly and by contrast, only 2% 
of the total insulin receptors in CHO T10 cells were recovered in the VLPs generated 
in these particular cells. Indeed, no significant difference in insulin receptor content 
was observed between VLPs derived from CHO K1 and CHO T10 cells as 
determined by Western blot analysis. As insulin receptors, upon activation by insulin 
binding, accumulate to the lipid rafts in the plasma membrane, it may be possible 
that the number of lipid-raft structures in CHO T10 cell membrane is inadequate to 
account for the enormous number of insulin receptors overexpressed in CHO T10 
plasma membrane. Hence, by this postulate, the VLPs that egress from the lipid-raft 
regions in the plasma membrane harbour only those receptors that are localized in 
these regions of the membrane. Given that the insulin receptors function normally in 
the lipid rafts in the plasma membrane, the limitation in the localization of the insulin 
receptors in lipid-rafts could be one another possible reason for the observed 
disconnect in downstream signalling pathway in CHO T10 cells. Thus, the impact of 
receptor distribution in lipid rafts and other membrane micro-domains must be 
considered whilst employing overexpressing cell models for studying receptor 
function, especially for those receptor proteins that are associated with these micro-
domains in the plasma membrane for their normal function such as the insulin 
receptors.  
In conclusion, this Thesis demonstrated a strong influence of cell membrane 
cholesterol content on insulin binding to insulin receptors in numerous experimental 
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models including several cultured cell models, liver plasma membranes of high fat 
fed and atorvastatin treated mice, and insulin receptor bearing VLPs. The generation, 
characterization and application of the latter as a suitable model for study of insulin-
insulin receptor interactions in context of the complexity of a cell membrane 
environment represents another novel aspect of this Thesis. The Thesis also discusses 
possible mechanisms underlying these findings and their implications in 
understanding insulin-insulin receptor interactions in the membrane’s native 
environment. Additional and novel observations discussed in this Thesis also include 
the limitations of overexpressing cell models in receptor-ligand interaction studies, 
cell-type specific effects on insulin binding in response to changes in membrane 
cholesterol content, the effect of high-fat diet on plasma membrane cholesterol 
content and insulin binding.  
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ABBREVIATIONS 
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1.0. LITERATURE REVIEW 
Diabetes mellitus comprises of a group of metabolic disorders characterized by 
chronic hyperglycemia. According to the atlas of the International Diabetes 
Federation, 2017, there are approximately 415 million adults affected by this disease. 
The number is expected to increase to ~ 642 million by 2040 [1]. The rise in the 
number of cases and lack of cost-effective treatment make this global pandemic a 
serious health and economical issue. The disease is classified into two main types 
(Type 1 and 2 Diabetes Mellitus), a clear distinction between which was made in 
1936 [2]. Although diabetes is one of the oldest diseases known to mankind, the 
complexity of this disorder is not yet fully understood. 
1.1. Pathophysiology of diabetes mellitus 
Type 1 diabetes mellitus is characterized by a failure of adequate insulin secretion by 
the pancreas in response to an increase in blood glucose. It is an autoimmune 
disorder that results in the destruction of the pancreatic β-cells which are responsible 
for insulin secretion [3]. The factors that initiate this autoimmune condition are not 
clearly understood, however, environmental and genetic factors contribute to its 
development [4].  
Type 2 diabetes mellitus is the more commonly occurring form of the disease 
accounting for about 95% of all diabetics. It is characterized by decreased insulin 
sensitivity at target tissues as a result of insulin resistance as well as decreased 
production of insulin due to pancreatic β-cell dysfunction [5]. The development of 
type 2 diabetes mellitus involves a complex interplay between genetic and 
environmental factors.   Risk factors can be categorized into modifiable factors such 
as diet and sedentary life-style and non-modifiable genetic factors [6]. 
1.2. Structure and function of insulin and insulin receptor 
1.2.1. Insulin 
Insulin, secreted by pancreatic β-cells, plays a pivotal role in the regulation of cell 
metabolism, growth and division. The molecular mass of insulin is 5808 Da. The 
molecular structure of monomeric insulin comprises of two chains; an A-chain that 
consists of 21 amino acid residues and a B-chain that consists of 30 amino acid 
residues. Amino acids such as leucine and isoleucine cluster in the middle forming 
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the hydrophobic core. Charged amino acids such as arginine and glutamate cover the 
surface, contributing to water solubility.  The secondary structure of the A-chain and 
B-chain include three α-helices (amino acid residues A1 to A8, A12 to A18 and B9 
to B19) [7]. The two chains are linked by two inter-chain (A7-B7 and A20 – B19) 
and one intra-chain (A6 – A11) disulphide bonds. These disulphide linkages were 
shown to be involved in the self-association of insulin and the binding of insulin to 
the insulin receptor [8].  
The self-association of insulin is essential for the stability of the molecule during 
storage in pancreatic β-cells and when secreted into blood [9]. In 1926, the 
3-dimensional structure of insulin was elucidated using X-ray crystallography and 
since then, the contribution of 2-D NMR studies led to development in the 
knowledge of monomeric and multimeric forms of insulin [10, 11]. Insulin dimerizes 
at micromolar concentrations and in the presence of zinc (10 mM Zn
++
), and at 
favourable pH 6.0, it self-assembles into higher-order conformations such as 
hexamers [12]. Insulin is stored in pancreatic β-cells as granules consisting of 
insoluble crystalline hexamers, with the six molecules of insulin arranged as three 
dimers [13]. The antiparallel β-sheets at the carboxy-terminus of the B chain on each 
monomer play a key role in the formation of the dimeric form of insulin. While these 
β-sheets are exposed to the outer surface of the insulin dimers, two nonpolar surfaces 
at the interface of the dimers form the hydrophobic core. One of two nonpolar 
surfaces is buried by a β-pleated sheet structure and the other extensive surface 
becomes buried when dimers associate to form hexamers [11, 12]. The same surface 
that is involved in self-association is also shown to be involved in receptor binding 
[7, 14].  
1.2.2. The insulin receptor 
Insulin receptors are transmembrane signalling proteins that belong to the family of 
ligand-activated receptor tyrosine kinases (RTKs) [14]. The insulin receptor has a 
role in several important physiological functions such as cell growth, differentiation 
and metabolism. The additional role of the insulin receptor in regulating cell 
metabolism makes it unique from other families of receptor tyrosine kinases such as 
epidermal growth factor receptors and fibroblast growth factor receptors that are 
involved only in cell growth and/or differentiation. Structurally, the unique feature of 
the insulin and closely related receptors (eg; insulin-like growth factor receptor,  
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IGF-R) among other receptor tyrosine kinases is their ability to form covalently 
linked functional dimers facilitated by disulphide bonds [15]. The unique structure 
and sub-unit composition of the insulin receptor are detailed below. 
The insulin receptor is comprised of two α subunits that lie completely in the 
extracellular region and two β subunits that extend from the extracellular region 
(segment involved in disulphide bond formation with α-subunits) through the plasma 
membrane to the intracellular region (segment that includes the tyrosine kinase 
domains) spanning the bilayer with a single transmembrane link [16]. Each α-subunit 
comprises 723 amino acids with a molecular mass of 130 kDa and each β-subunit 
comprises 620 amino acids with a molecular mass of  95 kDa [17].  Each α-subunit is 
linked with a β-subunit forming two αβ-monomers, which link to form functionally 
active (αβ)2-homodimers. These linkages are facilitated by two different classes of 
disulphide bonds (S-S). Class I disulphide bonds link the α-subunits of the 
homodimer and can be reduced under mild reducing conditions to give two 
αβ-monomers. Interestingly, these αβ-monomers bind insulin but with lower affinity 
than the holoreceptor, a structurally complete and functional state of the receptor  
[18]. Class II disulphide bonds between αβ monomers require stronger reducing 
conditions to form individual α and β subunits [19, 20]. Following synthesis, each 
disulphide linked αβ monomer, that is heavily glycosylated (N-linked), is transported 
to the plasma membrane and positioned in such a way that the whole α-subunit and 
194 residues of the β-subunit lie in the extracellular region and comprises the 
ectodomain (extracellular region) of the mature receptor [21].   
Typically, the αβ ectodomain comprises six domains; L1 (large domain 1), CR 
(cysteine rich domain), L2, three FnIII (fibronectin type III) domains (Fn0-2), an 
insert domain (ID) that splits the middle FnIII domain and includes the carboxy 
terminal of the α-subunit (α-CT) and the amino terminus (N-terminal) of each  
β-subunit [14]. The intracellular region of the β-subunit includes the juxtamembrane 
portion containing the kinase catalytic domain and docking sites for insulin receptor 
substrates. A carboxy-terminal tail of the β-subunits includes two phopshotyrosine 
binding sites [9].  
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1.2.3. Insulin receptor synthesis and its isoforms 
The insulin receptor is encoded by a single 22-exon gene located on chromosome 19; 
the mature receptors exist in two different isoforms, the A and B isoforms resulting 
from an alternative splicing of the primary transcript [22, 23]. The maturation 
process of the receptor involves synthesis of α and β subunits as a single precursor 
polypeptide (proIR) [24]. In the process of maturation in golgi compartments, this 
precursor polypeptide is cleaved on the carboxyl side tetrabasic amino acid sequence 
(Arg-Lys-Arg-Arg735) located at the junction between two subunits [16]. Though 
there are several endoproteases being linked in the maturation of membrane proteins 
such as the insulin receptors, furin, a major pro-protein convertase that is found in 
the trans-golgi network is shown to be involved in the cleavage of protein precursors 
[25, 26].  
The two isomeric forms (IR-A and IR-B) differ slightly in their amino acid 
composition and physiological functions [27], and their distribution is regulated in a 
tissue-specific manner [28]. The absence (A-isoform) or presence (B-isoform) of the 
additional 12 amino acid sequence encoded by exon 11 makes the isoforms 
structurally and functionally distinct [28]. Isolation and characterization of human 
insulin receptor cDNA predicted the sizes of proreceptors of A and B isoforms to be 
1343 and 1355 amino acid residues, the difference in sizes being due to the absence 
or presence of a 12-amino acid segment at the carboxy-terminal end of the insulin 
receptor α-subunit [22, 29, 30]. The maturation process of both these isoforms in 
vitro by recombinant furin was very similar [31]. However, a detailed statistical 
analysis of furin cleavage sites investigated within the 3D crystal structure of the 
furin catalytic domain suggested that the cleavage sites for furin extend beyond the 
tetrabasic consensus sequence up to 20 amino acids [32]. The extended sequences 
identified as the cleavage sites for furin included 10 amino acids of IR-B exon 11 
which suggest that the recognition sites for cleavage can differ from IR-A [33]. In 
addition to furin, there are other proprotein convertases reported to be involved in the 
maturation that are specific to the isoform of the insulin receptor. This distinction in 
the maturation process is thus linked to the structural and functional differences 
between the A and B-isoform of the insulin receptors [33].  
It is widely accepted that alternative splicing of the insulin receptor can be specific to 
cell type. Additionally, the relative abundance of the two isoforms varies with 
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development, aging and different disease states [34]. The A-isoform, dominant 
during the fetal and early developmental stages, is ubiquitously present during adult 
stages, whereas the proportion of B-isoform is higher in liver, kidney, skeletal 
muscle, adipose tissue and pancreatic-beta cells [35]. The affinity of the B-isoform of 
the insulin receptor for insulin is about two-fold higher than that for the A-isoform. 
Additionally, a relatively higher rate of internalization and recycling has been 
observed for the A-isoform receptor compared to the B-isoform [36, 37], however 
this observation remains inconclusive with contradictory evidence [38]. The factors 
that determine the relative abundance of the isoforms across various tissue types are 
currently unknown. 
Following the first report made on the insulin receptor isoforms [16], several studies 
emerged that investigated the significance of the structural differences to their 
functions and the consequence of defects in the maturation process of these isoforms 
in the development of diabetes [39-41]. Increasing knowledge about the differences 
in the function between these isoforms reveals a correlation with their distribution in 
various tissues  [42].  
1.3. Insulin – Insulin receptor interaction 
Since the insulin receptor was first characterized biochemically using 
125
I radioligand 
binding studies in the early seventies, numerous studies over several decades have 
helped unravel the downstream signalling mechanism of insulin [21].  However, the 
molecular events underlying this interaction and influences of the membrane 
environment on this interaction remain elusive. Though the latter aspect forms the 
basis of the current study, existing knowledge of the possible molecular events 
facilitating the insulin-insulin receptor interaction is briefly addressed below. 
It is known that the insulin molecule binds the preformed dimeric insulin receptor 
with a sub-nanomolar affinity which leads to autophosphorylation of the receptor and 
subsequent initiation of the intracellular signalling events. However, knowledge 
about the molecular events involved in the insulin-insulin receptor interaction and 
conformational changes leading to autophosphorylation are still being studied. 
Insulin binding to cell membranes, as analyzed by Scatchard plots, showed 
curvilinear binding isotherms which was interpreted as an indication of negative 
cooperativity since there was limited knowledge available on the structure and 
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composition of the insulin receptor [43]. However, this interpretation led to several 
controversies which were mitigated soon after the realization of its possible capacity 
to bind two insulin molecules due to the dimeric structure of the functional insulin 
receptor [13].  
Affinity labelling studies with insulin and its analogues identified only the α-subunits 
of the insulin receptor and therefore, the ligand-receptor complex was believed to 
occur in this subunit [13]. Studies based on three dimensional structure of the insulin 
receptor ectodomain using x-ray crystallography showed an “inverted V” 
arrangement of α-subunits where the first three domains; L1-CR-L2, form one leg 
and three FnIII domains of the α-subunit form the other leg [44, 45]. The domain 
arrangement derived from the crystal structure suggested two potential ligand 
binding sites with varying affinity for insulin (site 1: low affinity and site 2: high 
affinity) and that site 2 may involve one or more FnIII domains [46, 47]. This was 
later confirmed by a study based on four crystal structures of insulin bound to 
truncated insulin receptor constructs. This study showed minimal direct interaction 
between the L1 domain of the insulin receptor and the insulin molecule, and the 
hormone’s propensity to engage with the α-CT segment.  
The interaction of insulin with the insulin receptor leads to two structural transitions, 
one in the insulin molecule: the residues at the C-terminus in the insulin B-chain are 
inverted against the other residues and are displaced on binding to α-CT segment of 
the receptor [48].  The other structural modification to favour the interaction occurs 
in the insulin receptor: the apo structure of the receptor, i.e., during the unbound 
state, the α-CT linkage can only be seen with the L1 domain. On the event of insulin 
binding, this linkage encounters a conformational change to rearrange the α-CT helix 
such that it binds both L1 and insulin [7]. This understanding also explains the 
changes in conformation of the insulin-insulin receptor complex which limit the 
contact of insulin with the L1 domain of the insulin receptor to only insulin’s B-
chain residues [7]. The above-mentioned conformational changes in the receptor and 
formation of a hormone-receptor complex were demonstrated to be closely linked 
with initiating the cross-phosphorylation of the kinase domains of β-subunits in the 
juxtamembrane region [7, 48].  
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1.4. Limitations of currently used membrane models  
The interaction of insulin with the insulin receptor has mostly been evaluated using 
detergent-solubilized or truncated insulin receptor constructs [15]. These 
conventional approaches provided information on (i) the interaction of insulin with 
the ligand binding sites on the insulin receptor, (ii) allosteric regulatory properties of 
insulin and (iii) the mode of receptor autophosphorylation, however, they did not 
consider the influences of dynamic associations of membrane lipids and cholesterol 
with the insulin receptor in the course of this interaction [15, 49]. Insulin receptors, 
like most other transmembrane proteins, when solubilized may likely lose potential 
interactions with other membrane proteins and lipids that may have some key 
regulatory functions  [50, 51].  Therefore, it becomes essential to employ a model 
that enables us to consider the influence of the functional membrane lipid 
environment and the native conformation of receptor proteins while studying the 
characteristics of insulin-insulin receptor interaction.  
1.4.1. Virus-like particles  
Transmembrane proteins such as insulin receptors consist of an integral membrane 
component which is tightly associated with the dynamic lipid-bilayer [49]. There is 
evidence that failing to consider this protein-lipid interplay could make it difficult to 
study their molecular interaction or may lead to wrong conclusions [49, 52]. The 
recent use of a novel cell membrane model known as virus-like particles (VLPs) 
enables receptor-ligand interactions in a protein’s native conformation [53], and 
could be employed to study insulin receptor function. 
 VLPs are uniform, nano-sized spherical particles that extrude from the cell 
membrane of a host cell in a manner similar to that of a retroviral budding process 
[54]. VLPs are generated by co-expressing the membrane protein of interest and a 
retroviral core protein (Gag) in mammalian cells. The Gag protein self-assembles to 
form multimers and extrudes from the host cell with an intact portion of the cell 
membrane, complete with receptors and other membrane proteins in their native 
conformation (Fig. 1) [55]. Thus, unlike other membrane models, preparation of 
VLPs does not involve mechanical disruption or the use of solubilizing detergents. 
VLPs were known to extrude from specific regions of the plasma membrane that are 
rich in cholesterol. The effects of plasma membrane cholesterol content on viral 
protein  
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Picture adapted from the website of Integral Molecular. 
(http://www.integralmolecular.com/application-notes.php#tab_lipoparticle)  
  
Figure 1. The generation of virus-like particles (VLPs) from 
cultured cells. VLPs consisting of an intact cell membrane portion with 
membrane proteins in their native conformation.  
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assembly, budding and, therefore on viral replication processes have been addressed 
in several studies [56-59]. VLPs offer many advantages over conventional models 
for studying membrane protein interaction mechanisms. VLPs are reportedly stable 
and viable at a range of different temperatures (-80 °C, – 20 °C, 4 °C or 25 °C) and 
have a considerably longer shelf-life. Furthermore, it was estimated that the target 
receptor protein concentration in the VLPs is 10 to 100 fold more than what can be 
found in cells [54]. VLPs are also uniform in size and shape making them a suitable 
candidate model for detailed receptor-ligand studies using optical biosensor 
platforms such as surface plasmon resonance (SPR) [53].  
1.5. Insulin signalling 
Insulin, secreted by pancreatic β-cells in response to a postprandial increase in blood 
glucose, mediates its effect by binding to the insulin receptor on the cell membrane 
of target tissues. This ultimately promotes numerous metabolic processes including 
glucose uptake for energy production or storage (Fig. 2) [60]. The signalling pathway 
is initiated by the binding of insulin to the extracellular domain of the insulin 
receptor [61]. Insulin binding to the receptor α-subunit triggers transphosphorylation 
between β-subunits at specific tyrosine residues, in an activation loop which results 
in an increase in kinase catalytic activity [62]. Additionally, the receptor also 
undergoes autophosphorylation at a number of specific tyrosine residues present in 
the juxtamembrane region of the β-subunit [61].  
The binding of insulin to the insulin receptor and its subsequent activation further 
activates a family of membrane-associated insulin receptor substrate proteins (IRS1 
to 4) by tyrosine phosphorylation. This further activates phosphatidylinositol-3 
kinase (PI3K). This enzyme catalyzes the synthesis of phosphatidylinositol (3,4,5)-
trisphosphate (PIP3) by phosphorylation of phosphatidylinositol (4,5)-bisphosphate 
(PIP2) [62]. The increase in PIP3 levels leads to the recruitment of proteins 
containing pleckstrin homology (PH) domain, including phosphoinositide-dependent 
kinase 1 or PDK1 [63]. Activation of PDK1 is crucial for the activation of Akt 
(protein kinase B) which, after specific steps, leads to the translocation of a pool of 
glucose transporters (Glut) to the membrane and facilitates glucose uptake [64].  
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Figure 2. The key metabolic aspects of the insulin signalling pathway 
 
The sequence of events is shown in an anti-clockwise direction. INS – insulin, IR – 
insulin receptor, p - phosphorylation, IRS-1 – insulin receptor substrate-1, PI3K – 
phosphotidyl-inositol 3 kinase, PTEN – phosphatase and tensin homolog, PDK-1 - 
phosphoinositide-dependent kinase 1, AKT – protein kinase B, GSK3β – glycogen 
synthase kinase 3β, PIP2 - phosphatidylinositol (4,5)-bisphosphate, PIP3 - 
phosphatidylinositol (3,4,5)-trisphosphate, AS160 – Akt substrate, Rip11 – Rab11 
interacting protein, GLUT – glucose transporter. 
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While the above process describes the metabolic aspect of insulin signalling 
pathway, the other principal component of insulin signalling in cells is the regulation 
of growth-related gene expression via the Ras/MAP kinase pathway or the mitogenic 
aspect [65]. The growth signalling in cells in response to insulin binding to its 
receptor is initiated by the recruitment of adaptor/guanine nucleotide exchange factor 
(Grb2/SOS) complexes at Shc and insulin receptor substrates (IRS-1/2). This leads to 
the activation of small GTPase Ras which initiates a cascade of phosphorylation 
events resulting in the activation of MAP kinase. Activation of MAP kinase then 
leads to phosphorylation of various substrate proteins that promote the transcription 
of genes and synthesis of proteins involved in cell growth, differentiation and 
survival [42, 65]. Further to influences on receptor-ligand interactions, changes in 
membrane lipid composition also influence signalling events that occur in 
association with the plasma membrane. Some of the key signalling events pertinent 
to the insulin signalling pathway, such as activation by transphosphorylation at β-
subunits of the insulin receptor, activation of IRS-1/2 and PI3K, conversion of PIP3 
to PIP2, activation of Akt by PDK-1 and translocation of the glucose transporters 
that occur in or adjacent to the plasma membrane were found to be impaired as a 
consequence of alterations in membrane cholesterol content [49, 66, 67]. The 
importance of plasma membrane composition/environment is the central aspect of 
this Thesis and is thus discussed below.  
1.6. The plasma membrane environment 
The lipid bi-layer structure of the plasma membrane is a dynamic environment that 
enables constant movement of lipids and membrane associated proteins. It enables 
several vital physiological transport mechanisms and forms the cytoplasmic 
boundary for all cells. It acts as a physical barrier between cells and controls the 
movement of substances into or out of cells [68]. The structure and organization of 
plasma membrane can be explained by the ‘fluid mosaic model’, first described by 
Singer and Nicholson in 1972 [69].  
According to this model, the principal components of plasma membrane are 
amphiphilic phospholipids which consist of a polar phosphate head group and non-
polar tail group. Due to their amphiphilic nature, the phospholipids are spontaneously 
organized in a most thermodynamically stable configuration, with the polar head 
groups of the phospholipids facing the aqueous environment (intracellular or 
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extracellular side) and non-polar tail groups maximizing hydrophobic interactions 
[70]. This arrangement forms the basis of the phospholipid bi-layer structure of cell 
membrane.  
1.6.1. Cell membrane phospholipid composition  
The four main phospholipid components of cell membranes are phosphotidylcholine, 
phosphatidylethanolamine, phosphatidylserine and sphingomyelin.  An additional 
fifth type known as phosphoditylinositol is a minor component [71]. However, the 
distribution of different types of phospholipids between the outer and inner leaflets 
of the lipid bi-layer is asymmetrical. Phosphotidylcholine and sphingomyelin 
compositions dominate the outer leaflet whereas the most prevalent phospholipids of 
the inner leaflet are phosphatidylethanolamine and phosphatidylserine [71, 72].  
The distribution of different types of membrane lipids in the inner and outer leaflets 
of the cell membrane is determined by the difference in nature and structure of 
various lipids that form the bi-layer [73]. For example, phosphatidylserine and 
phosphoditylinositol, unlike sphingomyelin and phosphotidylcholine, carry negative 
charges in their phosphate heads and their distribution in the inner leaflet of the cell 
membrane is responsible for the overall negative charge in the cytosolic or inner 
leaflet. Differences in the arrangement and distribution of lipids contributes to the 
physical characteristics of the membrane such as the curvature of the membrane; for 
example, phosphotidylcholine that accounts for ~ 50% of the total phospholipid 
content of the cell membrane in most eukaryotes, has a near cylindrical geometry 
whereas phosphatidylethanolamine has a conical geometry in the bi-layer due to its 
smaller polar head groups relative to non-polar tails. Therefore, the distribution of 
phosphatidylethanolamine adjacent to phosphotidylcholine imposes a curvature 
stress on to the membrane that aids in vital cell to cell communications such as 
budding, cell fission and fusion  [73, 74].   
1.6.2. Cholesterol – structure and membrane topology 
In addition to the above-mentioned lipids, mammalian plasma membrane also 
contains cholesterol, which is the major sterol in the body. The biosynthesis of 
cholesterol takes place in the endoplasmic reticulum (ER) of the cell and its transport 
to the plasma membrane is facilitated by numerous membrane associated proteins 
including caveolin [75]. A loss in the regulation of cell cholesterol distribution 
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between plasma membrane and other organelle membranes is associated with several 
metabolic disorders [76]. The vast majority of a cell’s free cholesterol (i.e., 
unesterified cholesterol) is located in the plasma membrane and the remainder is 
found embedded in organelle membranes [77]. Structural aspects of the cholesterol 
molecule contributing to its overall hydrophobicity and the way these molecules 
interact with membrane phospholipids are addressed below.  
The structure and function of cholesterol was not well understood until the late 19
th
 
century. Although first identified in 1789 in its solid form in gall stones, the 
complexities in its biosynthetic mechanisms and structural assembly were still being 
discovered throughout the 20
th
 century [78, 79]. The polar region of this polycyclic 
amphipathic molecule consists of a single hydroxyl group. The remaining structure 
consists of four rigid hydrocarbon rings having a sterane backbone and an isooctyl 
sidechain that is strongly hydrophobic or non-polar [80]. The polar hydroxyl group 
of a cholesterol molecule is relatively smaller than the non-polar region and is thus 
unable to sufficiently protect the hydrophobic regions in an aqueous environment. 
For this reason, when introduced in aqueous solutions, free cholesterol molecules 
form cholesterol monohydrate crystals [81]. Therefore, despite its amphipathic 
nature, cholesterol molecules cannot form a bilayer in a biological environment and 
instead tend to interact with membrane lipids [82, 83]. The structure of the 
hydrophobic region of a cholesterol molecule possesses an asymmetry with two 
distinct faces, referred to as α and β faces [80, 84]. The β-face has a relatively 
significant irregular surface due to the presence of two methyl groups and a short 
eight carbon chain (iso-octyl chain) attached to C-17 of the sterane backbone 
whereas the α-face displays a flat or planar surface with no substituents [85, 86].  
Structure – function relationship 
The most important structural role of cholesterol in cellular membranes is its 
contribution to membrane strength and permeability. It not only limits membrane 
permeability to water and dissolved gases [87-89], but also controls the lateral 
diffusion of membrane lipids and proteins [90] by which it regulates the fluidity and 
phase transition properties of the membrane [91].  
The importance of the structural arrangement of cholesterol and its associations with 
various membrane lipids have been identified in ordering and condensation of lipids 
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in the membrane [92, 93]. The structure of cholesterol includes a four ring steroid 
group out of which three are six-carbon rings and one is a five-carbon ring. The rings 
connected in trans orientation forms the flat, smooth and planar surface (α-face) 
while methyl substituents at the 10
th
 and 13
th
 position in relative cis orientation forms 
the rough surface (β-face), thus leading to an asymmetry in structure. The structure 
of cholesterol differs from structures of other sterols such as desmosterol and 
lanosterol in its limited addition of substituents to α and β faces and the presence of 
only one double bond between C-5 and C-6 in ring B [94]. 
1.6.3. Interaction of cholesterol with membrane lipids and proteins  
The structural factors of phospholipids that influence cholesterol positioning in the 
bilayer are; head group structures, the length of hydrocarbon chains and the degree of 
unsaturation of the latter [95-97]. The orientation of cholesterol in the lipid bilayer is 
based on the interaction of its hydroxyl group and hydrophobic regions with the 
phosphate and hydrocarbon tail of the phospholipids, respectively [98]. The 
interactions of cholesterol with phosphatidylcholine and sphingomyelin, the most 
abundant phospholipids in cell membranes, have been well studied and the latter 
forms the basis of sphingolipid-cholesterol rich membrane microdomains  known as 
lipid-rafts [99]. Studies on structural aspects of the interaction between cholesterol 
and phospholipids reveal there is a hierarchy to these interactions, with the 
interaction between cholesterol and sphingomyelin being more favourable than that 
with phosphatidylcholine due to the presence of saturated acyl chains and a 
trans-unsaturated sphingosine backbone which maximizes the Van der Waals 
interactions [100].  
The umbrella model, proposed to explain cholesterol-lipid interactions, suggests that 
the four hydrocarbon rings of the cholesterol molecule that are strongly hydrophobic 
cannot be sufficiently shielded by the small, polar headgroup; therefore, association 
with large head-groups of phospholipids such as phosphotidylcholine and 
sphingomyelin becomes necessary for its positioning in the bi-layer [83].  Through 
these interactions, cholesterol also increases the order of saturated acyl chains of 
phospholipids therefore leading to a decrease in surface area of the lipids (lipid 
ordering effect) [85]. The surface area of the lipid bilayer in the presence of 
cholesterol is less than the sum of surface areas of individual components of the lipid 
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bilayer [101]. Also, cholesterol increases the surface density (condensing effect) of 
the membrane by decreasing its permeability [86, 102].  
The bulky hydrophobic sterol rings and relatively smaller hydroxyl head group only 
confers a weakly amphipathic nature to the molecule [103]. A rise in cholesterol 
content of the bilayer results in an inadequate protection from the adjacent aqueous 
environment for the hydrophobic regions of the newly added cholesterol molecules. 
This consequently leads to the lateral redistribution of phospholipids and 
reorientation of their polar head-groups [82]. There exists a similar concept for lipid-
protein interactions in the bilayer which is crucial for the stability and functioning of 
the membrane-bound proteins [104].  
Similar to its interaction with lipids, cholesterol also interacts with proteins within 
transmembrane (TM) domains. The hydroxyl group of cholesterol can form 
hydrogen bonds with the polar group of the membrane protein whereas the aliphatic 
spikes on the rough β-face can bind to the side-chains of branched amino acids such 
as Ile, Val or Leu in the protein through Van der Waals interactions [105].  It is 
important to note that the association of cholesterol with a specific type of 
phospholipid in the bilayer can in turn influence its association with membrane 
proteins and thereby the functional aspect of that protein. For example, the 
interaction of cholesterol with phosphatidylcholine leaves both α and β faces 
available for interaction with the transmembrane domain of membrane proteins [84]. 
Additionally, the inadequate shielding for the hydroxyl group of cholesterol in 
phosphotidylcholine-cholesterol complexes favours its establishment of a hydrogen 
bond with the transmembrane domain of a membrane protein.  
Alternatively, when complexed with sphingolipids (glycosphingolipids) cholesterol 
forms condensed lipids [106]. In this complex, the hydroxyl group of cholesterol 
forms a stable hydrogen bond with the polar head group of the sphingolipid whereas 
the smooth α-face of cholesterol interacts with the hydrophobic tails. The flexible 
acyl chain of phospholipids aligns effectively to complement the neighbouring 
cholesterol molecule to maximize the hydrophobic interactions and enable tight 
packing [107].  This leaves the rough β-face available for interaction with 
transmembrane domains of membrane proteins [108, 109]. Therefore, the difference 
in types of lipids between exofacial and cytoplasmic leaflets of the membrane and 
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preferential complexing of cholesterol with sphingolipids causes an asymmetry in the 
trans-bilayer distribution of cholesterol. This means that the accessibility of 
cholesterol for membrane protein interaction can be limited in the exofacial leaflet of 
the bilayer due to its higher sphingolipid content.  
In addition to the advantages of cholesterol-lipid complexes in membrane protein-
cholesterol interactions, the role of trans-bilayer cholesterol dimers leading to the 
activation of membrane protein by dimerization eg; G-protein coupled receptor, has 
been described [110]. Cholesterol dimerizes in the bilayer in two distinct ways 
through Van der Waals interactions; formation of trans-bilayer tail-to-tail dimers 
[111] and interaction of the planar α-faces leaving the β-faces of cholesterol 
molecules available for protein interactions [110]. Nevertheless, the membrane-
spanning domain of the proteins and presence of cholesterol in both the leaflets in 
different orientations provides a large scope for specific interactions between 
cholesterol and cholesterol recognition motifs on the transmembrane domains of 
proteins in the bilayer [112].   
1.7. Cholesterol synthesis and distribution in cells 
Cholesterol biosynthesis 
Cholesterol can be acquired by our body in two ways; either by de novo synthesis or 
from dietary intake. The production of cholesterol is highly regulated in the body 
such that when dietary intake of cholesterol is low, the de novo synthesis is 
upregulated and conversely, when the intake is high, excretion of cholesterol 
increases and the rate of synthesis decreases [78, 113]. In 1926, Heilbron, Kamm and 
Owens suggested that squalene is the precursor of cholesterol. However, Konrad, 
Bloch and Robert Langdon, in 1952, demonstrated that acetate is a more proximal 
precursor for both squalene and cholesterol. The biosynthesis of cholesterol is a 
complex process involving more than 20 enzymes and occurs in various subcellular 
regions such as cytosol, endoplasmic reticulum (ER) and peroxisomes. Due to the 
involvement of hydrophobic enzymes, substrates and products in the final steps of 
the biosynthetic pathway, synthesis partially occurs in the membrane environment 
[78]. 
The first phase of the cholesterol biosynthetic pathway involves the production of 
mevalonate from acetate. This occurs in the presence of an acetyl-coenzyme A  
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Figure 3. Cholesterol biosynthetic pathway 
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acetyltransferase (ACAT) enzyme known as thiolase, which catalyzes the 
condensation of two molecules of acetyl-coenzyme A (acetyl-CoA) to form 
acetoacetyl-CoA. HMG-CoA synthase catalyzes the addition of the third acetyl-CoA 
to acetoacetyl-CoA, which results in the formation of 3-hydroxy-3-methylglutaryl 
CoA (HMG-CoA). As a final step in the first phase, HMG-CoA is reduced to form 
mevalonate by HMG-CoA reductase (HMGCR) in the presence of the cofactor, 
NADPH. This reaction is catalyzed by HMGCR and is the rate limiting step in the 
biosynthetic pathway [78, 114]. 
Subsequently, mevalonate undergoes a series of phosphorylation steps and ATP 
dependent decarboxylation to form isopentynyl pyrophosphate (IPP), which is an 
activated isoprenoid molecule. Then, IPP undergoes 1:1 condensation with its 
isomer, dimethyl allylpyrophosphate (DMPP) to form geranyl pyrophosphate (GPP), 
which further condenses with one IPP molecule to generate farnesyl pyrophosphate 
(FPP). In the presence of squalene synthase and NADPH, head-to-tail condensation 
of two FPP molecules yields a 30-carbon molecule, squalene. Squalene, the 
precursor of all steroids, undergoes further cyclization processes, catalyzed by 
squalene monooxygenase and squalene 2,3-epoxidase enzymes, and this results in 
the formation of lanosterol [115]. Then, lanosterol undergoes a series of nineteen 
steps, in the presence of nine different enzymes, to form the 27 carbon molecule,  
cholesterol [116]. 
Cholesterol distribution in membranes 
The preferential localization of cholesterol molecules in cellular membranes and 
their orientation dynamics with membrane lipids were discussed earlier in section 
1.5.3. The distribution of cholesterol in cells and their trafficking within and between 
cells are tightly regulated by various cellular mechanisms. Cholesterol in cells is 
heterogeneously distributed among plasma membrane and other cellular membranes. 
While highly concentrated in plasma membranes, cholesterol is also found 
abundantly in intracellular vesicles, in increasing amounts from the cis to trans 
region of the golgi apparatus [117] and is in least abundance in the endoplasmic 
reticulum [118]. The processing steps of newly synthesized cholesterol are highly 
regulated and occur across various subcellular regions hence the transport of 
cholesterol between these regions is also crucial. The transport of cholesterol within 
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and between cells has been long known to occur via both vesicular and non-vesicular 
transport [119]. While a lot is known about endocytic, exocytic and luminal transport 
of cholesterol between and inside cells [120, 121], knowledge about the molecular 
mechanisms involved in the non-vesicular transport of cholesterol and lipids has not 
been well described [122-124]. However, over the last decade, knowledge has 
accrued on sterol binding proteins and their ability to transfer sterols in a membrane 
specific manner [125-128].  
Compared to all other cellular membranes, the plasma membrane has the highest 
content of free or unesterified cholesterol [118]. Additionally, the amount of 
cholesterol relative to membrane lipids in plasma membrane was estimated to be ~ 
35 mol% whereas it is ~ 5 mol% in endoplasmic reticulum (ER) [129]. The 
cholesterol content in intracellular membranes can be manipulated with exogenously 
applied interventions that alter plasma membrane cholesterol content such as 
desorption by cyclodextrins (CD) [130, 131]. Indeed, studies have suggested that 
reduction in plasma membrane cholesterol content could reflect on the ER 
cholesterol content, which may regulate a homeostatic mechanism upstream of ER so 
as to replenish the loss in plasma membrane [131, 132]. Lange et al (1999) 
demonstrated a concomitant reduction of ER cholesterol by 80% following a 
reduction in plasma membrane cholesterol by 25% when treated with 2% 
hydroxypropyl-β-cyclodextrin.  Taken together, these findings may suggest that the 
changes in ER cholesterol levels as a consequence of changes in plasma membrane 
cholesterol content could be homeostatic mechanisms that occur to replenish the loss 
in plasma membrane cholesterol content.  
1.8. Membrane cholesterol alterations by cyclodextrins  
The preference of cells to maintain optimal plasma membrane cholesterol content at 
the cost of relative changes in intracellular membrane cholesterol content indicates 
the significance of cholesterol in plasma membrane functionalities. The influence of 
changes in plasma membrane cholesterol on membrane stability, receptor 
functioning and organelle functions have associations with the pathophysiology of 
metabolic disorders [133-135] and cancer [136-138]. This awareness of the 
physiological importance of plasma membrane cholesterol content eventually led to 
an increase in studies that involved manipulation of membrane cholesterol to study 
the impact on various aspects of membrane function [139]. 
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The most common method to manipulate membrane cholesterol uses cyclodextrins, a 
class of pharmacological compounds known for their high affinity for cholesterol and 
ability to sequester cholesterol [140]. Cyclodextrins are cyclic oligosaccharides that 
are degradation products of starch. Their ability to completely dissolve in water and 
still sequester hydrophobic compounds accounts for their long recognition as 
effective carriers of hydrophobic drugs [140, 141]. Cyclodextrins exist as α 
(hexamer), β (heptamer) and Ƴ (octomer) forms and their degree of oligomerization 
accounts for the size of the hydrophobic cavities, which in turn determines the 
overall hydrophobicity of different forms of cyclodextrins [141, 142].  
β-cyclodextrins, compared to other forms, have the highest affinity for cholesterol 
[142, 143]. With a high affinity for cholesterol, β-cyclodextrin, among the three 
forms, is the least water-soluble form [140]. However, its solubility in water 
significantly increases in derivatives that include hydrophilic modifications such as 
methylated and 2-hydoxypropylated derivatives [141]. Therefore, in this study, 
methyl-β-cyclodextrin (MBCD), which features the highest affinity for cholesterol 
and complete solubility in water, was used to alter membrane cholesterol content of 
cells and model membranes (VLPs). 
The ability of MBCD to effectively alter membrane cholesterol arises from a 
combination of its properties; high solubility in water, an ability to directly access the 
plasma membrane of cells, the presence of a hydrophobic core that has high affinity 
for cholesterol and their relatively smaller size that maximizes the frequency of 
collisions with free cholesterol molecules [144]. The degree of cholesterol depletion 
in cells depends on factors such as the concentration of MBCD used, duration of 
incubation and cell type [144-146].  
While MBCD, due to its affinity for cholesterol, reduces cell membrane cholesterol, 
it can also be used to deliver and enrich cholesterol in cell membranes when pre-
loaded with cholesterol [147, 148]. Sheets et al. [149] demonstrated that cholesterol 
content in mast cells, which were subjected to cholesterol reduction and enrichment 
conditions serially with MBCD and cMBCD, respectively, was 3.5 fold higher than 
the untreated cells. Consistent with this study, several studies confirm the ability of 
MBCD to deliver cholesterol to membranes in different cells, however, the degree of 
cholesterol repletion varies slightly with the type of cell and to a greater degree with 
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variations in the molar ratio of cholesterol and MBCD and period of incubation 
[150].  
1.9. Statins 
Increasing evidence linking elevated plasma cholesterol levels with cardiovascular 
diseases led to the search for drugs that could lower plasma cholesterol. There was 
particular interest in synthesizing compounds homologous to one or more 
intermediates in the cholesterol biosynthetic pathway that could block this multi-step 
process. The search resulted in several compounds which were found to be effective 
in animals; however only Triparanol, a synthetic cholesterol lowering drug was 
introduced into clinical use in the U.S. in 1959 [151]. Since this drug acts by 
inhibiting 24-dehydrocholesterol reductase, an enzyme that catalyzes the conversion 
of desmosterol to cholesterol [152], it resulted in increased tissue accumulation of 
desmosterol, causing several side-effects including increased risk of atherosclerosis 
[153]. For this reason, this drug was withdrawn from the market in 1962 [154, 155].  
The search for compounds alternate to statins included those that interfere with 
intestinal absorption of cholesterol, however the efficacy of these drugs under in vivo 
conditions were significantly compromised and various deleterious side-effects 
became evident [156-158]. Soon after that, the focus turned towards the rate 
controlling enzyme in cholesterol biosynthesis, HMG-CoA reductase. In the early 
1970s, A Endo et al., observed strong inhibitory effects of two compounds isolated 
from fungal culture broths on HMGCoA reductase activity [159]. However, one was 
associated with risk of renal toxicity [160] and the other led to concomitant increases 
in the expression of the enzyme following inhibition, which compromised its 
efficacy [161]. Following this, as a result of intense research and clinical trials 
spanning more than a decade, lovastatin became the first commercially available 
statin in 1987 [162]. The discovery of lovastatin subsequently led to the discovery of 
several other naturally occurring statins such as simvastatin and pravastatin and 
synthetically developed statins such as rosuvastatin, pitavastatin, fluvastatin, 
atorvastatin and cerivastatin [163].   
1.9.1. Beneficial and adverse effects of statin therapy  
Statins have become one of the most widely prescribed groups of drugs to treat 
hypercholesterolemia in patients globally [164]. A meta-analysis conducted in 2010 
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revealed that statin therapy significantly reduced major vascular risk events including 
myocardial infarction and ischaemic stroke [165]. Due to the accumulation of strong 
evidence supporting its use in patients, statin therapy is recommended as per the 
guidelines of the American Heart Association and the European Society of 
Cardiology [166, 167].  
In addition to the cholesterol-lowering ability of statins, there is evidence for 
beneficial effects in patients with dementia, hepatocellular carcinoma and colonic 
neoplasia [168, 169]. In several population-based studies, statins were also shown to 
decrease the risk of developing oesophageal and gastric cancers [170, 171]. 
However, there are some concerns being expressed regarding the potential side-
effects of statin therapy and use of statins for longer periods of time. Almost all of 
the statins were reported to be associated with musculoskeletal side-effects, although 
the severity of side-effects from current statin use are shown to be quite low [172]. 
There have been very few reports made on the association of statin therapy with 
hepatic dysfunction. Clinical trials have shown statins to be associated with increases 
in serum alanine aminotransferase (ALT) in 3% of patients on statin medication, 
which was considered to be clinically insignificant in the majority of instances [173]. 
Surprisingly, a study showed that atorvastatin treatment in patients with non-
alcoholic fatty liver disease (NAFLD) and coronary artery disease not only reduced 
cardiovascular events significantly but also reduced mean serum ALT levels in these 
patients [174]. A similar study demonstrated that statin treatment in NAFLD patients 
significantly reduced the level of hepatic steatosis [175].  
Elsewhere, a number of studies have demonstrated the influence of statins on key 
signalling events of the insulin signalling pathway and pancreatic beta cell function 
and therefore suggest a potential diabetogenic property for statins [176]. A number of 
other studies have also indicated that simvastatin and atorvastatin could induce 
insulin resistance and worsen glucose uptake in skeletal muscle cells and adipocytes, 
respectively, through completely different mechanisms [177, 178].  However, not all 
statins were shown to be associated with new onset diabetes and those that were 
shown to be associated had effects only at higher doses [179, 180]. Also, there is no 
strong evidence that suggests further complications due to the use of statins in 
diabetics. In summary, statins are believed to be safe and effective drugs with strong 
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evidence in cholesterol-lowering and cardio-protective effects outweighing the 
concerns about their side-effects which in most cases were not considered clinically 
significant [181]. In relevance to the current study, there is some evidence that 
supports the ability of statins to alter cholesterol in cellular membranes [135, 182] 
but the actual mechanisms involved in statin-mediated alterations in plasma 
membrane cholesterol remain largely unclear [183, 184].  
1.10. Conclusion 
The first event of insulin signalling is the interaction of insulin (INS) with the insulin 
receptor (IR) which then leads to a sequence of intra-cellular events in order to retain 
the glucose homeostasis. The IR is a heterodimeric transmembrane receptor with two 
extracellular α-subunits and transmembrane β-subunits belonging to the large class of 
receptor tyrosine kinases (RTKs). Each β-subunit spans the plasma membrane with a 
typical 22 amino acid lipophilic sequence. Thus, it is perhaps not surprising that there 
is strong evidence implicating imbalances in insulin receptor dysfunction with 
certain changes in lipid composition and distribution within plasma membrane of 
cells. This study principally focuses on the influence of plasma membrane 
cholesterol content on the interaction between insulin and the insulin receptor. It is 
evident from the literature that alterations in plasma membrane lipid composition 
impair key insulin signalling events but to date, the influence of cell membrane 
cholesterol on insulin-insulin receptor interaction has not been comprehensively 
studied. Therefore, this study aims to investigate: 
 
 The influence of acute changes in plasma membrane cholesterol content 
using methyl-β-cyclodextrins (MBCD) on insulin-insulin receptor 
interactions and signalling in insulin sensitive cell types such as hepatocytes 
and skeletal muscle cells. 
 The effects of chronic cholesterol reduction using a clinically relevant drug, 
atorvastatin on insulin-insulin receptor interaction and signalling in 
hepatocytes and skeletal muscle cells. 
 The effects of diet and/or statin treatment on insulin-insulin receptor 
interaction in liver plasma membranes isolated from mice fed with high-fat 
diet and/or treated with atorvastatin. 
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 The use of a novel cell membrane model, virus-like particles (VLPs), to study 
the interaction of insulin with its receptor in its native cell membrane 
environment but in the absence of other cellular components.   
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2.0. MATERIALS AND METHODS 
2.1. Materials  
Chinese hamster ovary (CHO K1) and human hepatocarcinoma (HepG2) cell lines 
were purchased from the ATCC, Manassas, VA, USA. Human skeletal muscle cells 
and myoblasts (HSMM) and skeletal muscle cell growth media and supplements 
(SkGM-2 BulletKit) were purchased from Lonza, Basel, Switzerland. Fetal bovine 
serum, which was used to supplement the growth media, was purchased from 
HyClone®, VIC, Australia. NuncTM tissue culture flasks (25, 75 and 175 cm2) and 
penicillin/streptomycin (10,000 U/mL) for cell culture were purchased from 
ThermoFisher Scientific, MA, USA. Recombinant human insulin (dry powder), 
methyl-β-cyclodextrin (MBCD) powder, cholesterol powder and catalase solution 
were purchased from Sigma-Aldrich, CA, USA. Atorvastatin calcium trihydrate and 
dimethyl-sulfoxide (cell culture grade) were also purchased from Sigma-Aldrich. 
Amplex
®
 Red cholesterol assay kit and PierceTM BCA protein assay kit were 
purchased from ThermoFisher Scientific. Phosphate buffered saline (PBS; 10 mM 
disodium phosphate (Na2HPO4) and 1.8 mM monopotassium phosphate (KH2PO4), 
pH 7.2 containing 137 mM sodium chloride (NaCl) and 2.7 mM potassium chloride 
(KCl)) was purchased from HyClone. RIPA buffer (25 mM Tris-HCl, pH 7.6 
containing 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate and 0.1% sodium 
dodecyl sulphate (SDS) was purchased from ThermoFisher Scientific. Protease and 
phosphatase inhibitor cocktails were purchased from Sigma-Aldrich. NuPAGETM 
LDS sample buffer, NuPAGETM sample reducing agent, NovexTM Sharp pre-
stained protein standards, NuPAGETM MES SDS Running Buffer (20X), BoltTM 4-
12% Bis-Tris Plus Gels (10-wells), Mini Gel Tank and iBlotTM transfer stacks were 
also purchased from ThermoFisher Scientific. Amersham ECL prime Western 
blotting detection reagent was purchased from GE Healthcare Life Sciences (IL, 
USA). Tyrosine A14 [125I] monoiodoinsulin (125I insulin) was purchased from 
PerkinElmer (#NEX196010UC, PerkinElmer, OH, USA). MembraneProTM 
functional protein expression kits and support kits (InvitrogenTM) for VLP 
generation were purchased from ThermoFisher Scientific. All antibodies were 
purchased from abcam, Cambridge, UK. Unless otherwise stated, all other growth 
media and reagents for cell culture were also purchased from Sigma-Aldrich. The 
major equipment used for this study include swinging bucket centrifuge (Allegra® 
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X-12R, BeckmanCoulter), Sorvall WX ultracentrifuge (ThermoScientific), an 
EnSpire Multimode Plate Reader (PerkinElmer®), 2470 WIZARD2TM gamma 
counter (PerkinElmer), BD LSRFortessaTM flow cytometer, Zetasizer Nano ZS 
(Malvern®) and field emission-scanning electron microscope (MIRA3-TESCAN). 
2.2. Methods 
2.2.1. Cell based study 
2.2.1.1. Development of CHO T10 clone  
Chinese Hamster Ovary (CHO) cells overexpressing human insulin receptor isoform 
– A (CHO T10) were previously developed in our laboratory using CHO K1 cells. 
Human insulin receptor cDNA (isoform-A) was donated by Dr Takashi Kadowaki, 
NIH, USA.  The insulin receptor cDNA (5.2 kb) was inserted at the Hind III 
restriction site of pSV2neo, a mammalian transfection vector containing neomycin 
and ampicillin resistance.  Briefly, CHO K1 cells were transfected with a mixture of 
lipofectamine and the aforementioned plasmid expressing the human insulin 
receptor. Cells were selected for neomycin resistance by supplementing the culture 
medium with geneticin.  Single clones were isolated by limiting dilution and cells 
overexpressing insulin receptors were selected by measuring insulin binding to the 
cells. The cell line overexpressing insulin receptors used in this study was denoted as 
the CHO-T10 clone. CHO T10 cells or CHO K1 (wild-type) cells were used to 
generate VLPs.  
Cells were either grown in RPMI-1640 or DMEM/F-12 (1:1) media supplemented 
with 10% fetal bovine serum and 100 U/ml penicillin/streptomycin.  Cells were 
grown to form monolayers in 75 cm
2
 or 25 cm
2 
tissue culture flasks at 37 °C in a 
humidified incubator equilibrated with 5% CO2. Cells were passaged or prepared for 
storage by decanting the culture media from tissue culture flasks and rinsing the cells 
twice with phosphate buffered saline (PBS). Adherent cells were detached from the 
culture plates by treatment with 0.25% trypsin at 37 °C for up to 15 min. After 
achieving cell detachment, trypsin action was neutralized by adding an equal volume 
of culture media supplemented with 10% fetal bovine serum to minimise further 
proteolytic effects of trypsin on the cells. Cell suspensions were then transferred to 
15 ml falcon tubes and centrifuged at 1000 g for 5 min in a swinging bucket 
centrifuge (Allegra
®
 X-12R, BeckmanCoulter) maintained at room temperature (~ 23 
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°C). The supernatants were discarded and pellets were dispersed in complete culture 
media. Cells were either subcultured in appropriate well-plates for experiments or 
processed for cryopreservation. 
2.2.1.2. Cholesterol alteration in cells 
Cells were seeded either in 48-well or 6-well cell culture plates. Cell seeding 
densities were kept constant across all cell types used for this study; 1.65 X 10
5
 cells 
per well for 48-well plates and 5 X 10
5
 cells per well for 6-well plates. The cells 
were allowed to adhere to plates for at least 8 h at 37°C. Methyy-β-cyclodextrin 
(MBCD) or cholesterol-loaded MBCD (cMBCD) stocks were diluted in appropriate 
fetal bovine serum-free media to prepare working concentrations ranging from 1 to 
10 mM. The cells were then incubated for 30 min at 37 °C with either media 
containing no fetal bovine serum or MBCD or cMBCD. Alternatively, cholesterol 
reduction in cells was achieved by treating the cells with 10 µM atorvastatin for 48 h 
at 37 °C in DMEM or RPMI supplemented with 10% lipoprotein deficient serum 
(LPDS), which was prepared as described below in this section. Since atorvastatin 
stocks were made up in di-methyl sulfoxide (DMSO), the control group was treated 
with media containing DMSO (0.1% v/v) (volume of DMSO equivalent to the 
volume of 10 mM atorvastatin stock solution added to the media). The treatments 
were stopped by aspirating the media containing MBCD, cMBCD or atorvastatin and 
washing twice with PBS, pH 7.2.  
Preparation of MBCD and cMBCD stocks 
Methyl-β-cyclodextrin (MBCD) powder was dissolved in PBS, pH 7.2 to make a 100 
mM stock and stored at – 20 °C. Methyl-β-cyclodextrin loaded with cholesterol 
(cMBCD), of molar ratio ~ 20:1 was prepared by vortexing MBCD powder and 
cholesterol powder in PBS, pH 7.0 for 10 min. A homogenous state was attained 
after sonication in a probe sonicator (Misonix s-4000, QSonica) at 50% vibration 
amplitude at which the amplitude is ~ 60 μm (as recommended by the manufacturer), 
for at least 30 min or until there were no visible suspensions. The homogenous 
samples were then filter sterilized using 0.2 µm syringe filters and stored at – 20 °C 
[185].  
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Preparation of atorvastatin stocks  
Atorvastatin calcium trihydrate was prepared as 10 mM stocks in cell culture grade 
dimethyl-sulfoxide (DMSO) and stored as 20 µl aliquots at – 80 °C. 
Lipoprotein deficient serum (LPDS) 
The density of fetal bovine serum was adjusted to 1.21 g/ml which was achieved by 
dissolving sodium bromide to a final concentration of 3.4 M. The mixture was 
centrifuged for 2 min at 700 g, in a swinging bucket centrifuge maintained at room 
temperature (~ 23 °C) to remove air bubbles and non-dissolved sodium bromide. The 
mixture were then transferred to 11.5 ml polyallomer ultracrimp tubes and 
centrifuged for 20 h at 70000 g using a Sorvall T-1270 rotor in a Sorvall WX 
ultracentrifuge (ThermoScientific). LPDS was collected by making a hole near the 
neck of the tube for air flow and piercing the base of the tube with a butterfly needle. 
About 9.5 ml of LPDS was collected from the bottom in a fresh plastic tube leaving 
out the floating layer of lipoproteins in the centrifuge tube. The collected LPDS was 
then dialysed for 24 h with two changes of PBS, pH 7.2 at 4 °C. The dialysed 
samples were then sterilized by filtration through a 0.2 µm filter and stored as 10 ml 
aliquots at -20 °C.  
2.2.1.3. Lipid extraction 
Following treatment with MBCD, cMBCD or atorvastatin, media was aspirated and 
cells were washed twice with PBS, pH 7.2. A volume of 200 µl of hexane:2-propanol 
(3:2, v/v) was then added. After 2 to 3 min incubation, the mixture was aspirated and 
transferred to ‘v’-bottomed 96-well plates, and dried in a fume hood. After complete 
evaporation, the precipitates were redissolved in 40 µl of 1:1 mixture of 1x reaction 
buffer (0.1 M potassium phosphate buffer, pH 7.4, containing 0.5 M sodium 
chloride, 5 mM cholic acid and 0.1% Triton
®
 X-100) from the cholesterol kit 
described below, and 2-propanol, for cholesterol measurements [186].  
2.2.1.4. Cholesterol quantification 
Cholesterol was quantified using an Amplex
®
 Red cholesterol assay kit (#A12216, 
ThermoFisher Scientific) with strict adherence to the manufacturer’s protocol. In 
brief, the precipitates obtained from the step mentioned above were dissolved in 40 
µl of a 1:1 (v/v) mixture of reaction buffer (Component E in the AmplexRed
®
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cholesterol assay kit, ThermoFisher Scientific; contains 0.1 M potassium phosphate, 
pH 7.4, 0.5 M sodium chloride, 5 mM cholic acid and 0.1% Triton® X-100) and 2-
propanol. The dissolved samples were further diluted in the same mixture prior to 
assaying. A range of cholesterol standards were prepared by dilution of the calibrator 
provided in the kit as per the manufacturer’s guidelines using the same buffer used 
for diluting the samples. 
Since this assay measures the amount of hydrogen peroxide released from the 
oxidation of free cholesterol in the samples, catalase was added to eliminate any 
hydrogen peroxide generated by the partial oxidation of 2-propanol. Prior to the 
addition of samples and standards, 10 µl of 500 U/ml catalase was added to the wells 
of a black flat bottomed 96-well plate. Calibrators or diluted samples (40 μl) were 
then added to wells containing catalase and left for incubation at 37 °C for 15 min 
[186]. Subsequently, 50 µl of working reagent (prepared as per manufacturer’s 
guidelines) was added to the wells containing samples or calibrators and incubated 
for 30 min at 37°C. The fluorescence was then measured in an EnSpire Multimode 
Plate Reader (PerkinElmer
®
) set to an excitation of 560 nm and emission wavelength 
of 590 nm. The linear relationship between the concentration of the calibrators and 
the corresponding fluorescence values were ensured using a line of best fit. This 
standard curve was then used to estimate cholesterol content in the samples. 
2.2.1.5. Cell viability assay 
Cells were seeded at a seeding density of 3 X 10
4
 cells per well in 96-well plates and 
incubated overnight at 37 °C. The cells were either treated with MBCD/cMBCD or 
atorvastatin for 30 min or 48 h, respectively. The treatment was stopped by aspirating 
the media and washing twice with PBS, pH 7.2. The viability of cells was then 
evaluated using an alamarBlue
®
 cell viability assay (#DAL1025, ThermoFisher 
Scientific) with strict adherence to the manufacturer’s protocol. Briefly, media (100 
µl) containing 1x alamarBlue
®
 reagent was then added to all wells except the wells 
used for background correction and incubated at 37 °C for 3 h. The resulting 
fluorescence was measured using an EnSpire Multimode Plate Reader 
(PerkinElmer
®
) set to an excitation wavelength of 570 nm and emission wavelength 
of 580 nm.  
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2.2.1.6. Protein quantification  
The effects of various treatments on protein content of cells were estimated using 
BCA protein assay kit with strict adherence to the manufacturer’s protocol. Briefly, 
well plates were placed on ice and cells lysed in 1x RIPA buffer. The lysates and 
bovine serum albumin standards from the kit were diluted appropriately in lysis 
buffer. Cell lysates or standards (25 μl) were pipetted in to a clear, flat-bottomed 96-
well plate. Working reagent was prepared as per manufacturer’s guidelines. Working 
reagent (200 µl) was added to wells containing lysates or standards and briefly mixed 
on a plate shaker. The plates were covered and incubated at 37 °C for 30 min. The 
plates were equilibrated to room temperature and the absorbance was measured at 
562 nm using an EnSpire
®
 Multimode Plate Reader (PerkinElmer
®
). The linear 
relationship between the concentration of the calibrators and the corresponding 
absorbance values were ensured using a line of best fit. This standard curve was then 
used to estimate protein content in the samples. 
2.2.1.7. Insulin binding assay 
Insulin stocks 
Unlabelled insulin stocks were prepared as 206 µM stocks as described: 12 mg of 
recombinant human insulin powder was weighed, transferred to a 15 ml falcon tube 
and dissolved in 450 µl of 0.02 M HCl. This solution was immediately made up to 10 
ml with 50 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), pH 
7.6 containing 0.1% bovine serum albumin. The preparations were then filtered 
through a 0.2 µm syringe filter and aliquots stored at -20 °C. Typically, for binding 
assays, ~ 150 Bq/mmol of A14 [
125
I] monoiodoinsulin (
125
I-insulin; specific activity 
of 370 KBq/mmol) prepared in a binding buffer comprising 50 mM HEPES, pH 7.6 
and 0.1% bovine serum albumin was used. 
Insulin binding was evaluated by measuring the binding of 
125
I insulin to the insulin 
receptors on cells in the presence of a range of unlabelled human insulin 
concentrations (0 to 20.6 μM) using a 2470 WIZARD2 TM gamma counter 
(PerkinElmer). Briefly, cells were grown and treated in 48-well plates (except for 
HSMMs, which were grown, differentiated and treated in 6-well plates). Following 
treatments, media was aspirated and cells were washed twice with PBS, pH 7.2. The 
treated cells were then incubated overnight at 4°C with media containing unlabelled 
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and labelled insulin. After the incubation, media was aspirated from the cells, which 
were then gently washed three times with ice-cold PBS, pH 7.2. The cells were lysed 
in 1% SDS for ~ 5 min and the lysates were then transferred to 3DT tubes for count 
estimations. Radioactivity in the tubes was measured using 2470 gamma counter. 
The displacement of 
125
I-insulin by increasing concentrations of unlabelled insulin 
was plotted and non-linearly fitted to a one-site fit model using GraphPad
®
 PRISM. 
Non-specific binding of 
125
I-insulin, as determined based on the best-fit values, was 
used to calculate its specific binding by subtracting it from the binding values 
obtained at each concentration (0 to 20.6 μM) of unlabelled insulin. The best-fit 
values (top and bottom values for total and non-specific binding respectively and 
affinity (KD) were used to derive maximal binding (Bmax) and estimate the effects of 
various treatments on these parameters.  
2.2.1.8. Flow cytometry  
The effect of changes in cell cholesterol on insulin receptor density on the cell 
surface was studied using flow cytometry (BD LSRFortessa
TM – BD Biosciences). 
Following cholesterol altering treatments, the cells were detached from the culture 
flasks by treating with 0.25% trypsin for not more than 5 min. Following 
detachment, the cells were recovered by centrifugation at 700 g for 5 min and cell 
pellets were resuspended in ice-cold Tris-buffered saline or TBS (50 mM Tris-HCl 
buffer, pH 7.5, containing 150 mM NaCl) and cell counts were estimated using a 
hemocytometer. The cells were aliquoted to ‘U’ bottomed 96-well plates at a density 
of 1 x 10
6
 cells per well. The plates were then chilled on ice and centrifuged at 700 g 
for 4 min at 4 °C. The pelleted cells were resuspended and washed twice in cell 
staining buffer (BioLegend
®
), again at 4 °C.  
A Zombie NIR
TM
 fixable viability kit (BioLegend
®
) was used to quantify dead cells 
in all treatment groups. The lyophilized Zombie NIR
TM 
dye was reconstituted in 100 
µl of DMSO and stored at – 20 °C as a stock solution. Prior to use, this was diluted 
1:500 in TBS with no added fetal bovine serum or bovine serum albumin. Staining of 
cells involved resuspension of the cells in 100 µl of this working solution and a 10 
min incubation at room temperature, prior to removal of the staining solution by 
centrifugation at 700 g for 4 min at 4°C.  For the immunostaining procedure, 
optimized dilutions of primary and secondary antibodies were made up in cell 
staining buffer. The cell pellets were resuspended in 100 µl of mouse anti-insulin 
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receptor alpha antibody and incubated for 45 min at room temperature (~ 23°C). The 
plates were centrifuged again at 700 g for 4 min at 4°C, supernatants aspirated and 
cell pellets were washed twice with 150 µl of cell staining buffer. The cell pellets 
were then resuspended in 100 µl of goat-anti-mouse IgG antibody (#ab150113, 
abcam) and incubated for 30 min at room temperature (~ 23°C). The plates were then 
centrifuged at 700 g for 4 min at 4°C to remove media containing secondary 
antibody and the cell pellets were then washed twice with 150 µl of cell staining 
buffer and finally resuspended in 100 µl of the same buffer for FACS analysis. A 
control group with no staining was prepared for all cell types to correct for 
autofluorescence. The samples were analyzed in a BD LSRFortessa
TM 
flow 
cytometer using BD FACSDIVA
TM
 software. After priming the system with double 
distilled water, the samples were transferred to 3DT tubes and docked to the system 
ensuring the probe was completely immersed into the sample. The system was 
assigned to count a maximum of 50,000 events and this was kept constant for all the 
treatments and replicates in all experiments. The gating for live/dead cells and insulin 
receptor positive events was done using the gating tool in the software. Median 
fluorescence intensities in various treatments were measured and compared using 
Flowlogic
TM
 7.2 software (Inivai Technologies
TM
) or FLOWJO (BD Medical 
Technology).  
2.2.1.9. Western blotting for cultured cells 
Sample preparation 
Cells were grown and treated in 6-well plates. The treatments were stopped by 
removing the media and washing the cells with TBS. The plates were placed on ice 
and 100 µl of ice-cold RIPA buffer containing protease and phosphatase inhibitor 
was added to all wells and allowed to incubate for 2 min. The wells were scraped 
with a 1 ml micropipette tip with the end cut off and the lysed samples were 
collected in pre-chilled 1.5 ml Eppendorf tubes. In order to achieve complete cell 
disruption and lysis, the lysates were then sonicated in a Bioruptor
®
 Plus bath 
sonicator (diagenode
TM
) with six successive 15 second cycles including a five second 
break between each cycle. The lysed samples were then centrifuged in a microfuge at 
14000 g for 10 min at 4 °C. The supernatants containing proteins were transferred to 
fresh tubes. About 15 to 20 µl of lysates were used for protein quantification using a 
  
51 
 
BCA assay as described in section 2.1.6. The remaining lysates were stored at – 80 
°C for Western blotting.  
SDS-PAGE 
Lysates containing ~ 30 μg of protein were mixed with NuPAGETM LDS sample 
buffer and NuPAGE
TM
 sample reducing agent. The mixture was heated in a heat 
block at 95 °C for 3 min and briefly spun for 30 s in a mini-centrifuge to retrieve the 
condensates generated in the heating step. The solubilized samples were separated by 
electrophoresis in a Bolt
TM
 4-12% Bis-Tris Plus Gel along with Novex
TM
 Sharp pre-
stained protein standards. Electrophoresis was carried out in a Mini Gel Tank filled 
with 1x NuPAGE
TM
 MES SDS Running Buffer for 80 min at a constant voltage of 
120 V. The proteins were electrophoresed. The separated proteins were then 
transferred to a nitrocellulose membrane in a dry blotting system.  
Protein transfer by electroblotting  
Following electrophoresis, the gels were layered along with iBlot
TM
 transfer stacks 
according to the manufacturer’s guidelines for dry transfer of proteins to a 
nitrocellulose membrane. The dry transfer was carried out in an iBlot
TM
 gel transfer 
device. Briefly, the gels were layered on top of the nitrocellulose membrane fixed to 
the anode of the transfer stacks. A filter paper pre-soaked in double-distilled water 
was layered on top of the gels and air bubbles between the layers were removed with 
the help of a “debubbling” roller. Finally, the anode stack was placed on the top and 
the stacking was completed by putting the disposable sponge in place and the 
assembly was compressed by closing the lid. A preset program (20 V for 7 min) was 
chosen for transfer of proteins to the nitrocellulose membrane. After the run, the 
stacks were dismantled and the membrane containing transferred proteins was 
retrieved for the blocking step. In the blocking step, the membranes were incubated 
in blocking buffer comprising Tris-buffered saline, pH 7.6 containing 3% bovine 
serum albumin and 0.2% Tween-20 for 1 h at ~ 23 °C. 
Immunoblotting  
After the blocking step, the membranes were incubated in primary antibodies, 
prepared in the same buffer used in the blocking step, on a rocker for at least 8 h at  
4 °C. Following incubation with the primary antibodies, the membranes were then 
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Table 1. List of protein targets and their respective antibodies used in Western 
blot analyses 
Protein targets Primary antibody 
Secondary 
antibody 
Insulin receptor ab5500 
ab6721 
Insulin receptor-α-subunit 
ab36550 
monoclonal (83-7) 
ab150113 
Phosphorylated (tyr 1361) in the 
β-subunit of insulin receptor 
ab60946 
ab6721 
Phosphorylated GSK 3β (Ser9) ab131097 ab6721 
Akt ab126811 ab6721 
Phosphorylated Akt (Thr308) CST #4056 ab6721 
HMGCR ab174830 ab6721 
MyoD CST #13812 ab6721 
Lentiviral-Gag ab100970 ab6721 
β actin ab8227 ab6741 
GAPDH ab8245 ab6789 
Na+/K+ ATPase ab76020 ab6721 
Syntaxin - 6 ab140607 ab6721 
SDHA ab139181 ab6721 
KDEL ab176333 ab6721 
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 incubated for 1 h at room temperature with horseradish peroxidase (HRP) 
conjugated secondary antibody prepared in blocking buffer. Specific details on 
protein targets, corresponding primary and secondary antibodies are listed in Table 1. 
Finally, the membranes were given a minimum of three 5 min washes using 1x Tris-
buffered saline, pH 7.6 containing 0.2% Tween-20. The membranes were then 
incubated for 5 min in ~ 150 µl freshly prepared 1:1 mixture of luminol enhancer 
(solution A) and peroxide solution (solution B) provided in the Amersham ECL 
prime Western blotting detection reagent kit. The membranes were transferred to a 
ChemiDoc
TM 
MP system (Bio-Rad) for imaging and densitometry analyses were 
performed using ImageLab
®
 software (Bio-Rad).  
2.2.2. Animal studies  
2.2.2.1. Diets and treatments 
In this study, liver tissue samples were opportunistically collected from mice used for 
a related project from my supervisor’s laboratory which was originally designed to 
investigate the effects of high-fat diet and statin treatment on pancreatic β-cell 
function. The liver tissue samples obtained from mice were used to investigate the 
effects of the same on insulin-insulin receptor interaction characteristics in plasma 
membrane and insulin signalling. Male C57B1/6J mice aged 8 weeks were obtained 
from the Animal Resource Centre, Murdoch, Western Australia. The mice were 
delivered to the animal facility, Curtin University and left to acclimatise for a week. 
Following acclimatisation, mice were randomly assigned to two diet groups: normal 
(ND) and high-fat diet (HFD) (Speciality Feeds, Glen Forrest, Western Australia), 
then each diet group was subsequently assigned to two treatment groups; A –
atorvastatin and P - pravastatin treated groups, making 6 groups in total including 
controls. The original study and procedures involved in handling the animals were 
carried out in strict accordance with the guidelines of the National Health and 
Medical Research Council of Australia as approved by Curtin Animal Ethics 
Committee (AEC_2016_17) for the project titled “Statins & islet function”.  
2.2.2.2. Harvesting of mouse liver 
Mice were administered 200 μl of either water or atorvastatin or pravastatin 
(suspended or dissolved in water, respectively) at 10 mg/kg/day by gastric gavage 
daily from weeks 4 to 16. Following completion of the treatment period, mice were 
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starved for 6 h and anaesthetized in an isoflurane chamber before euthanized by 
cervical dislocation. Liver samples were collected in pre-chilled 1.5 ml Eppendorf 
tubes and snap-frozen either in dry ice or liquid nitrogen upon removal from the 
carcass. The tissue samples were stored at – 80 °C for later use. A protocol described 
by JM Suski et al., 2014 was adapted to process the liver tissue samples and collect 
various sub-cellular fractions for the study of effects of high-fat diet and statin 
treatment on cholesterol content and insulin signalling [187].  
2.2.2.3. Liver tissue homogenization  
The glassware used in this process were autoclaved and rinsed with double distilled 
water. The pH adjustments for all reagents and buffers used in this procedure were 
done at 4 °C. The general reagents used to prepare buffers were 1M Tris-HCl, pH 
7.4, 0.5 M HEPES, pH 7.4, 100 mM EDTA, pH 7.4 and 100 mM EGTA, pH 7.4. 
Liver tissues were retrieved from -80 °C storage and weights of wet tissue samples 
were recorded. The tissue samples were washed at least thrice with ice-cold starting 
buffer comprising 30 mM Tris-HCl (pH-7.4), 225 mM mannitol and 75 mM sucrose. 
The washed tissue samples were then transferred to a 10 ml glass/Teflon Potter-
Elvehjem homogenizer containing 5 ml of ice-cold isolation buffer-1 (0.5% (wt/vol) 
bovine serum albumin and 0.5 mM EGTA and 1% (v/v) protease and phosphatases 
inhibitor cocktail in starting buffer) and homogenized manually by 18-20 strokes. 
The homogenates were then transferred to 15 ml centrifuge tubes and centrifuged at 
800 g at 4 °C for 5 minutes in a Beckman Coulter swinging bucket centrifuge. The 
supernatants were centrifuged again under identical conditions and the pellets were 
discarded. A small volume of the crude homogenates were collected and stored at  
-80 °C for cholesterol and protein estimation, and Western blotting.  
2.2.2.4. Isolation of plasma membrane from mice liver samples 
Crude mitochondrial isolation 
The supernatants from the step above were then transferred to fresh thick-wall 10 ml 
polypropylene tubes and centrifuged at 10000 g for 10 minutes in a 70.1 Ti rotor and 
Beckman Coulter ultracentrifuge. The supernatants containing crude plasma 
membrane and cytosolic fractions were transferred to a fresh tube. The crude 
mitochondrial pellet was carefully resuspended in 5 ml of ice-cold starting buffer  
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  Figure 4. A schematic representation for plasma membrane isolation from 
mouse liver 
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with a 1 ml micropipette with the tip cut off. The tubes were then centrifuged using 
similar conditions to wash the mitochondrial fraction. The mitochondrial pellets were 
then resuspended in 500 μl of mitochondrial resuspension buffer comprising 5 mM 
HEPES (pH 7.6), 250 mM mannitol, 0.5 mM EGTA and 1% (v/v) proteases and 
phosphatases inhibitor cocktail and stored at – 80 °C.  
Crude plasma membrane isolation 
The supernatant containing plasma membrane and cytosolic fractions were 
transferred to fresh tubes and centrifuged at 25000 g for 20 min at 4 °C. The 
supernatants containing the cytosolic fraction were collected and stored on ice. The 
cytosolic fraction was processed later together with the sucrose gradient 
centrifugation step mentioned below. The pellet containing crude plasma membrane 
was resuspended in 10 ml of ice cold starting buffer and centrifuged again using 
similar conditions to remove microsomal and cytosolic contamination. After 
discarding the supernatant, the crude plasma membrane pellet was resuspended in 1 
ml of ice-cold plasma membrane resuspension buffer comprising 5 mM Bis-Tris 
powder and 0.2 mM EDTA (adjusted for pH 6.0 using KOH or HCl).  
Sucrose gradient centrifugation 
A discontinuous sucrose gradient was set up in a 14 ml thin-walled polyallomer 
ultracentrifuge tube. Sucrose solutions were prepared as described above in the 
reagent set-up section. The tubes were serially filled with increasing concentrations 
of sucrose solutions in the following way; 3 ml of 53% sucrose solution was added to 
the tube followed by layering 4 ml each of 43% and 38% sucrose solutions. The 
resuspended plasma membrane pellet and the cytosolic fractions collected previously 
were then layered on top of individual discontinuous sucrose gradients. 
Approximately, 2 ml of ice cold PMRB was added to fill up to the neck of the tubes, 
which were then weight matched. The tubes were centrifuged in an SW 40 Ti rotor at 
95000 g for 2.5 h. This step resulted in three dense bands; band 1) on top of 38% 
sucrose gradient containing plasma membrane associated membranes or PAMs, 
band 2) at the interface between 38% and 43% sucrose gradient solutions containing 
mitochondria tightly interacting with plasma membranes and band 3) at the interface 
between 43% and 53% sucrose gradient solutions containing plasma membrane. The 
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bands 1 and 3 were carefully collected using a transfer pipette and transferred to 
fresh tubes. The tubes were filled completely with ice-cold starting buffer and 
centrifuged at 95000 g as previously for 1 h at 4°C.  
The supernatants containing cytosolic fractions were included in the sucrose gradient 
centrifugation step mentioned above to separate microsomes. After high speed 
centrifugation, the supernatants containing cytosolic fractions were transferred to 
fresh tubes and microsomal pellets were resuspended in 10 ml of ice-cold starting 
buffer and re-centrifuged with bands 1 and 3 mentioned above. PAM and plasma 
membrane pellets were resuspended in 100 μl of ice-cold IB-2 containing 1x protease 
and phosphatase inhibitor cocktail and microsomal pellets were resuspended in 500 
μl of ice-cold IB-2 and all were stored at – 80 °C.  
2.2.2.5. Protein and cholesterol estimation  
All fractions obtained from whole liver tissues of mice from various treatment 
groups were estimated for total protein and cholesterol content using bicinchoninic 
(BCA) assay and AmplexRed
®
 cholesterol assay respectively. Briefly, liver fractions 
were solubilized in 1% SDS in PBS and quantified for total protein content using 
BCA assay kit as described in Section 2.2.1.6. Liver fractions were diluted in 1x 
reaction buffer (Component E provided in the AmplexRed
®
 cholesterol assay kit, 
ThermoFisher Scientific) containing 0.1 M potassium phosphate, pH 7.4, 0.5 M 
sodium chloride, 5 mM cholic acid and 0.1% Triton
®
 X-100 and total cholesterol 
contents were estimated as described in Section 2.2.1.4.   
2.2.2.6. Insulin binding assay  
Insulin binding analyses in liver fractions were done using competition binding 
analysis. Liver fractions were diluted in binding buffer containing 50 mM HEPES, 
pH 7.6 and 0.1% bovine serum albumin and incubated with 
125
I insulin and 
unlabelled insulin in 3DT tubes for ~ 18 h at 4 °C. Following incubation, a mixture 
of 20% polyethylene glycol (PEG) and 0.4% bovine gamma globulin (5:1, v/v) was 
added to the tubes and gently vortexed. The tubes were then placed on ice for 15 min 
and centrifuged for 25 min at 10,000 g at 4° C in a refrigerated centrifuge (Avanti
®
 J-
E). The 3DT tubes were placed in polycarbonate adapters to fit in a fixed angle rotor 
(JA 20.1) and to avoid breaking during centrifuge. Following centrifugation, the 
supernatants were discarded and the pellets were read for 
125
I counts in a gamma 
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counter (2470-WIZARD2
TM
 PerkinElmer). The data from the displacement of 
125
I 
insulin by increasing concentrations of unlabelled insulin (~ 40 pM to 20.6 µM) was 
fitted to a one-site fit model using GraphPad
®
 PRISM software and the best-fit 
values were used to estimate maximal binding and affinity of insulin receptors for 
insulin.   
2.2.2.7. Insulin signalling by Western blotting  
The effects of diet and statin treatments on hepatic insulin signalling of mice were 
estimated using Western blot analysis. Approximately, 20 – 25 µg of total protein, as 
measured by BCA assay, was loaded onto each well of a 10-well, 1 mm thick, 4 – 
12% Bis-Tris gradient gel and electrophoresed as per conditions mentioned and 
Western blot analyses were conducted as described in section 2.1.9. Separate loading 
controls were used for membrane (Na
+
/K
+
 - ATPase) and cytosolic fractions 
(GAPDH).  
2.2.3. Model membrane - virus-like particles (VLPs)  
2.2.3.1. VLP generation  
CHO T10 or CHO K1 cells were grown to 85% confluence in T-175 tissue culture 
flasks in RPMI-1640 containing 10% fetal bovine serum and 1 % 
penicillin/streptomycin.  After achieving 85% confluence, CHO T10 or CHO K1 
cells were fed with fresh RPMI-1640 containing 4% fetal bovine serum and 
incubated overnight at 37°C, in an atmosphere equilibrated with 5% CO2. From this 
point, the cells were maintained in an antibiotic-free media. VLP generation was 
carried out over a three day period. Following overnight incubation, the transfection 
procedure for VLP generation was carried out in CHO T10 or CHO K1 cells and 
according to the manufacturer’s protocol. 
 
In brief, the cells were fed with 25 ml of fresh RPMI-1640 containing 4% fetal 
bovine serum and the prepared transfection mixture was then added dropwise and 
incubated overnight at 37°C. The transfection mix was prepared as follows: A 9 
ng/mL solution of the lentiviral Gag protein was prepared by gently adding and 
mixing 36 µl of MembranePro
TM
 reagent containing 1 µg/ml of lentiviral Gag 
protein, to 4 ml of freshly prepared RPMI-1640 containing 2% fetal bovine serum in 
a 15 ml centrifuge tube. In a separate 15 ml centrifuge tube, a solution containing 45 
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µg/ml of the provided cationic lipid solution was prepared by gently mixing 180 µl 
of 1 mg/ml Lipofectamine
®
 2000   in 4 ml of RPMI-1640 containing 2% fetal bovine 
serum. The mixtures were then combined in one 15 ml centrifuge tube and incubated 
for 20 min at room temperature to allow formation of Gag protein-Lipofectamine
®
 
2000 complexes. After ~18 h of incubation, the media containing the transfection 
mixture was decanted and cells were either fed with fresh RPMI-1640 containing 4% 
fetal bovine serum, or for insulin stimulatory studies, fresh RPMI-1640 containing 
4% fetal bovine serum and insulin at a final concentration of 100 nM. After a 24 h 
incubation, the VLP-containing media was collected in 50 ml centrifuge tubes and 
cells were again fed with fresh RPMI-1640 containing 4% fetal bovine serum. From 
this point, media (~ 32 ml) was collected every 24 h for up to a 72 h time point. The 
collected media was briefly centrifuged in a swinging bucket centrifuge at 800 g for 
5 min at ~ 23 °C to remove debris. A volume of 30 ml was transferred to a fresh 
centrifuge tube using a serological pipette, whilst avoiding collection of the last few 
mL close to the debris. After careful transfer of the suspensions, 6 ml of 
MembranePro
TM
 precipitation mix was added and mixed gently by inverting the 
tubes several times and incubated overnight at 4 °C. This was then centrifuged at 
2800 g for 1 h at 4 °C. The supernatants were carefully discarded without dislodging 
the pellets containing VLPs. VLP pellets were then washed with 5 ml of 
MembranePro
TM
 reagent: PBS, pH 7.2 (1:5, v/v) and centrifuged at 2800 g at 4 °C 
for 15 min. The supernatants were discarded and pellets were resuspended in 50 mM 
HEPES, pH 7.6 and stored at - 80 
o
C. 
2.2.3.2. Dynamic light scattering analysis for VLPs 
VLPs were diluted in PBS, pH 7.2 and transferred to plastic disposable cuvettes and 
analyzed in a Zetasizer Nano ZS (Malvern
®
) which uses dynamic light scattering to 
determine particle size and size uniformity. This system uses a standard 4 mW laser 
operating at a wavelength of 633 nm and the observed intensity of the scattered light  
resulting from the dispersity of VLPs due to Brownian motion in suspension was 
used to determine particle size and size uniformity. The analysis was performed with 
the help of Malvern
®
 software.  
2.2.3.3. Electron microscopy for VLPs 
The size and morphology of the VLPs were also examined by field emission-
scanning electron microscopy (FE-SEM) using a MIRA3 (TESCAN). Sample 
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preparation involved formalin fixation and ethanol dehydration. A volume of 100 µl 
of VLPs and 4% paraformaldehyde was sequentially pipetted on to a glass cover slip 
mounted on an aluminium stub. The sample was then left overnight for fixation at 
room temperature. Following fixation, samples were dehydrated by serial treatment 
with increasing concentrations of ethanol: specifically, by treatment with 150 µl each 
of 10, 20, 40, and 90% ethanol solutions for 10 min at each concentration. After 
complete evaporation, the glass slide was mounted on the aluminium stub using 
sticky carbon conductive tape. The imaging was performed in the Microscopy and 
Microanalysis Facility located within the John de Laeter Centre, Curtin University, 
Bentley, WA.  
2.2.3.4. Insulin binding assays for VLPs 
The presence of functional insulin receptor in VLPs generated from cells was 
examined by competition binding analysis. The assay set-up was designed in a 
similar fashion to that in cell models but with slight alterations; the assays were 
carried out in 3DT tubes as opposed to multi-well plates since VLPs tend to remain 
suspended in solution and the retrieval process involved a polyethylene glycol 
precipitation step. The reaction mixture consisted of 50 µl VLPs, 25 µl each of 
125
I-
insulin (~ 2.5 to 3 pM) and increasing concentrations (0 to 20 µM) of unlabelled 
insulin prepared as described in Section 2.2.1.7. The tubes were capped and 
incubated at 4°C for approximately 18 h.  Following incubation, a mixture of 20% 
polyethylene glycol (PEG) and 0.4% bovine gamma globulin (5:1, v/v) was added to 
the tubes, which were then gently vortexed. The tubes were then placed on ice for 15 
min and centrifuged for 25 min at 10,000 g at 4° C in a refrigerated centrifuge 
(Avanti
®
 J-E). The supernatants were discarded and the pellets were analyzed by 
radio-counting on a gamma counter (2470-WIZARD2
TM
 PerkinElmer).  
2.2.3.5. Insulin receptor quantification  
Receptor concentration was approximated in cells and VLPs based on a method 
described by DeBlasi et al., 1989 [188], the equation for which is shown below. 
Bmax = B0 * [KD/L] 
In this equation, Bmax represents the maximum binding, B0 represents the difference 
between the highest and lowest values of the one-site model fit, KD represents the 
affinity of insulin for insulin receptors and L  represents the concentration of 
125
I-
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insulin [188].  The number of insulin receptors present per cell was estimated using 
the following equation: 
 
In this equation, Bmax represents the maximum binding of insulin and 6.023 x 10
23 
is 
the Avogadro’s constant.  
2.2.3.6. Cholesterol and protein estimation 
To measure cholesterol content, VLPs were extracted for non-polar lipids with a 
mixture of hexane/2-propanol (3:2, v/v) in ‘v-bottom’ 96 well plates. A volume of 
50 µl of VLP suspension derived from CHO T10 or CHO K1 cells, diluted 1:4 in 50 
mM HEPES, pH 7.6, was added to ‘v-bottom’ 96-well plates. A volume of 150 µl of 
hexane/2-propanol (3:2, v/v) mixture was then added to all the wells containing 
VLPs and left to evaporate in a fume hood. After complete evaporation, the dried 
extracts were dissolved in a 1:1 mixture of the assay 1x reaction buffer (component E 
in the AmplexRed
®
 cholesterol assay kit, ThermoFisher Scientific; contains  
0.1 M potassium phosphate, pH 7.4, 0.5 M sodium chloride, 5 mM cholic acid and 
0.1% Triton
®
 X-100) and 2-propanol and used for cholesterol quantification using 
the Amplex
®
 Red cholesterol assay (Section 2.1.4). For protein quantification, 50 µl 
of VLPs, diluted 1:4 in 50 mM HEPES, pH 7.6 was solubilized in 50 µl of 1% SDS 
in PBS and quantified for total protein content using the BCA protein assay (Section 
2.1.6). 
2.2.3.7. Western blotting of virus-like particles 
The presence of insulin receptors was also confirmed by Western blot analysis. VLPs 
were solubilized in 1% SDS in PBS and estimated for total protein content using 
BCA assay. Solubilized VLP samples containing ~ 20 µg of total protein were mixed 
with loading buffer containing 1 x Laemmli buffer and 1.42 M 2-mercaptoethanol as 
the final concentration. These mixtures were then heated at 95 °C for 2 min. The 
samples were loaded onto 10-well, 1 mm thick, 4-12% Bis-Tris gradient gels for 
SDS-PAGE. Western blotting was carried out in a similar manner to that used for 
whole cell models (Section 2.1.9). The membranes were incubated overnight at 4 °C 
in anti-insulin receptor, anti-Gag, anti-Na+/K+ ATPase or anti-GAPDH primary 
antibodies followed by 1 h incubation at room temperature (~ 23 °C) with respective 
horseradish peroxidase conjugated secondary antibodies. Both primary and 
Receptor number per cell = Bmax * [6.023 x 10
23
 / Number of cells] 
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secondary antibodies were prepared in Tris-buffered saline, pH 7.6 containing 0.2% 
Tween-20 and 3% bovine serum albumin. After incubation, the membranes were 
washed thrice with TBS, pH 7.6 containing 0.2% Tween-20. The membranes were 
then imaged and densitomery analyses were conducted as described in section 2.1.9.  
2.2.3.8. Modulation of membrane cholesterol content in VLPs    
Alterations in membrane cholesterol content of VLPs were achieved by treatment 
with 10 mM methyl-β-cyclodextrin (MBCD) or cholesterol loaded-MBCD (cMBCD) 
for 30 min at room temperature (~ 23 °C). VLPs were then pelleted by centrifugation 
in the presence of MembranePro
TM
 reagent (1 in 5 dilution). The VLP pellets were 
resuspended in 30 µl of hexane/2-propanol (3:2, v/v) and added to ‘v-bottom’ 96 
well plates. The effects of MBCD or cMBCD treatments on insulin-insulin receptor 
interactions, cholesterol and protein content, and were examined in VLPs as 
described in Sections 2.2.3.6.  
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3.0 RESULTS 
3.1. Effect of cyclodextrins and statins on cholesterol content and insulin 
action in cultured cells 
Chinese Hamster Ovary cells over-expressing the insulin receptor (CHO T10), 
human hepatocarcinoma cells (HepG2), human skeletal muscle cells and myoblasts 
(HSMM) differentiated into myotubes were treated with either MBCD or cMBCD, 
as an approach to manipulate membrane cholesterol levels or with atorvastatin to 
reduce cholesterol biosynthesis in cells (see Methods, Section 2.2.1.2). The viability 
of each of these cell lines was not significantly affected by treatment with up to 10 
mM MBCD (Fig 5A, 5C and 5E)
 1
.  However, whilst up to 10mM cMBCD also did 
not affect the viability of CHO T10 cells (Fig 5B),  a slight but significant increase 
and decrease in cell viability was observed as a function of cMBCD concentration in 
HepG2 and HSMM cells, respectively (Fig 5D and 5F). Atorvastatin treatment did 
not affect the viability of CHO T10 cells (Fig. 6A), however, it significantly 
decreased the viability of HepG2 cells (P < 0.05) and undifferentiated HSMMs  
(P < 0.0001) (Fig. 6B and 6C).  
Cell cholesterol decreased significantly in each cell type following an acute 30 min 
treatment with increasing concentrations of MBCD (Fig. 7A - C).
 1
  Cell cholesterol 
decreased by about a 2-fold ratio in each cell type following treatment with the 
maximal dose of 10 mM MBCD. Conversely, cholesterol levels increased in each 
cell type following an acute 30 min treatment with increasing concentrations of 
cMBCD (Fig. 7A - C). The concentration of cholesterol increased by about 2-fold in 
each cell type following treatment with the maximal dose of 10 mM cMBCD. Cell 
cholesterol content also decreased significantly in all three cell models after they 
were treated for 48 h at 37 °C with 10 μM atorvastatin in the presence of lipoprotein 
deficient serum (Fig. 8A – C).  
The specific binding of 
125
I-insulin to all three cell models decreased significantly in 
a concentration-dependent manner following treatment with either MBCD or 
cMBCD (Fig. 9A – C).1 This suggests that there may be an optimal cholesterol  
                                                             
1A linear fit is only used to fit data herein to illustrate the correlation between increasing 
concentrations of MBCD, cMBCD or atorvastatin on viability of cells, cell cholesterol content or 
insulin binding. 
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C D 
E F 
Figure 5. Effect of MBCD or cMBCD treatment on cell viability. CHO T10 
(A and B), HepG2 (C and D) and undifferentiated HSMM (E and F) cells were 
treated for 30 min at 37 °C with increasing concentrations of MBCD or 
cMBCD. Following treatment, cell viability was measured as described in 
section 2.2.1.5. The resulting fluorescence values were normalized relative to 
the untreated cells. The experiment was conducted three times in triplicate but 
only one representative data set is illustrated, with each data point shown as the 
mean ± SD (n=3). 
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C 
Figure 6. Effect of atorvastatin treatment on cell viability. CHO T10 (A), 
HepG2 (B) and undifferentiated HSMM (C) cells were treated for 48 h at 37 °C 
with atorvastatin in the presence of lipoprotein deficient serum. Following 
treatment cell viability assay was conducted as described in Section 2.1.5. The 
resulting fluorescence was measured in all cell types and values normalized to 
their respective control groups were plotted. The resulting fluorescence values 
were normalized relative to the untreated cells. The experiment was conducted 
three times in triplicate but only one representative data set is illustrated, with 
each data point shown as the mean ± SD (n=3). Data from all three experiments 
were used for statistical analysis (Paired t-test: ns – not significant, * P < 0.05,  
** P <0.01, n = 9). 
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Figure 7. Effect of MBCD or cMBCD treatment on cholesterol content of 
cells in culture. CHO T10 (A) and HepG2 (B) cells, and differentiated myotubes 
(C) were treated for 30 min at 37 °C with increasing concentrations of MBCD  
(     ) or cMBCD (    ). Following treatments, cholesterol was extracted from cells 
and measured as described in the Methods, section 2.2.1.3 and 2.2.1.4, 
respectively. The experiment was conducted three times in triplicate but only one 
representative data set is illustrated, with each data point shown as the mean ± SD 
(n=3). 
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Figure 8. Effect of atorvastatin treatment on cholesterol content of cells in 
culture. CHO T10 (A) cells, HepG2 (B) cells and differentiated myotubes (C) were 
treated for 48 h at 37 °C with 10 µM atorvastatin in the presence of lipoprotein 
deficient serum. Following treatments, cholesterol was extracted from cells and 
measured as described in the Methods, section 2.2.1.3 and 2.2.1.4., respectively. The 
experiment was conducted three times in triplicate but only one representative data 
set is illustrated, with each data point shown as the mean ± SD (n=3). Data from all 
three experiments were used for statistical analysis (Paired t-test: *** P < 0.001,  
**** P < 0.0001, n=9). 
  
  
B A 
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Figure 9. Effect of MBCD or cMBCD on 
125
I-insulin binding in cultured cells.  
CHOT10 (A) cells, HepG2 (B) cells and differentiated myotubes (C) were treated for 
30 min at 37 °C with increasing concentrations of MBCD ( ) or cMBCD ( ). 
Following treatments, insulin binding assays were conducted as described in the 
Methods, Section 2.1.7. The experiment was conducted three times in triplicate but 
only one representative data set is illustrated, with each data point shown as the mean 
± SD (n=3). 
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concentration in cells supporting maximal insulin binding. The effect of acute 
treatment with MBCD and cMBCD on decreasing insulin binding to CHO T10 and 
HepG2 cells was evaluated in greater detail using radio-ligand competition binding 
studies conducted over a wide range of competing unlabelled insulin concentrations 
(Fig. 10)
2
. Analysis of the competitive binding plots (Table 2) suggested that MBCD 
or cMBCD treatment decreased in insulin binding in CHO T10 cells by decreasing 
the number of available cell surface insulin receptors (MBCD or cMBCD, P < 
0.0001); there was no apparent change in the affinity of insulin to insulin receptors in 
CHO T10 cells (MBCD, P = 0.3; cMBCD, P = 0.2). Similarly, based on competitive 
binding analysis, MBCD or cMBCD treatment decreased insulin binding in HepG2 
cells by decreasing the number of available cell surface insulin receptors (MBCD:  
P < 0.01; cMBCD: P < 0.05); no apparent change in the affinity of insulin to the 
insulin receptors was observed (MBCD, P = 0.4; cMBCD, P = 0.5). It is notable that 
in HepG2 cells, the largest decrease in binding was observed with MBCD treatment 
while in CHO T10 cells the largest decrease in binding was observed with cMBCD 
treatment. Thus, the impact of cholesterol loading or depletion in the membrane on 
insulin binding appears to be cell type specific.  
As a more direct approach to evaluate the influence of cyclodextrins on the number 
of insulin receptors on the surface of cells, CHO-T10 and HepG2 cells were first 
treated with either 10 mM MBCD or cMBCD and then insulin receptors were 
detected by incubating the cells serially with a monoclonal antibody raised against 
the α-subunit of the anti-insulin receptor (83-7) and then a fluorophore (Alexaflour-
488) conjugated secondary antibody (see Methods, Section 2.2.1.8). The effects of 
the treatments on cell surface insulin receptor density in CHO T10 and HepG2 cells 
were then detected by flow cytometry. Treatment with either MBCD or cMBCD 
significantly decreased the density of insulin receptors on the surface of CHO-T10 
and HepG2 cells (Fig. 11 A and B respectively). It is interesting to note cMBCD 
treatment had a greater effect on decreasing the apparent number of insulin receptors 
in CHO T10 cells than in HepG2 cells. This observation is consistent with the trends 
observed for the specific binding of 
125
I-insulin to CHO T10 and HepG2 cells as  
                                                             
2 For binding analyses, it was assumed that there is a single class of binding sites for ligand binding 
and that there was no cooperativity between the ligand binding sites. 
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Figure 10. Effect of MBCD or cMBCD treatment on the competitive binding 
of 
125
I-insulin to CHO T10 and Hep G2 cells. Following treatment with either 
10mM MBCD ( ), 10 mM cMBCD ( ) or untreated (     ), CHO T10 (A) and 
HepG2 (B) cells were incubated for 18 h at 4 °C with a wide concentration range 
of competing unlabelled insulin (0 to 20.6 μM,) and a single concentration of 125I- 
insulin (approximately 3 pM) as described in the Methods, section 2.1.7. The 
binding data were fitted to a one site-fit model and compared using GraphPad 
PRISM
®
. The experiment was conducted three times in duplicate but only one 
representative data set is illustrated, with each data point shown as the mean of 
duplicates. 
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Table 2. The effect of MBCD and cMBCD treatments on membrane insulin 
receptor number and affinity in CHO T10 and HepG2 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The affinity and receptor number values were estimated based on non-linear curve 
fitting analysis of the competition binding curves shown in Fig.12. The reported  
p-values for treatments are based on the comparisons with respective controls 
(ANOVA- Dunnette’s multiple comparison test: ns – not significant, *P < 0.05,  
*** P < 0.001, **** P < 0.0001).  
 
Cell Models Treatments 
Affinity  
KD (nM) 
Receptor number 
per cell  
(x 105) 
 Control 1.8 ± 0.4  5.3 ± 0.2  
CHO T10 MBCD 1.1 ± 0.5 
(ns) 
          3.1 ± 0.1*** 
 
 cMBCD 1.3 ± 0.6
 
(ns) 
      2.3 ± 0.4**** 
 
    
    
 Control 
 
1.1 ± 0.4 
 
         0.41 ± 0.05 
HepG2 MBCD 
 
1.7 ± 0.3 
(ns) 
 
0.18 ± 0.02*** 
 
 
cMBCD 
 
1.1 ± 0.3 
(ns) 
 
0.28± 0.02* 
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B A 
D C 
Figure 11. Effect of MBCD or cMBCD treatment on cell surface insulin 
receptor density in CHO T10 and HepG2 cells. Following treatments with 
MBCD or cMBCD, CHO T10 and HepG2 cells were incubated with anti-insulin 
receptor-α antibody and respective secondary antibody, and flow cytometry 
analysis was conducted as described in the Methods, section 2.2.1.8. One 
representative histogram out of three separate experiments is shown in plots A 
(CHO T10) and C (HepG2) that depicts the insulin receptor positive events in 
control (green), 10 mM MBCD (orange) and 10 mM cMBCD (red) treated 
groups. Comparative plots of median fluorescence intensity (MFI) values of 
insulin receptor positive events obtained from the histograms are illustrated in 
plots B (CHO T10) and D (HepG2). The experiment was conducted three times 
in triplicate but only one representative data set is illustrated as mean ± SD (n=3). 
Data from all three experiments were used for statistical analysis (Tukey’s 
multiple comparisons test: ** P < 0.01, *** P < 0.001, **** P < 0.0001, n=9). 
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shown in Fig. 10. This reinforces the apparent cell-specific nature of the impact of 
cholesterol loading or depletion on insulin binding and the apparent insulin receptor 
number detected. 
The association between cholesterol content and insulin binding in cultured cells was 
further examined using two approaches. In the first approach, the cells were allowed 
to “naturally” recover from MBCD or cMBCD mediated alterations in cell 
cholesterol, by maintaining the cells in complete media, i.e., media supplemented 
with 10% fetal bovine serum for a period of 24 h following treatments. In CHO T10 
and HepG2 cells, a substantial increase or decrease in cell cholesterol content, 
approaching the level observed in the control cells, was observed after 24 h 
following MBCD or cMBCD treatment respectively (Fig. 12A and 12B). 
Contrastingly, in differentiated myotubes, no considerable change in cell cholesterol 
was observed after the recovery period following MBCD treatment; however, a 
substantial decrease in cell cholesterol, approaching the level observed in the control 
cells, was observed after the recovery period following cMBCD treatment (Fig. 
12C). The specific binding of 
125
I-insulin increased substantially in all three cell 
types after the recovery period following either MBCD or cMBCD treatment, 
approaching the level observed in control (untreated) cells (Fig. 13). Interestingly, no 
considerable change in binding was observed in differentiated myotubes after the  
24 h recovery period following MBCD treatment (Fig. 13C), in which the cholesterol 
content was also observed to be unaltered (Fig. 12C).  
As an alternative approach to evaluate the association between cholesterol and 
insulin binding, CHO T10 cells were treated sequentially with MBCD and then 
cMBCD or vice versa, and their effects on cell cholesterol content and insulin 
binding were estimated. The effects of MBCD or cMBCD on cell cholesterol content 
in CHO T10 cells were reversed by the sequential treatment with cMBCD or MBCD, 
respectively (Fig. 14A), in each case approaching the level observed in the control 
cells. As would be expected if membrane cholesterol and insulin binding were 
linked, the specific binding of 
125
I-insulin in CHO T10 cells was also normalized 
towards the control level when sequentially treated with MBCD and then with 
cMBCD or vice versa (Fig. 14B). Thus, the decrease in insulin binding in cells 
treated with MBCD or cMBCD is not likely due to a secondary effect of the  
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Figure 12. Normalization of cell cholesterol content by cultured cells following 
MBCD or cMBCD treatment. CHO T10 cells (A), HepG2 cells (B) and 
differentiated myotubes (C) were treated for 30 min at 37 °C with media alone 
(control), 10 mM MBCD or 10 mM cMBCD. The cells were then washed twice with 
PBS and cultured for a further 24 h at 37 °C in fresh media containing fetal bovine 
serum. A separate batch of cells was cultured for 24 h prior to treatment for 30 min 
with either MBCD or cMBCD (0 h recovery). Cells were extracted for cholesterol 
and protein as described in Methods, section 2.2.1.3, 2.2.1.4 and 2.2.1.6 respectively. 
Changes in cell cholesterol were normalized to total protein content and reported as 
percentages of control. The experiment was conducted three times in triplicate but 
only one representative data set is illustrated as mean ± SD (n=3). 
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Figure 13. Normalization in 
125
I-insulin binding in cultured cells following 
MBCD or cMBCD treatment. CHO T10 cells (A), HepG2 cells (B) and 
differentiated myotubes (C) were treated for 30 min at 37 °C with media alone 
(control), 10 mM MBCD or 10 mM cMBCD. The cells were then washed twice 
with PBS and cultured for a further 24 h at 37 °C in fresh media containing fetal 
bovine serum. A separate batch of cells was cultured for 24 h prior to treatment 
for 30 min with either MBCD or cMBCD (0 h recovery). Insulin binding assays 
were then conducted on treated cells as described in the Methods, section 
2.2.1.7. Changes in insulin binding were normalized to total protein content and 
reported as percentages of control (untreated). The experiment was conducted 
three times in triplicate but only one representative data set is illustrated. 
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Figure 14. Effect of sequential treatment with MBCD and cMBCD on 
cholesterol content and 
125
I- insulin binding. CHO T10 cells were treated for 30 
min at 37 °C in media containing 10 mM MBCD in the absence of fetal bovine 
serum (control). A separate batch of cells was sequentially treated for 30 min at 37 
°C in media first containing 10 mM MBCD and then in media containing 10 mM 
cMBCD or vice versa.  Following treatments, suspension media containing MBCD 
or cMBCD was removed and the wells were rinsed twice with PBS. Cholesterol 
measurements and binding assay were then conducted as described in the Methods, 
sections 2.2.1.3 and 2.2.1.7 respectively.  Changes in cholesterol (A) and insulin 
binding (B) were normalized to total protein content and reported as percentages of 
the control. The experiment was conducted two times in triplicate but only one 
representative data set is illustrated. Data from all experiments were used for 
statistical analysis (Tukey’s multiple comparisons test: ** P < 0.01, 
 **** P < 0.0001, n=6). 
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treatment. Rather, the observations (Fig. 13 and 14) support the conclusion that the 
changes in cholesterol content are directly linked with the changes in insulin binding 
and apparent insulin receptor number in cultured cells.  
The influence of a 48 h atorvastatin treatment on insulin binding in CHO-T10 and 
HepG2 cells was also evaluated. Despite atorvastatin lowering cholesterol levels in 
each cell type (Fig. 8), it had no effect on insulin binding in either CHO T10, HepG2 
(Fig. 15) or differentiated myotubes (data not shown). Analysis of the competitive 
binding data in Fig. 15A and B, assuming a one-site model, confirmed that there was 
no apparent effect of atorvastatin on either the affinity of insulin for insulin receptors 
or the number of insulin receptors present in CHO T10 cells or HepG2 (Table 3). 
These results were somewhat surprising given the clear effect of MBCD mediated 
cholesterol alteration on insulin binding in these cell types. Possible reasons for this 
apparent conundrum are further detailed in the Discussion section 4.1 of this Thesis. 
A summary of the effects of the MBCD, cMBCD or atorvastatin treatment in CHO 
T10, HepG2 and differentiated myotubes on insulin binding and receptor content is 
shown in Table 4. 
The effects of various treatments on the total insulin receptor content 
phosphorylation of the β-subunit of the insulin receptor, Akt and GSK3β were 
evaluated (Fig. 16 - 21). There was no significant effect of MBCD or cMBCD on the 
total insulin receptor content in CHO T10, HepG2 or differentiated myotubes (Fig. 
16B, 17B and 18B). This may appear at odds with the earlier observations based on 
the binding and flow cytometry analyses, which suggests that MBCD and cMBCD 
decreases insulin binding in CHO T10 and HepG2 cells by decreasing the apparent 
number of insulin receptors on the surface of cells. However, it should be noted that 
the quantitation of insulin receptors in the Western blots herein were based on the 
total cell lysates whereas quantitation based on binding and flow cytometry analysis 
would have measured cell surface insulin receptors and not total cellular receptor 
levels.  
The treatment of CHO T10 cells with MBCD resulted in a significant decrease in 
phosphorylation of the β-subunit of the insulin receptor and Akt (Fig. 16C and D;  
P < 0.001 in both cases), despite having no effect on total insulin receptor content. 
These decreases coincided with the binding data shown in Fig.10; however, no  
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B 
A 
Figure 15. Effect of atorvastatin treatment on the competitive binding of 
125
I-insulin to CHO T10 and HepG2 cells. Following 48 h treatment at 37 °C 
with 10 μM atorvastatin  CHO T10 (A) and HepG2 (B) cells were incubated for 
18 h at 4 °C with a wide concentration range of competing unlabelled insulin ( 0 
to 20.6 µM) and a single concentration of 
125
I-insulin (approximately 3 pM) (see 
Methods, section 2.2.1.7 for assay procedure). The specific binding of 
125
I-
insulin in control ( ) and atorvastatin treated groups ( ) were fitted to a 
one site-fit model and compared using GraphPad PRISM
®
. The experiment was 
conducted three times in duplicate but only one representative data set is 
illustrated, with each data point shown as the mean of duplicates. 
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Table 3. The effect of atorvastatin treatment on insulin receptor number and 
affinity in CHO T10 and Hep G2 cells. 
 
 
The affinity and receptor number values were estimated based on non-linear curve 
fitting analysis of the competition binding curves to one-site fit binding model using 
GraphPad PRISM
®
 (see Methods, Section 2.2.1.7). The reported p-values for 
treatments in CHO T10 cells and HepG2 cells are based on the comparisons with the 
respective controls (An F-test was used for affinity comparisons with the control and 
unpaired t-test (two-tailed) was done for comparing receptor number; ns – not 
significant).  
  
Cell Models Treatments 
Affinity  
KD (nM) 
Receptor number 
per cell 
(x 105) 
CHO T10 
Control 3.8 ± 1.1  4.9 ± 0.7  
Atorvastatin 3.9 ± 1.2
 
(ns)  
4.5 ± 0.6 
(ns)   
    
HepG2 
Control 2.2 ± 1.4  0.14 ± 0.04 
Atorvastatin 1.9 ± 1.3
 
(ns) 
0.16 ± 0.03 
(ns) 
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Table 4. A summary of the effects of MBCD, cMBCD or atorvastatin treatment 
on insulin binding and insulin receptor content in cultured cells. 
 
 
The effects of MBCD or cMBCD or atorvastatin treatment on cell cholesterol 
content, insulin binding and receptor content estimation  by binding assay and flow 
cytometry were summarized in this table (    denotes a decrease,      denotes an 
increase, ‘ ns ‘ denotes no significant change, ‘nd’ denotes ‘not determined’ and  
‘ * ’ denotes ‘not examined’).  
 
Cholesterol 
content 
Insulin 
binding 
Receptor 
content 
estimated 
by binding 
assay 
Receptor 
content  
estimated  
by flow 
cytometry 
Treatments 
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10 mM MBCD       ns ns *   * 
10 mM cMBCD       ns ns *   * 
10 µM Atorvastatin    ns ns nd ns ns * * * * 
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Figure 16. Effect of MBCD and cMBCD treatments on insulin signalling in 
CHO T10 cells. Cells were treated for 30 min with 10 mM MBCD or 10 mM 
cMBCD and then for 7 min at 37 °C with 100 nM insulin. Following treatments, the 
cells were lysed in RIPA buffer and Western blot analysis was conducted as 
described in the Methods, section 2.2.1.9. One representative Western blot image out 
of three separate experiments is shown in (A). Bands representing total insulin 
receptor expression (B), the phosphorylation of IR-β (Tyr 1361) (C), phosphorylation 
of Akt (Tyr 308) (D) and phosphorylation of GSK3β (Ser 9) (E) were quantitated by 
densitometry analysis and normalised to β-actin expression. Data from all three 
experiments were plotted as mean ± SD (Tukey’s multiple comparisons test: ns – not 
significant, * P < 0.05, ** P < 0.01, **** P < 0.0001, n = 3).  
 
B 
A 
C 
D E 
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Figure 17. Effect of MBCD and cMBCD treatments on insulin signalling in 
HepG2 cells. Cells were treated for 30 min with 10 mM MBCD or 10 mM cMBCD 
and then for 7 min at 37 °C with 100 nM insulin. Following treatments, the cells 
were lysed in RIPA buffer and Western blot analysis was conducted as detailed in 
Methods, Section 2.2.1.9. One representative Western blot image out of three 
separate experiments is shown in (A). Bands representing total insulin receptor 
expression (B), the phosphorylation of IR-β (Tyr 1361) (C), phosphorylation of Akt 
(Tyr 308) (D) and phosphorylation of GSK3β (Ser 9) (E) were quantitated by 
densitometry analysis and normalised to β-actin expression. Data from all three 
experiments were plotted as mean ± SD (Tukey’s multiple comparisons test: ns – not 
significant, * P < 0.05, ** P < 0.01, **** P < 0.0001, n = 3).  
B C 
A 
D E 
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Figure 18. Effect of MBCD and cMBCD treatments on insulin signalling in 
differentiated myotubes. Differentiated myotubes were treated for 30 min with  
10 mM MBCD or 10 mM cMBCD and then for 7 min at 37 °C with 100 nM 
insulin. Following treatments, myotubes were lysed in RIPA buffer and Western 
blotting analysis was conducted as described in Methods, Section 2.2.1.9. One 
representative Western blot image out of three separate experiments is shown in 
(A). Bands representing total insulin receptor expression (B), the 
phosphorylation of IR-β (pTyr 1361) (C), phosphorylation of Akt (pTyr 308) (D) 
and phosphorylation of GSK3β (Ser 9) (E) were quantitated by densitometry 
analysis and normalised to β-actin expression. Data from all three experiments 
were plotted as mean ± SD (Tukey’s multiple comparisons test: ns-not 
significant, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, n = 3). 
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significant effect was observed in phosphorylation of GSK3β (Fig. 16E). Whilst the 
proportion of phosphorylated insulin receptors was significantly decreased following 
cMBCD treatment (Fig. 16C, P < 0.0001), the amount of pAkt detected was 
substantially increased (Fig. 16D; P < 0.001). As was observed with MBCD 
treatment of CHO T10 cells, there was no corresponding change in the 
phosphorylation of GSK3β (Fig. 16E; P = 0.1) after cMBCD treatment. Thus, there 
does not appear to be a clear link between the decreased autophosphorylation of the 
insulin receptors in CHO T10 cells following treatment with either MBCD or 
cMBCD and its downstream signalling outcomes in Akt and GSK3β 
phosphorylation. Some possible reasons for these somewhat counterintuitive results 
are detailed in the Discussion of this Thesis in section 4.1. 
In contrast to the observations made in CHO T10 cells, there appears to be a clear 
link between the effect of insulin binding and insulin signalling outcomes in both 
HepG2 and differentiated myoblasts (Fig. 17 and 18, respectively).   The proportion 
of insulin receptors that were autophosphorylated decreased significantly when 
HepG2 or differentiated myoblasts were treated with either 10 mM MBCD or 
cMBCD (Fig. 17C and 18C), coinciding well with the decreased insulin binding.  
Moreover, the changes observed in autophosphorylation of the insulin receptor in the 
presence of either MBCD or cMBCD corresponded with the changes observed in the 
expression of either pAkt or pGSK3β in HepG2 cells and myotubes (Fig. 17 and 18).  
The expression of total insulin receptor protein was unaffected in CHO T10, HepG2 
or differentiated myoblasts following treatment with atorvastatin (Fig. 19, 20 and 
21). Whilst decreasing cholesterol levels in CHO T10, HepG2 and differentiated 
myotubes (Fig. 8A - C), atorvastatin treatment did not impact insulin binding to these 
cells (Fig. 15). This finding contrasts with the effect of MBCD in decreasing 
cholesterol levels (Fig. 10A and B), which corresponded with the decreased insulin 
binding to these cells (Table 2). Given that atorvastatin had minimal if any effect on 
insulin binding to these cells in culture, it was expected that it would have little 
impact on the autophosphorylation of insulin receptors and downstream signalling 
pathways. Indeed, atorvastatin treatment of CHO T10 and Hep G2 cells appeared to 
have minimal impact on the activation of their insulin receptors, Akt or GSK3β (Fig. 
19 – 20). On the other hand, atorvastatin did substantially impact 
autophosphorylation of insulin receptors, Akt and GSK3β in differentiated myotubes 
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Figure 19. Effect of atorvastatin on insulin signalling in CHO T10 cells. 
Cells were treated for 48 h with 10 µM atorvastatin and then treated for 7 min at  
37 °C with 100 nM insulin. Following treatments, the cells were lysed in RIPA 
buffer and Western blot analysis was conducted as described in the Methods, 
section 2.2.1.9. One representative Western blot image out of three separate 
experiments is shown in (A). Bands representing total insulin receptor 
expression (B), the phosphorylation of IR-β (Tyr 1361) (C), phosphorylation of 
Akt (Tyr 308) (D) and phosphorylation of GSK3β (Ser 9) (E) were quantitated 
by densitometry analysis and normalised to β-actin expression. Data from all 
three experiments were plotted as mean ± SD (Paired t-test: * P < 0.05, ns – not 
significant, n = 3). 
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Figure 20. Effect of atorvastatin on insulin signalling in HepG2 cells. Cells 
were treated for 48 h with 10 µM atorvastatin and then treated for 7 min at 37 
°C with 100 nM insulin. Following treatments, the cells were lysed in RIPA 
buffer and Western blot analysis was conducted as described in the Methods, 
section 2.2.1.9. One representative Western blot image out of three separate 
experiments is shown in (A). Bands representing total insulin receptor 
expression (B), the phosphorylation of IR-β (Tyr 1361) (C), phosphorylation of 
Akt (Tyr 308) (D) and phosphorylation of GSK3β (Ser 9) (E) were quantitated 
by densitometry analysis and normalised to β-actin expression. Data from all 
three experiments were plotted as mean ± SD (Paired t-test: * P < 0.05, ** P < 
0.01, n = 3). 
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Figure 21. Effect of atorvastatin on insulin signalling in differentiated 
myotubes. Differentiated myotubes Cells were treated for 48 h with 10 µM 
atorvastatin and then treated for 7 min at 37 °C with 100 nM insulin. 
Following treatments, the cells were lysed in RIPA buffer and Western blot 
analysis was conducted as described in the Methods, section 2.2.1.9. One 
representative Western blot image out of three separate experiments is 
shown here (A). Bands representing total insulin receptor expression (B), 
the phosphorylation of IR-β (Tyr 1361) (C), phosphorylation of Akt  
(Thr 308) (D) and phosphorylation of GSK3β (Ser 9) (E) were quantitated 
by densitometry analysis and normalised to β-actin expression. Experiment 
was conducted three times and data from all three experiments were plotted 
as mean ± SD (Paired t-test: * P < 0.05, ** P < 0.01, n = 3).  
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Table 5. A summary of the effects of MBCD, cMBCD or atorvastatin treatment 
on insulin signalling events in cultured cells. 
 
 
The effects of MBCD or cMBCD or atorvastatin treatment on cell cholesterol 
content, insulin binding and affinity, and surface insulin receptor content were 
summarized in this table (     denotes a significant decrease,     denotes a significant 
increase, ‘ ns ‘ denotes no significant change and ‘ * ’ denotes ‘not examined’). 
  
 
 
 
Total IR pIRβ pAKT pGSK3β 
Treatments 
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10 mM MBCD ns ns ns          ns    
10 mM cMBCD ns ns ns          ns    
10 µM Atorvastatin ns ns ns ns     ns      ns     
pIRβ 
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(Fig. 21). A summary of the effects of the MBCD, cMBCD or atorvastatin treatment 
in CHO T10, HepG2 and differentiated myotubes on insulin signalling events is 
shown in Table 5.     
3.2. Effects of a high fat diet and atorvastatin treatment on cholesterol 
content and insulin action in mouse liver 
Mice were fed for 12 weeks with either a normal or high-fat diet in the presence or 
absence of atorvastatin as described in Methods, Sections 2.2.2.1. Whole livers were 
then collected, and various membrane and cytosolic fractions were isolated from the 
tissue samples as described in Methods, Section 2.2.2.2. Each fraction obtained from 
the liver tissue samples was characterized by Western blotting analysis based on the 
presence or absence of characteristic protein markers.  The plasma membrane 
fractions isolated for this study were enriched in Na
+
/K
+
 ATPase and were largely 
free of contamination by mitochondrial (SDHA) and endoplasmic reticulum (KDEL) 
protein markers (Fig. 22). However, the presence of syntaxin-6 in the plasma 
membrane fraction suggests some contamination by golgi membranes. The presence 
of the insulin receptor was found to be significantly higher in the plasma membrane 
fraction compared to all other fractions (Fig.22). Likewise, the specific binding of 
125
I insulin was also highest in the plasma membrane fractions, irrespective of diet 
and atorvastatin treatment (Fig. 23). Taken together, these findings suggest that the 
membrane fraction isolated for this study was highly enriched in plasma membranes 
and that they contained functional insulin receptors that specifically bound insulin.  
The total cholesterol content of liver homogenates was unaffected by high-fat 
feeding (Fig. 24 and 25). Interestingly, and by contrast, atorvastatin treatment 
generally resulted in an increase in cholesterol content in all fractions examined 
including liver homogenate, plasma membrane and cytosolic fractions, reaching 
statistical significance in all but the plasma membrane fraction for mice on a normal 
diet (Fig. 25). In contrast to results on homogenate, there was a substantial decrease 
in the cholesterol content of the plasma membrane and cytosolic fraction of mice that 
were fed a high-fat diet (HFD) (Fig. 24 and 25).  Interestingly, when mice were fed 
the high fat diet and also treated with atorvastatin (HFD-A), the cholesterol content 
of their cytosolic and plasma membrane fractions increased substantially and were  
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Figure 22. Characterization of mouse liver fractions based on specific protein 
markers. Total protein content in liver fractions was estimated using a BCA assay as 
described in the Methods, section 2.2.3.5. Protein (20 µg) was separated by  
SDS-PAGE and Western blot analysis was conducted as described in the Methods, 
section 2.2.3.7. A representative Western blot image illustrating the specific marker-
based characterization of liver fractions is shown here; plasma membrane (PM); 
plasma membrane-associated membrane (PAM); cytoplasm; mitochondria, and 
microsomes. The presence of membrane-specific markers was monitored in each 
fraction: Na
+
/K
+
 - ATPase (plasma membrane marker); succinate dehydrogenase 
(SDHA - mitochondrial membrane marker); endoplasmic reticulum c-terminal 
tetrapeptide (Lys-Asp-Glu-Leu; represented as KDEL) and syntaxin-6 (golgi 
apparatus membrane marker); and the insulin receptor (IR-Total).  
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Figure 23. Specific binding of 
125
I-insulin in mouse liver fractions. Insulin 
binding to liver fractions was determined as described in the Methods, section 
2.2.3.6. In brief, liver fractions were diluted in binding buffer and incubated for 18 h 
at 4°C with approximately 3 pM of 
125
I-insulin in the presence (non-specific binding) 
or absence (total binding) of unlabelled insulin (~20 µM). Specific binding was 
calculated in each fraction from the difference between the total and non-specific 
binding of the 
125
I-insulin. Insulin binding was evaluated in plasma membrane (PM), 
plasma membrane-associated membrane (PAM), cytoplasm, mitochondria and 
microsomes obtained from three randomly selected mice from each group (ND, ND-
A, HFD and HFD-A). The experiment was conducted three times in triplicate and the 
mean values of each fraction obtained from each mouse within the same group were 
pooled, with data shown as mean ± SD (one-way ANOVA: **** P < 0.0001, n = 3). 
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HOMOGENATE PLASMA MEMBRANE 
CYTOSOL MICROSOMES 
Figure 24. Effect of diet and atorvastatin treatment on cholesterol 
content per milligram of protein. Mice were fed for 12 weeks with either a 
normal diet (ND), a high fat diet (HFD), a normal diet whilst treated with 
atorvastatin (ND-A) or a high fat diet whilst treated with atorvastatin (HFD-
A) as described in Methods, section 2.2.3.1.  Livers from each of seven mice 
in each group were individually fractionated as described in Methods, section 
2.2.3.3 and 2.2.3.4. The cholesterol content in each fraction from each mouse 
was then determined in triplicate as described in Methods, section 2.2.3.5 and 
normalised to total protein content.  The data is shown as the mean ± SD of 
cholesterol levels determined from the seven mice in each group.  A Tukey’s 
multiple comparison test was performed to determine the levels of statistical 
difference between groups:  ns – not significant; * P < 0.05 ** P < 0.01;  
*** P < 0.001; **** P < 0.0001. 
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HOMOGENATE PLASMA MEMBRANE 
CYTOSOL MICROSOMES 
Figure 25. Effect of diet and atorvastatin treatments on total cholesterol 
content per gram of liver tissue. Mice were fed for 12 weeks with either a 
normal diet (ND), a high fat diet (HFD), a normal diet whilst treated with 
atorvastatin (ND-A) or a high fat diet whilst treated with atorvastatin (HFD-
A) as described in Methods, section 2.2.3.1.  Livers from each of seven mice 
in each group were individually fractionated as described in Methods, section 
2.2.3.3 and 2.2.3.4. The cholesterol content in each fraction from each mouse 
was then determined in triplicate as described in Methods, section 2.2.3.5 and 
the changes in total cholesterol content were illustrated here.  The data is 
shown as the mean ± SD of cholesterol levels determined from the seven mice 
in each group. A Tukey’s multiple comparison test was performed to 
determine the levels of statistical difference between groups:  ns – not 
significant; **** P < 0.0001. 
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essentially indistinguishable from those fed a normal diet (ND) (Fig. 24 and 25). The 
other notable finding, and in contrast to the observations in plasma membrane and 
cytosolic fractions of mice that were fed a high-fat diet (HFD), was a substantial 
increase in the cholesterol content of the microsomal fraction in HFD group 
compared all other groups (Fig. 24D and 25D). These findings were somewhat 
counterintuitive and unexpected and are discussed in greater detail in the Discussion 
section 4.2 of this Thesis. 
The competitive binding of 
125
I-insulin to plasma membranes isolated from mice that 
were fed a normal or high fat diet and the effect of atorvastatin treatment in each 
group is illustrated in Fig. 26 for each of seven animals in each treatment group (Fig. 
26 A-G). The specific binding of 
125
I-insulin in mice that were fed the high-fat diet 
(HFD) was markedly decreased in the plasma membrane fraction isolated from each 
mouse from that group compared to mice that were fed the normal diet (ND) (Fig 
26).  This appeared to be due to the substantial decrease (P < 0.0001) in membrane 
insulin receptors content in mice that were fed the high fat diet (Fig. 28) and not as a 
consequence of the slight decrease in the affinity of insulin for insulin receptors (Fig. 
26 and Table 6, P < 0.01).  
The effect of the high fat diet in reducing the specific binding of insulin was 
ameliorated in each of the seven mice by atorvastatin treatment (Fig. 26). Analysis of 
the competitive binding data suggest that this recuperative effect is due to an almost 
10-fold increase in affinity of insulin for insulin receptor and at least a 5-fold 
decrease in available insulin receptors (Table 6). Perhaps, atorvastatin recruits a 
small class of high affinity receptors to the plasma membranes in the mice fed a high 
fat diet.  Alternatively, as eluded to previously when evaluating insulin binding in the 
cell culture models used in this study, the binding model used to analyse the data 
may not adequately describe the data. Indeed, Western blot analysis clearly illustrates 
that atorvastatin most likely ameliorates the loss of insulin binding in mice that were 
fed a high-fat diet by increasing the number of insulin receptors available to bind 
insulin (Fig. 28). Whilst atorvastatin ameliorated the loss of insulin binding in 
plasma membranes from mice fed a high fat diet, it is notable that atorvastatin had 
little effect on the specific binding of insulin receptors in any of the seven mice that 
were fed the normal diet (Fig. 26). Indeed, compared to the control (ND) group, no 
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Figure 26. Effect of diet and atorvastatin treatments on the competitive binding 
of 
125
I-insulin to plasma membranes obtained from mouse liver. Plasma 
membranes were individually isolated from livers of mice that were fed either a 
normal diet (ND, n=7,  ), a normal diet whilst simultaneously being treated for 12 
weeks with atorvastatin (ND-A, n=7,       ); a high-fat diet (HFD, n=7,  ), or a 
high-fat diet whilst simultaneously being treated for 12 weeks with atorvastatin 
(HFD-A, n=7, ), as described in detail in Methods, section 2.2.2.2. The binding of 
125
I-insulin to the membranes isolated from each animal was determined as described 
in Methods, section 2.2.2.6. Each competitive displacement curve was fitted to a one-
sit fit model using GraphPad PRISM
®
. The binding data for one of the seven animals 
from each of the four groups is shown in each plot (A to G). Each data point in each 
plot is a mean of duplicate determinations. 
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Table 6. Effect of diet and atorvastatin treatments on insulin binding 
parameters in plasma membrane isolated from mice liver tissue.  
 
 
 
 
 
 
 
The affinity (KD) values and receptor numbers in each of the treatments were 
determined from the competitive binding plots shown in Fig. 27 using a one-site fit 
model. 
 
The data shown as the mean ± SD of data obtained from the seven animals 
for each treatment group. Statistical analyses, as shown below, was conducted using 
ANOVA - Tukey’s multiple comparison test. 
 
Affinity (KD)                 Receptor number  
ND vs ND-A, ns- not significant, P = 0.3     ND vs ND-A, P = 0.1, ns 
ND vs HFD, ** P < 0.01                               ND vs HFD, ***P < 0.001 
ND-A vs HFD-A, ****P < 0.0001               ND-A vs HFD-A, ****P < 0.0001 
HFD vs HFD-A, ****P < 0.0001                 HFD vs HFD-A, ****P < 0.0001 
 
 
 
  
Treatment  
groups  
Affinity (KD) 
(nM) 
Receptor number per mg 
of plasma membrane 
protein ( X 10
9
) 
 
ND 
 
6.9 ± 0.8  
 
1.3 ± 0.2 
ND-A         6.1 ± 0.4  1.03  ± 0.07 
HFD 
 
9.4 ± 0.9 
0.57  ± 0.04 
HFD-A 0.9 ± 0.3 0.09  ± 0.03 
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significant difference could be observed in either the affinity (P = 0.3) of insulin 
receptors for insulin or in the number of insulin receptors present per mg of 
membrane protein (P = 0.1) in mice that were fed the normal diet and treated with 
atorvastatin (ND-A). In context of the influence of membrane cholesterol content on 
insulin binding, treatment of liver plasma membranes of mice that were fed a normal 
diet, with 10 mM MBCD or cMBCD, also decreased insulin binding to these 
membranes (Fig. 27), in a manner similar to that observed in cultured cells and 
VLPs. This is interesting because unlike cultured cells, purified plasma membranes 
and VLPs lack a cytoplasmic organization to account for the possibility of receptor 
internalization or recycling process. Thus, it may suggest that the observed decrease 
in insulin binding following changes in membrane cholesterol may not be due to a 
decrease in the apparent number of receptors present in the membrane but could 
likely be due to a decrease in the availability of these receptors for the binding of 
insulin or antibodies directed towards their extracellular domains. This point is 
further expanded in the Discussion, section 4.1. 
The influences of diet and atorvastatin on insulin receptor expression and its 
phosphorylation in the plasma membrane fraction, and, Akt and GSK3β 
phosphorylation in the cytosolic fraction were assessed by Western blot analysis. It is 
clear from Fig. 28 that both diet and statin treatment influenced the apparent total 
insulin receptor content in the plasma membrane fraction and its phosphorylation. 
Insulin receptor expression and its phosphorylation were decreased substantially in 
mice that were fed the high-fat diet (HFD), compared to mice that were fed a normal 
diet (ND) (Fig. 28). The decrease in insulin receptor number and phosphorylation in 
the plasma membrane observed in high-fat diet feeding was recovered by atorvastatin 
treatment; compared to the HFD group, ~ 2-fold and 4-fold increases in insulin 
receptor expression and phosphorylation, respectively, were observed in the HFD-A 
group (Fig. 28). These results are consistent with the observations from the binding 
analysis (Fig. 27). Atorvastatin treatment had no such effect on mice that were fed 
the normal diet, with the insulin receptor expression and its phosphorylation being 
very similar in the ND-A and ND groups. No difference was observed in total Akt 
expression across all four treatments (Fig. 29B) as a function of diet and/or 
atorvastatin treatment. However, total GSK3β expression varied significantly 
between the treatment groups (Fig. 29E). While there was no effect of high-fat diet 
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Figure 27. Effect of MBCD or cMBCD treatment on insulin binding to 
plasma membranes obtained from mouse liver. Plasma membranes were 
isolated from liver tissues of mice that were fed a normal diet (ND) for 12 weeks 
as described in Methods, section 2.2.3.4.  Membranes were treated with either 10 
mM MBCD or cMBCD for 30 min at room temperature (~ 23°C) and insulin 
binding assay was conducted as described in Methods, section 2.2.2.6. Total 
protein content of the membranes following treatment with either MBCD or 
cMBCD was determined using a BCA assay as described in section 2.2.3.5. The 
experiment was conducted two times in triplicate using membranes from a 
different mice in every instance but only one representative data-set is illustrated 
as mean ± SD (n = 3). Data from both the experiments was considered for 
statistical analysis (Dunnett’s multiple comparisons test: * P < 0.05, **P < 0.01). 
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Figure 28. Effect of diet and atorvastatin treatments in mice on membrane 
insulin receptor content and its phosphorylation status. Plasma membrane 
fractions from liver tissue were isolated from mice that fed either a normal diet (ND) 
or a high fat diet (HFD) or a normal diet whilst treated for 12 weeks with atorvastatin 
(ND-A) or a high fat diet whilst treated for 12 weeks with atorvastatin (HFD-A) as 
described in Methods, section 2.2.3.4.  Total protein content in each fraction was 
determined using a BCA assay as described in section 2.2.3.5. Total membrane 
protein (20 µg) was separated using SDS-PAGE and Western blot analysis was 
conducted as described in section 2.2.3.7. A representative Western blot image is 
shown in (A). Bands representing total insulin receptor content (B) and its 
phosphorylation status (Tyr 1361) (C), were quantitated by densitometry analysis and 
normalised to Na
+
/K
+
 - ATPase expression. The ratio of phosphorylated insulin 
receptor-β to total insulin receptor is shown in (D).  Data shown as mean ± SD is 
from seven separate experiments conducted for all the animals in each group 
(Tukey’s multiple comparisons test: ns – not significant, **** P < 0.0001, n = 7 
animals per group). 
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Figure 29. Effects of diet and statin treatment on Akt and glycogen synthase 
kinase 3β (GSK3β) phosphorylation. Cytosolic fractions were isolated from mice 
that were fed for 12 weeks either a normal diet (ND), a high fat diet (HFD), a normal 
diet whilst treated with atorvastatin (ND-A) or a high fat diet whilst treated with 
atorvastatin (HFD-A) as described in Methods, section 2.2.3.4. Total protein content 
in liver cytosolic fractions was estimated by BCA assay as described in section 
2.2.3.5 and 25 µg of total cytosolic protein was separated using SDS-PAGE and 
Western blot analysis was conducted as described in section 2.2.3.7. One 
representative Western blot image out of seven experiments is shown in (A).  Bands 
representing total (B) and phosphorylated (Thr 308) Akt (C), and total (E) 
phosphorylated (Ser 9) GSK3β (F) were quantitated by densitometry analysis and 
normalised to GAPDH expression. The ratios of phosphorylation of Akt and GSK3β 
to total Akt and GSK3β are shown in D and G. Data shown as mean ± SD is from 
seven separate experiments conducted for all the animals in each group (Tukey’s 
multiple comparisons test: ns – not significant, * P < 0.05, ** P < 0.01,  
**** P < 0.0001, n = 7 animals per group).  
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on Akt phosphorylation, a diet-dependent effect of atorvastatin was observed. A 
substantial decrease or increase in Akt phosphorylation was observed in mice treated 
with atorvastatin and fed the normal (ND-A) or high-fat diet (HFD-A), respectively 
(Fig. 29C). In contrast to Akt expression, total GSK3β expression decreased 
substantially as a result of high-fat diet and atorvastatin treatment (Fig. 29E). The 
decreases observed in total GSK3β as a result of diet and atorvastatin treatment 
almost mirrored the phosphorylation of GSK3β (Fig.  29F). The clear disconnect 
between the changes in phosphorylation of the insulin receptors and the effects on 
subsequent phosphorylation of Akt and GSK 3β is expanded in the Discussion 
sections 4.1 and 4.2 of this Thesis. 
3.3. Development and characterization of virus-like particles as a novel 
membrane model to study the influence of membrane cholesterol on 
insulin binding  
The cell and animal studies in this Thesis suggest a correlation between cell 
cholesterol content, insulin binding, and signalling. To complement these studies, the 
interaction of insulin with its receptor was studied in a novel membrane model, 
known as virus-like particles (VLPs). VLPs were generated from CHO K1 cells3 
[189], and CHO-T10 cells, which were derived from CHO K1 cells transfected with 
a mammalian transfection vector for insulin receptor-A overexpression as described 
in the Methods, Section 2.2.3.1.  Since VLPs are generated from the cell membrane 
and are largely free of cellular components, they enable the interaction of insulin 
with its insulin receptor to be studied in a more “controlled” membrane environment.  
In particular, the influence of membrane cholesterol on the interaction of insulin with 
its receptor can be readily evaluated by treating the VLP membranes with either 
MBCD or cMBCD.  Other advantages of using VLPs include their longer shelf-life 
and they eliminate the requirement of growing cells in culture under aseptic 
conditions. 
The morphology of the VLPs extruded from the CHO-T10 cells was evaluated using 
both dynamic light scattering (DLS) and field emission scanning electron 
microscopy (FE-SEM) methods (Fig. 30A and 30B respectively). The dynamic light 
scattering (DLS) profile of VLPs derived from CHO T10 cells was consistent with 
                                                             
3
 CHO K1 cells were originally developed from a biopsy of an ovary of an adult Chinese hamster. 
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the presence of particles that were highly uniform in both size and shape (Fig 30A). 
The VLP particles were estimated to have an average diameter of ~159 nm. The 
narrow peak with polydispersity index (PDI) value of 0.332 observed in the DLS 
profile of VLPs indicates uniformity in size distribution of the particles and presence 
of minimal aggregates (Fig. 30A). The second peak towards the far right may 
indicate the presence of larger membrane fragments; however, larger particles scatter 
more light and therefore a small amount of them may be sufficient to result in the 
peak observed [190]. Field Emission - Scanning Electron Microscopy (FE-SEM) 
analysis of these VLPs confirmed the presence of uniform spherical particles with a 
diameter ranging from 140 – 150 nm (Fig. 30B).  
Interestingly, the recovery of 
125
I-insulin specific binding in the VLPs generated 
from CHO T10 cells was improved up to 3-fold (Fig. 31) by treating the cells with 
100 nM insulin for approximately 18 h post-transfection of the cells with the 
lentiviral-Gag protein, as described in Methods section 2.2.3.1. This finding is not 
surprising as insulin receptors, when activated, accumulate to lipid-rafts [49, 191, 
192]. Also, the multimerized-lentiviral-Gag protein in the cell egresses the cell by 
membrane fission (a process known as viral budding) in the lipid-raft region of the 
plasma membrane [193-195]. Thus, the co-occurrence of insulin receptor 
accumulation and VLP generation in the lipid-raft regions of the membrane may 
collectively lead to the increased recovery of insulin receptors in VLPs. This 
treatment of cells for 24 h with 100 nM insulin, post-transfection of cells with the 
lentiviral-Gag protein, was included for VLP generation in the current study.  
However, great care was taken to ensure that the VLPs were thoroughly washed to 
minimize the amount of free insulin that might carry over in the procedure as 
contaminating insulin would interfere with interpretation of the subsequent insulin 
binding study. The concentration of insulin in the VLP preparations at the dilution 
used for the competition binding study was estimated by ELISA to be about 5 pM. 
This residual concentration of insulin in the VLP preparations was accounted for 
during competitive binding analysis. 
The comparison of insulin binding to CHO K1 and CHO T10 cells is shown in Fig. 
32. As expected, the specific binding of 
125
I-insulin to CHO T10 cells far exceeded 
that of the wild-type CHO K1 cells (Fig. 32). Based on a single-site fit to the data, 
CHO T10 cells expressed approximately 280-fold more receptors per cell than CHO  
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A 
B 
Figure 30. Morphological characterization of VLPs. A representative 
dynamic light scattering (DLS) profile of VLPs derived from CHO T10 
cells is illustrated in caption (A) and depicts the intensity size distribution 
plot (average of three measurements) Z- Average diameter – 158.6 nm; 
Polydispersity Index (PDI) – 0.332. A field emission-scanning electron 
microscopy image of a formalin-fixed virus-like particle (VLP) derived 
from CHO T10 cells is shown (B). Scale bar: 200 nm.  
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Figure 31. Influence of insulin pre-treatment of parental on insulin binding to 
generated VLPs. CHO T10 cells were transfected with the lenti-viral Gag protein as 
described in the Methods, section 2.2.3.1. After 24 h from transfection, the cells were 
cultured for 24 h with fresh RPMI media containing 0, 0.1, 1, 10 or 100 nM insulin. 
VLPs were harvested and insulin binding studies were conducted as described in the 
Methods, sections 2.2.3.1 and 2.2.3.4, respectively 
4
. The experiment was conducted 
three times in triplicate but only one representative data set is illustrated as mean ± 
SD (n=3). 
  
                                                             
4 The increases in 125I insulin specific binding to VLPs in response to insulin stimulations in cells 
whilst generating VLPs were fitted to a one-site saturation binding curve. However, this fit to data is 
only used to demonstrate the significance of the increase in insulin binding as a function of the insulin 
concentration used to pre-treat the cells and not for binding saturation analysis. 
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K1 cells (Table 7). Interestingly, however, the affinity of insulin receptors in CHO 
K1 cells was estimated to be about 5-fold higher than in CHO T10 cells (Table 7). 
This can also be visually observed by the clear rightward shift of the CHO T10 
binding curve in Fig. 32. The binding of insulin to VLPs generated from CHO K1 
and CHO-T10 cells is compared relative to their corresponding parental cell lines in 
Fig. 33. It is notable that the insulin binding curves for the parental cells and the 
corresponding VLPs generated from them are indistinguishable and this is reflected 
in the calculated affinity values for each parental cell and the derived VLPs (Fig. 33, 
Table 7). However, as was observed with the parental cell lines, there was about 5-
fold higher affinity of insulin receptors in VLPs derived from CHO K1 cells relative 
to those derived from CHO-T10 cells (Table 7).  
Quantitation of insulin receptor expression by Western blots of parental cell lysates 
(Fig. 34) and derived VLPs (Fig.35) generated from the cells generally supports the 
findings based on the competitive binding studies; more insulin receptors were 
detected in the CHO T10 cells than in the CHO K1 cells. However, the expression of 
insulin receptors in VLPs was surprisingly similar irrespective of whether the VLPs 
were generated from the CHO T10 or CHO K1 cell lines (Fig. 35). This is quite a 
remarkable observation given that the parental CHO K1 cell line expresses just a few 
percent of the insulin receptors that are expressed in the CHO T10 cell line (Table 7). 
It is evident from Fig. 35 that a large amount of insulin receptors still remain after 
VLP generation in the remaining CHO T10 cell matter, whereas insulin receptor 
content in the remainder CHO K1 cell matter appears to be essentially undetectable. 
As estimated by binding analysis, only about 2% of the insulin receptor population 
was captured in the VLPs generated from CHO T10 cells, whereas 105% (i.e. the 
entire insulin receptor population) was captured in the VLPs generated from the 
CHO K1 cells (Table 7).  The possible reasons for the above somewhat surprising 
observations are detailed in the Discussion section 4.3 of this Thesis. 
The effects of alterations in cholesterol content in CHO K1 and CHO T10 cells and 
VLPs generated from these cells on insulin binding were estimated. Similar to the 
observations in other cell culture studies, alterations in membrane cholesterol 
following treatment with either 10 mM MBCD (reduction) or cMBCD (enrichment) 
(Fig. 36) resulted in a significant decrease in insulin binding (Fig. 37). These results  
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Figure 32. The competitive binding of 
125
I-insulin to CHO K1 and CHO T10 cells.  
Competitive binding assays were conducted in wild-type CHO K1 ( ) cells and 
CHO T10 (over-expressing the A-isoform of human insulin receptors) (  ) cells as 
described in Methods, Sections 2.2.1.7 and 2.2.3.4. Briefly, cells were incubated for 
18 h at 4 °C with a single concentration of 
125
I-insulin (~ 3 pM) and a wide range of 
competing unlabelled insulin (0 to 20.6 μM). The binding of 125I-insulin to the VLPs 
was non-linearly fitted to a one-site model using GraphPad PRISM
®
. The binding 
curve for CHO K1 cells is expanded in the inset to the figure. The experiment was 
conducted three times in duplicate but only one representative data set is illustrated, 
with each data point shown as the mean of duplicate determinations. 
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Figure 33. The competitive binding of 125I-insulin to CHO K1 and CHO T10 
cells and the VLPs generated from both parental cell lines. CHO K1 (A) and 
CHO T10 (B) cells ( ) and derived VLPs ( ) were incubated for 18 h at 4 °C 
with a single concentration of 
125
I-insulin (~ 3 pM) and a wide range of competing 
unlabelled insulin (0 to 20.6 μM) as described in Methods, section 2.2.3.4. The 
binding of 
125
I-insulin was non-linearly fitted to a one-site model using GraphPad 
PRISM
®
. The experiment was conducted three times in duplicate but only one 
representative data set is illustrated, with each data point shown as the mean of 
duplicate determinations. Statistical comparisons for affinity values were based on 
the data pooled from the three separate experiments (CHO K1 cells vs VLPs derived 
from CHO K1 cells, P = 0.1, CHO T10 cells vs VLPs derived CHO T10 cells, P = 
0.2, see Table 7). 
 
A 
B 
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Table 7. Insulin receptor number and affinity estimates in parental cells and 
derived VLPs based on competitive binding analysis. 
The estimates of affinity and receptor number are based on a one-site fit of the data 
shown in Fig. 32. *For the parental cells, the reported affinity and receptor number 
are based on the basal state of expression, i.e., receptor expression prior to 
transfection of the parental cells for VLP generation. 
# 
The estimates on receptor 
recovery in the VLPs were calculated using receptor number per seeded parental 
cells, i.e., receptor number in parental cells prior to transfection for VLP generation.  
 
  
 
CHO K1 CHO T10 
 
 
Cells  VLPs Cells VLPs 
 
Affinity  
KD (nM) 
 
0.5 
(± 0.1)* 
 
0.4 
(± 0.1) 
 
 
2.3 
(± 0.4)* 
 
2.1 
(± 0.4)
 
 
Receptor per cell 
or 
Receptors in VLPs 
per cell 
1926 
(± 311)* 
2021 
(± 412)
#
 
541625 
(± 11032)* 
10957 
(± 1403)
#
 
% Yield in VLPs
#
 - 105 - 2 
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Figure 34. Insulin receptor expression in CHO K1 and CHO T10 cells prior to 
VLP generation. Cells were grown and whole cell lysates were collected for 
Western blot analyses as described in Methods, Section 2.2.3.7. A representative 
Western blot image highlighting the expression of total insulin receptor (IR-Total) 
and corresponding glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is shown 
in (A). Bands representing the expression of insulin receptors were quantitated by 
densitometric analysis and normalised to GAPDH expression. The experiment was 
conducted three times and data from all three experiments is shown as mean ± SD 
(B) (Unpaired t-test: *** P = 0.0003, n = 3).  
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B 
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Figure 35. Insulin receptor expression in VLPs and remainder parental cells 
after VLP generation. VLPs and remainder cells
5
, post-VLP generation, were lysed 
and samples were processed for Western blot analysis for the detection of total 
insulin receptors (IR-Total), retroviral core protein (Gag p30), glyceraldehyde 3-
phosphate dehydrogenase (GAPDH-cytosolic marker) and sodium/potassium 
ATPase (Na+/K+ ATPase-plasma membrane marker), as described in the Methods, 
section 2.2.3.7. One representative Western blot image out of three separate 
experiments is shown.  
  
                                                             
5 The ‘remainder cells’ includes cell matter of CHO T10 and CHO K1 cells that were left over after 
VLP generation. 
A 
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Figure 36. Effect of MBCD or cMBCD treatment on cholesterol content of CHO 
cells. CHO K1 (A) and CHO T10 cells (B) were treated for 30 min at room 
temperature with 10 mM MBCD or cMBCD. Total cholesterol and proteins were 
measured as described in Methods, Section 2.2.3.6. The experiment was conducted 
three times in triplicate but only one representative data-set is illustrated as mean ± 
SD (n = 3). Data from all three experiments was used for statistical analysis 
(Dunnett’s multiple comparisons test: ** P < 0.01, *** P < 0.001, **** P < 0.0001,  
n = 9). 
A 
B 
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Figure 37. Effect of MBCD or cMBCD treatment on insulin binding to CHO 
cells. CHO K1 (A) and CHO T10 (B) cells were treated for 30 min at room 
temperature with MBCD or cMBCD and specific binding of 
125
I-insulin was 
estimated. Following treatments, the cells were incubated for 18 h 4 °C with 
125
I-
insulin (approximately 3 pM) either in the absence (total) or presence of competing 
unlabelled insulin (20.6 μM) (non-specific binding). Specific binding of 125I insulin 
was calculated from the difference between total and non-specific binding. The 
experiment was conducted three times in triplicate but only one representative data-
set is illustrated as mean ± SD (n = 3). Data from all three experiments is considered 
for statistical analysis (Dunnett’s multiple comparison test: **** P < 0.0001, n = 9). 
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Figure 38. Effect of MBCD or cMBCD treatment on cholesterol content of 
VLPs. VLPs derived from CHO K1 (A) and CHO T10 cells (B) were treated for 30 
min at room temperature with 10 mM MBCD or cMBCD. Following treatments, 
Total cholesterol and protein were measured as described in Methods, Section 
2.2.3.6. The experiment was conducted three times in triplicate but only one 
representative data-set is illustrated as mean ± SD (n = 3). Data from all three 
experiments was considered for statistical analysis (Dunnett’s multiple comparisons 
test: * P < 0.05, ** P < 0.01, **** P < 0.0001, n = 9). 
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Figure 39. Effects of MBCD or cMBCD treatment on insulin binding in VLPs 
derived from CHO cells. VLPs derived from CHO K1 (A) and CHO T10 (B) cells 
were treated for 30 min at room temperature with MBCD or cMBCD. Following 
treatments, VLPs were incubated for 18 h 4 °C with 
125
I insulin (approximately  
3 pM) either in the absence (total) or presence of competing unlabelled insulin  
(20.6 μM) (non-specific binding). Specific binding of 125I insulin was calculated 
from the difference between total and non-specific binding. The experiment was 
conducted three times in triplicates but only one representative data-set is illustrated 
as mean ± SD (n = 3). Data from all three experiments was considered for statistical 
analysis (Dunnett’s multiple comparisons test: **** P < 0.0001, n = 9). 
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in CHO K1 and CHO T10 were closely mirrored in the VLPs generated from either 
the CHO T10 or CHO K1 cells (Fig. 38 and 39). This indicates that VLPs retain 
important properties of the plasma membrane of their parental cells and might serve 
as a valuable tool for receptor-ligand interaction studies in a native membrane 
environment.  
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4.0. DISCUSSION  
4.1. Effects of cyclodextrins and statins on cholesterol content and insulin 
action in cultured cells 
 
Effect of MBCD or cMBCD on insulin binding 
Decreasing or increasing cholesterol content in CHO T10 cells, HepG2 cells and 
differentiated myotubes (HSMMs) using either MBCD (methyl-β-cyclodextrin) or 
cMBCD (cholesterol-loaded MBCD) significantly decreased insulin binding to the 
cells (Fig. 8A – C). In line with this observation, binding of  epidermal growth factor 
(EGF) to its receptor (EGFR), is also influenced by cholesterol content; increasing 
following cholesterol reduction and decreasing following cholesterol enrichment 
using MBCD and cMBCD, respectively [196]. In other but less directly comparable 
studies, i.e., not examining ligand binding, the activation of several other growth 
factor receptors such as insulin-like growth factor receptor (IGF-1R) and vascular 
endothelial growth factor receptor (VEGF-R), and their subsequent signal 
propagation are also impaired by reduction in membrane cholesterol content [197, 
198]. Thus, the present study adds to the evidence that plasma membrane cholesterol 
influences ligand binding to membrane receptor systems and suggests that, for the 
insulin receptor at least, there is an optimal cholesterol concentration in cells required 
for maximal insulin binding with either an increase or decrease of cholesterol in 
CHO T10, HepG2 or differentiated myotubes impairing binding. 
Contrary to the findings in the current study, membrane cholesterol depletion by 
MBCD in primary rat adipocytes was reported to have no effect on insulin binding 
[199]. However, the binding data collected in that study were pooled from three 
experiments without differentiating data points between the different experiments. 
Due to significant experimental variation, it is difficult to support the authors’ 
conclusion that cholesterol depletion in primary adipocytes does not affect insulin 
binding. It should also be noted that the binding experiments, in that study, were 
conducted at 37 °C, where ligand-induced receptor internalization and degradation of 
receptors can more readily occur [200], which further complicates the interpretation 
of their binding studies. By contrast, in the present study, the equilibrium of binding 
was measured at 4 °C to minimize the influence of receptor internalization and 
degradation on binding [201]. It is possible that the difference in observations 
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between the former and current studies may relate to cell specific differences. 
However, this is considered unlikely, given that in the present study insulin binding 
decreased with changes in cholesterol content by MBCD or cMBCD treatment in 
three different cell types. It will be interesting to further evaluate the effect of MBCD 
and cMBCD on insulin binding to primary adipocytes and other adipocyte cell 
culture models such as 3T3-L1 pre-adipocytes to investigate possible cell type-
specific differences.  
The decrease in insulin binding following treatment with either MBCD or cMBCD is 
most likely due to changes in plasma membrane cholesterol and not to changes in 
intracellular cholesterol levels. MBCD preferentially associates with the plasma 
membrane to alter its cholesterol content [139, 143, 202] and the majority of free 
cholesterol in most cells resides in the plasma membrane [118, 203]. MBCD 
primarily alters cholesterol content in plasma membranes, whilst minimally affecting 
the intracellular cholesterol content and other membrane lipids [142, 144, 204].  
The decrease in insulin binding following treatment with either MBCD or cMBCD 
does not appear to be due to secondary effects of either treatment; that is, due to 
MBCD per se rather than its ability to extract or deliver cholesterol from or to the 
cell membrane, respectively. Indeed, when CHO T10 cells were sequentially 
cholesterol depleted using MBCD and then subsequently cholesterol replenished 
using cMBCD, both cholesterol content and insulin binding approached levels that 
were observed in the untreated cells (Fig. 14A and B). Thus, it is clear from this 
observation that the changes in insulin binding are directly linked with the changes in 
plasma membrane cholesterol content and not due to some secondary effects of 
MBCD or cMBCD treatment. Furthermore, insulin binding improved in CHO T10, 
HepG2 cells and differentiated myotubes (Fig. 13A - C) when they were allowed to 
“naturally” recover, by incubating for a 24 h period in media supplemented with  
10% fetal bovine serum but free from MBCD or cMBCD. It is notable that the 
restoration in insulin binding was accompanied by restoration in cholesterol content 
in the recovery period following MBCD or cMBCD treatment (Fig. 12 and 13).  
The decrease observed in insulin binding in CHO T10 and HepG2 cells following 
treatment with either MBCD or cMBCD (Fig. 8A and B) appears to be due to a 
decrease in the availability or accessibility of insulin receptors at the surface of the 
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cells as demonstrated by immunostaining and flow cytometry (Fig. 11). Detailed 
competitive binding analysis also confirmed the decrease in insulin binding and the 
consequent decrease in the estimates of apparent receptor number in CHO T10 and 
HepG2 cells following treatment with either 10 mM MBCD or 10 mM cMBCD (Fig. 
10A, Table 2). There was no evidence that the affinity of insulin for its receptor 
changed following these treatments in CHO T10 and HepG2 cells. Thus, both 
detection of insulin receptors by flow cytometry and analysis by competitive binding 
plots confirmed that the decreased binding of insulin as cholesterol levels was altered 
in cells, was due to the decreased availability or accessibility of insulin receptors at 
the surface of the cells. 
The apparent decrease in insulin receptor number detected at the surface of cells 
following treatment with either MBCD or cMBCD cannot be explained by the 
process of receptor internalization because the binding of insulin to plasma 
membrane purified from mouse liver also decreased following treatment with either 
MBCD or cMBCD (Fig. 27). Furthermore, virus-like particles (VLPs), which are 
unable to internalize receptors, as they lack the cell cytoplasmic component [54], 
also have their binding of insulin significantly reduced following treatment with 
either MBCD or cMBCD (Fig. 39), and in a manner that mirrored the observations in 
CHO K1 and CHO T10 cells (Fig. 37) from which the VLPs were generated.  
One possible explanation for the observed decrease in insulin or antibody binding to 
the insulin receptors in the present study is that the changes in membrane cholesterol 
content by MBCD or cMBCD treatment could influence the disposition of insulin 
receptors in the membrane and subsequently limit their access to insulin. Indeed, 
such a scenario is observed with EGFR, which is localized in non-caveolar or 
caveolar raft regions, respectively, in the membrane following membrane cholesterol 
reduction or enrichment [196, 205]. Authors to the latter studies postulated that the 
increased probability of EGF-EGFR interactions results from the increased 
opportunity for EGFR dimerization favoured by the redistribution of the EGFR into 
non-caveolar regions of the plasma membrane following treatment with MBCD. 
However, it is difficult to explain the effect of MBCD or cMBCD on insulin binding 
and the availability of insulin receptors based on this postulate since insulin receptors 
are pre-formed, disulphide linked, dimers [206].  
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Another possible explanation for the effect of MBCD or cMBCD treatment on 
insulin binding and receptor “availability” is that the insulin receptors may associate 
with other membrane-associated protein(s) as it localizes in or out of the lipid-raft 
regions of the membrane. Indeed, the insulin receptor is known to interact with 
several other membrane-associated proteins [49, 207]. The localization of insulin 
receptors in caveloae is known to be crucial for its activation and signal propagation 
since disruption of caveolar invaginations by cyclodextrin treatment attenuates 
insulin receptor signalling [208], as also described in later discussion. Indeed, 
caveolin-1, a major structural protein of caveolae directly interacts with the insulin 
receptor, likely in the region containing amino acid residues 1175 – 1192 of the 
insulin receptor enhancing its tyrosine kinase activity [209]. As another example and 
by contrast, the interaction of the α-subunit of the insulin receptor with another 
transmembrane protein, plasma cell membrane glycoprotein (PC-1) decreases the 
insulin receptor’s tyrosine kinase activity [207]. However, there is yet no direct 
evidence for the effect of these membrane proteins on insulin binding capacity of the 
insulin receptor. A study in our laboratory (David J Chandler, unpublished honours 
thesis, 2000) however, concluded that a “modulator” of insulin binding was removed 
from the insulin receptor during purification on insulin-agarose columns, but that this 
“modulator” was not PC-1.   
Finally, the decrease in insulin binding or receptor availability following membrane 
cholesterol alterations could be related to the formation of insulin receptor clusters in 
various membrane micro-domains. The plasma membrane is organised into a number 
of sub-domains including the well-defined lipid rafts and membrane invaginations 
such as caveloae (consists of scaffolding protein, caveolin) and clathrin-coated pits 
[210]. For example, and in context of another tyrosine kinase receptor, disruption of 
these structures by membrane cholesterol depletion using MBCD results in the 
clustering of EGFR receptors to non-raft regions of the cell membrane and ligand-
independent activation [211]. This is distinct from the concept previously described 
for EGFR concerning movement between caveolar and non-caveolar regions in the 
membrane. Given the evidence that insulin receptors, either in the presence or 
absence of insulin, tend to form clusters [212], which could decrease insulin binding 
[213], it would be interesting in future to likewise explore the organization of insulin 
receptors in both membrane raft and non-raft regions in membrane cholesterol 
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reduced or enriched conditions using super resolution imaging methods such as 
single molecule localization microscopy (SMLM) [212].  
Effects of MBCD or cMBCD on insulin signalling 
The decrease in insulin binding in HepG2 cells (Fig. 10B) and differentiated 
myotubes (Fig. 11C) following MBCD or cMBCD treatment coincided well with 
decreases in insulin stimulated phosphorylation of the insulin receptor, Akt and 
GSK3β (Fig. 17 and 18, respectively). As mentioned previously, changes in plasma 
membrane cholesterol content have also been shown to impair the activation of other 
growth factor/tyrosine kinase receptors such as the vascular endothelial growth factor 
receptor (VEGF-R) and nerve growth factor receptor (NGF-R) and their downstream 
signalling pathways [198, 214]. Ligand binding studies weren’t conducted in the 
latter studies; therefore whether the effects observed were due to decreased binding 
or more distal events in receptor activation or signalling pathway hasn’t been studied 
and thus remains unclear.  
The link between decreased insulin binding and signalling events in HepG2 cells and 
differentiated myotubes following MBCD or cMBCD treatment was not observed in 
CHO T10 cells (Fig. 16). While a decrease in the autophosphorylation of the insulin 
receptors was observed in CHO T10 cells treated with both MBCD and cMBCD, Akt 
phosphorylation decreased following MBCD treatment but increased markedly 
following cMBCD treatment (Fig. 16D). Whilst it has been previously demonstrated 
that the disruption of lipid-rafts structures in the membrane by MBCD-mediated 
membrane cholesterol depletion impairs the full activation of Akt in response to 
other growth factor receptor signalling such as for IGF-1 [215, 216], the impact of 
cholesterol enrichment in the membrane on the integrity of lipid-raft structures, and 
subsequently, on Akt activity is unclear. Furthermore, no apparent change in GSK3β 
phosphorylation was observed following either MBCD or cMBCD treatment of CHO 
T10 cells, despite the apparent decrease in insulin receptor autophosphorylation (Fig. 
16E). The observed disconnect between the autophosphorylation of the insulin 
receptors and Akt and GSK3β activities, which form a part of the ‘metabolic 
pathway’ of insulin signalling, might in part be explained by the predominant 
expression of the A-isoform of the insulin receptor in CHO T10 cells. The A-isoform 
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of the insulin receptors is of more importance to the regulation of the ‘mitogenic 
pathway’ of insulin signalling [28, 217, 218].  
Another possibility for the apparent disconnect between insulin binding and 
signalling or action in CHO T10 cells, in particular, could be a lack of an adequate 
number of appropriate lipid-raft structures to accommodate the majority of 
overexpressed receptors on the surface of CHO T10 cells. The localization of the 
insulin receptor in these lipid-raft regions of the membrane is a key step in receptor 
activation and subsequent signal propagation [49, 191, 192]. That the majority of the 
insulin receptors are not located in these lipid-rafts in CHO T10 cells is supported by 
the observations in virus-like particles (VLPs) generated from CHO T10 and CHO 
K1 (wild-type) cells, detailed in section 3.3. Briefly, only 2% of the total insulin 
receptors expressed in CHO T10 cells were recovered in the VLPs (Table 7), the 
formation of which have an absolute requirement for lipid rafts [219, 220]. In future, 
it will be interesting to study the distribution of insulin receptors in various 
membrane micro-domains in CHO T10 cells and other insulin-sensitive cell types 
and how changes in membrane cholesterol content affect the distribution of insulin 
receptors. 
It is possible that changes in membrane cholesterol content in CHO T10 cells could 
have a direct effect on the activation of Akt, since this event occurs in close 
proximity to the membrane and involves membrane-associated mediators [221]. 
Indeed, the rapid activation of Akt by phosphorylation, in response to growth factor 
signalling, involves the association of Akt with lipid-raft domains of the plasma 
membrane, and thus, the disruption of lipid-raft structures using MBCD may impair 
the full activation of Akt [215, 216]. However, a strong increase in Akt 
phosphorylation was observed in the present study following cMBCD treatment of 
CHO T10 cells (Fig. 18D). While the decrease in Akt phosphorylation, in response to 
cholesterol reduction by MBCD treatment, can be explained by a decrease in the 
production of phosphatidylinositol (3,4,5)-trisphosphate, a cell membrane bound 
second messenger [216], possible reasons for the observed increase in Akt 
phosphorylation following cMBCD-mediated cholesterol enrichment (Fig. 16D) is 
yet to be understood.  
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Effect of atorvastatin on insulin binding  
Atorvastatin treatment of CHO T10 and HepG2 cells did not affect the binding of 
insulin to these cells (Fig. 15A and B), despite significant reductions in the total 
cholesterol content of these cells (Fig. 10). Whilst there is yet no evidence for the 
effects of statins on insulin binding, statins have been shown to impair insulin 
signalling and have been implicated in the development of insulin resistance and 
onset of diabetes [222, 223]. However, the results of the present study clearly 
demonstrate that there is no noticeable effect of atorvastatin either on insulin binding 
or on the affinity of insulin for its receptors in CHO T10 and HepG2 cells (Fig. 15, 
Table 3). These observations are in clear contrast to the insulin binding results from 
MBCD treatment of CHO T10 and HepG2 cells where even subtle decreases in 
cholesterol content decreased insulin binding to these cells (Fig. 9). One possible 
explanation for this observation could be that plasma membrane cholesterol content 
is much less affected by atorvastatin treatment.  
In the present study, atorvastatin treatment in cells was carried out in a lipoprotein-
deficient environment, which could be expected to limit the exogenous source of 
cholesterol for cells. Whilst statins lower cell cholesterol by limiting the de novo 
synthesis of cholesterol and promoting cellular uptake of cholesterol [224, 225], 
paradoxically, statin treatment also leads to an increase in the mRNA expression of 
HMGCR and other proteins involved in the upregulation of cholesterol synthesis in 
both in vitro and in vivo models [226]. This increase in cholesterol synthesis could 
potentially result in the transport of cholesterol from the endoplasmic reticulum to 
the plasma membrane, as this process is largely free of influences by other cellular 
stress conditions and regulatory mechanisms [227]. In the present study, it is notable 
that the high-fat diet-induced reduction in plasma membrane cholesterol content of 
mouse liver is restored by atorvastatin treatment (Fig. 24 and 25). Although this 
observation may not be directly comparable to the in vitro cell culture conditions of 
the present study, this regulatory effect of atorvastatin on cholesterol trafficking 
could be expected to also occur in cultured cells. Moreover, in the present study, 
cellular adaptations to the 48 h atorvastatin treatment may have occurred. In future, 
the effects of atorvastatin and other statins on cholesterol content should be 
investigated in purified plasma membrane preparations derived from cell culture 
models to explore these possibilities.          
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Effect of atorvastatin on insulin signalling 
That atorvastatin did not influence insulin binding in CHO T10 and HepG2 cells 
correlated with the observation that it also had no considerable effect on insulin 
signalling in these cells, except for a marginal decrease in the phosphorylation of Akt 
(Fig. 21) in CHO T10 cells and a marginal increase in all the downstream insulin 
signalling events in HepG2 cells (Fig. 20). In contrast, atorvastatin treatment of 
differentiated myotubes significantly reduced the autophosphorylation of the insulin 
receptors and the phosphorylation of Akt and GSK3β (Fig. 21), despite having no 
appreciable effect on insulin binding. This is in keeping with previous observations 
that various statins cause insulin insensitivity in skeletal muscles [228-231]. Given 
that insulin receptor autophosphorylation was significantly impaired in differentiated 
myotubes with no alteration in insulin binding, it is likely that statins influence 
insulin receptor autophosphorylation independent of insulin binding. Indeed, 
simvastatin treatment impairs insulin signalling in L6 myotubes by elevating the 
activity of protein kinase C (PKC), which in turn leads to the inactivation of both 
IRS-1 and the insulin receptor itself [178].  
While there are several intracellular modes of action (such as the increased PKC 
activity), proposed by which statins mediate insulin resistance [231, 232], it might 
also be possible that they influence more proximal events in the signalling pathway. 
Interestingly, the expression of caveolin-1, which promotes the tyrosine kinase 
activity of the insulin receptors following insulin binding, is decreased by statins in 
endothelial cells [233, 234]. Disruption of lipid-rafts/caveolae by inhibiting 
cholesterol bio-synthesis in 3T3-L1 pre-adipocytes also led to the redistribution of 
caveolin-1 out of caveolar invaginations to other regions in the membrane and 
subsequently impaired insulin signalling [67]. However, in contrast to signalling, 
there is no data on such effects insulin binding to its receptor. Other transmembrane 
proteins such as the plasma cell membrane glycoprotein (PC-1) have also been 
implicated to play a role in regulating the insulin receptor and its overexpression is 
observed in insulin resistant subjects [235, 236]. Thus, in future, studies may be 
focused on investigating the effects of atorvastatin, and other statins, on the 
interaction of the insulin receptor with these membrane-bound proteins by 
visualizing their co-localization using fluorescent probes or cross-linking mass 
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spectrometry to understand statin-mediated regulation of insulin sensitivity and 
action on target cells.  
4.2. Effects of a high fat diet and atorvastatin treatment on cholesterol content 
and insulin action in mouse liver 
Effect of high-fat diet on cholesterol content and insulin binding in mouse liver 
plasma membrane 
The effect of plasma membrane cholesterol on insulin binding observed in this study 
in cultured cells was further assessed in liver tissue obtained from mice that were fed 
either a normal or high-fat diet with or without atorvastatin treatment over a 12-week 
period as detailed in Methods, section 2.2.2.1. The cholesterol content in purified 
liver plasma membranes decreased markedly (about 10-fold) in mice fed the high-fat 
diet, relative to those fed the normal diet (Fig. 24 and 25). It is notable this decrease 
in plasma membrane cholesterol content appeared to be mirrored in the cytosolic 
fraction of the livers obtained from the high-fat diet fed mice. Interestingly, this 
decrease was accompanied by a substantial increase in cholesterol in the microsomal 
fraction (Fig. 24 and 25). Indeed, the decrease in total plasma membrane and 
cytosolic cholesterol in liver tissue was almost entirely accounted for by a 
redistribution of cholesterol to the microsomal compartment in the high-fat diet 
group (Fig. 24 and 25). The mode(s) by which a high-fat diet results in this 
redistribution of cholesterol from the plasma membrane to the microsomal 
compartment is unclear, but given this is a novel and quite remarkable finding, this 
needs further investigation. While it is understood that the trafficking between the 
plasma membrane and endoplasmic reticulum helps maintain cholesterol 
homeostasis, the specific biochemical processes and points of control need to be 
detailed before the effect of high-fat diet on these process can be resolved. Given that 
the pathways for the transport of cholesterol from the endoplasmic reticulum to the 
plasma membrane appears to be distinct from the transport of cholesterol from the 
plasma membrane to the endoplasmic reticulum [227], detailing this process of 
cholesterol homeostasis, including the influence of variables such as diet, might 
prove to be quite challenging. 
Insulin binding to the plasma membranes purified from the livers of mice that were 
fed the high-fat diet was markedly decreased relative to those from mice that were 
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fed the normal diet (Fig. 26). This observation is consistent with several other studies 
which have highlighted the negative regulatory effect of a high-fat diet to insulin 
binding in insulin sensitive tissues [237-239]. Notably, the latter studies did not 
examine the effects of high-fat diet on the changes in cell membrane cholesterol 
content. Analysis of the competitive binding data in this Thesis suggests that the 
decreased binding of insulin to the liver plasma membranes in response to the high-
fat diet was related to a 2-fold decrease in the apparent number of insulin receptors 
relative to that of plasma membranes from mice fed a normal diet (Table 6) and was 
also in keeping with the findings by Western blot for insulin receptors in the plasma 
membrane (Fig. 28). As was also observed in the VLPs (section 3.3) and cells in 
culture (section 3.1), there was a correlation between the decreased cholesterol in the 
liver plasma membrane and the decreased insulin binding in the mice. 
It is also notable that when plasma membranes, purified from the livers of mice fed a 
normal diet, were treated with either MBCD or cMBCD, insulin binding decreased 
(Fig.27) in a manner similar to that observed in the cultured cell models (Fig. 9) and 
VLPs (Fig. 39). The decreased binding of insulin in a membrane environment, as 
cholesterol content changes, cannot be due to receptor down-regulation, as the liver 
plasma membranes and VLPs that bud from plasma membrane are free of other 
cellular organisation that are essential for receptor internalisation or recycling. This 
may indicate that changes in membrane cholesterol content could potentially lead to 
the redistribution or other alterations in the organization of the insulin receptors in 
the membrane. Some possible explanations for this correlation between cholesterol 
composition in the plasma membrane and the apparent number of insulin receptors 
detected are articulated in section 4.1 and 4.3, respectively.  
Effect of high-fat diet on insulin signalling in mouse liver 
The decrease in available insulin receptors in the plasma membrane of the high-fat 
diet group was associated with a significant decrease in insulin receptor 
autophosphorylation (Fig. 28). However, the decrease in insulin receptor activation 
did not seem to have any appreciable effect on the phosphorylation of Akt (Fig. 29). 
Although this disconnect may appear counterintuitive, it is not totally unexpected, 
especially in in vivo models, since the activation of Akt is central to numerous 
pathways involved in cell regulation other than insulin signalling [240] and 
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influences by other growth factors and mediators may be at play. In addition, hepatic 
Akt, in response to insulin action, is only required to inhibit FOXO1, which is a 
transcription factor for several gluconeogenic enzymes and when FOXO1 is 
removed, the normal metabolic activities occurred in the absence of hepatic Akt 
[241]. Therefore, it is also likely that insulin may regulate the metabolic activities in 
liver through a pathway(s) that is independent from the participation of Akt.  
No significant change in GSK3β phosphorylation was observed high-fat diet group 
relative to normal diet group (Fig. 29), which correlates with the absence of an 
influence on Akt phosphorylation by high-fat diet. The activity of GSK3β is 
regulated by a spectrum of modalities including phosphorylation, subcellular 
compartmentalization, substrate priming etc., during various physiological states 
[242-244] and, therefore, the findings in the present study, may not directly represent 
the effects of insulin action alone [245]. Given that the activation of Akt and GSK3β 
are associated with various cellular functions other than insulin action per se [246, 
247], future studies should include screening for additional targets in both proximal 
insulin signalling events such as the activation of insulin receptor substrate family 
(IRS-1/2/3/4) and phosphatidylinositol 3-kinase (PI 3-K) [248], and downstream 
signalling events such as the regulation by mechanistic target of rapamycin complex 
1 (mTORC1) [249]. 
Effect of atorvastatin on cholesterol content and insulin binding in mouse liver 
plasma membrane 
In context of a normal diet, 12 weeks of atorvastatin treatment has no influence on 
the cholesterol content in plasma membrane and microsomes (Fig. 24 and 25). 
Similarly, insulin binding to the liver plasma membranes purified from the livers of 
these mice that were fed the normal diet was also unaffected by the atorvastatin 
treatment (Fig. 26). It is notable that total cholesterol content in cell culture models 
decreased following atorvastatin treatment in a lipoprotein deficient environment 
(section 3.1, Fig. 8). By contrast, atorvastatin treatment, in the presence of fetal 
bovine serum i.e., in presence of lipoproteins, did not change the total cholesterol 
content in these cultured cell models (figure not shown), which may indicate the 
ability of cells to uptake cholesterol from exogenous sources when the de novo 
synthesis of cholesterol is inhibited by statins [250, 251] and more closely reflects 
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the in vivo context. Hence, atorvastatin, in an in vivo context may not influence 
overall hepatic cholesterol possibly due to exogenous sources of cholesterol (eg: 
lipoproteins) compensating the deficiency. Interestingly, insulin binding to cultured 
cells, either in the presence of fetal bovine serum (figure not shown) or lipoprotein 
deficient serum, were unaffected by atorvastatin treatment (section 3.1, Fig. 15). 
Given the significance of cholesterol in the integrity of the plasma membrane and in 
the topology and functions of membrane bound receptors [252], it may be possible 
that cholesterol content in the plasma membrane of cell culture models is minimally 
affected by atorvastatin treatment. However, future studies are needed to clarify 
whether atorvastatin treatment specifically alters cholesterol content in the actual 
plasma membranes as opposed to total cholesterol content of cells in culture.  
By stark contrast to mice fed the normal diet, atorvastatin treatment dramatically 
influenced cholesterol and insulin binding in mice fed the high-fat diet; cholesterol 
levels in both the plasma membrane and microsomes approached the ‘normal’ levels 
observed in mice that were only fed the normal diet, and there was concomitant 
increase in insulin binding to plasma membranes towards those observed in mice fed 
the normal diet.  This is consistent with the observation that atorvastatin treatment in 
high-fat diet fed guinea pigs results in a ~ 30% reduction in its hepatic microsomal 
cholesterol content [253]. However, the mode by which atorvastatin treatment leads 
to the redistribution of cholesterol between the microsomal and plasma membrane 
compartment is unclear and thus, requires further investigation.  
The ‘normalizing’ effect of atorvastatin treatment on plasma membrane cholesterol 
and insulin binding in high-fat diet mice coincided with an increase in detectable 
total insulin receptor in the plasma membrane towards that observed in mice fed a 
normal diet (Fig. 28). Moreover, atorvastatin normalized the autophosphorylation of 
the insulin receptors in liver plasma membranes in mice that were fed the high-fat 
diet to levels indistinguishable from mice fed the normal diet. That the ratio of 
activated to total receptors increased significantly in mice fed the high-fat diet and 
treated with atorvastatin indicates that atorvastatin not only ‘normalized’ the 
availability of insulin receptors towards levels observed in mice fed the normal diet 
but acted to also promote the autophosphorylation of the insulin receptors by a 
mechanism independent of the expression of the receptor itself. 
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Effect of atorvastatin on insulin signalling in mouse liver 
The diet-dependent effect of atorvastatin was apparent in the phosphorylation status 
of Akt, decreasing in response to normal diet and increasing on a high-fat diet, 
respectively (Fig. 29C and 29D). These changes were independent of insulin receptor 
autophosphorylation or the expression of total Akt itself. The decrease in Akt 
phosphorylation on a normal diet is interesting given the potential link between statin 
therapy and insulin resistance and should be further investigated. Numerous other 
studies have demonstrated decreased activation of Akt and subsequently mTOR by 
statins [254, 255] and their cytotoxic effects in skeletal muscle cells [256-258]. 
Deleterious influences by atorvastatin on Akt activation have also been described in 
pancreatic cancer cells but is thought to have implications in cancer treatment by 
sensitizing cancer cells for chemotherapy drugs [259]. However, there is no direct 
explanation for the slight but significant increase in Akt activity following 
atorvastatin treatment in mice fed the high-fat diet (Fig. 29C). In contrast, the total 
expression and activity of GSK3β decreased following atorvastatin treatment but this 
effect was independent of the diet. (Fig. 29F and 29G). Further studies that detail the 
activity of additional downstream targets pertinent to the insulin signalling pathway 
should be conducted to improve the understandings of the effects of atorvastatin on 
insulin signalling in response to a high-fat diet. 
In conclusion, the high-fat diet had a remarkable impact on plasma membrane 
cholesterol content and insulin receptor availability in mice. This was reflected in a 
decrease in insulin binding and in the autophosphorylation of the insulin receptors. 
While the link between a high-fat diet and insulin resistance is well established, the 
impact of a high-fat diet on cholesterol distribution in cells needs further 
investigation. Atorvastatin treatment restores cholesterol and insulin receptor 
availability for insulin and entirely restores insulin receptor autophosphorylation in 
the plasma membrane of mice fed the high-fat diet. Thus, atorvastatin treatment 
appears to benefit insulin sensitivity in mice fed a high-fat diet but may have other 
consequences in mice fed a normal diet.  
  
133 
 
4.3. Development and characterization of virus-like particles as a novel 
membrane model to study the influence of membrane cholesterol on 
insulin binding  
Virus-like particles (VLPs), in the present study, were generated from either  
CHO K1 (wild-type) or CHO T10 (insulin receptor overexpressing) cells based on 
the self-assembly of a Gag-protein, which predominantly occurs in the lipid-raft 
regions in the plasma membrane [193, 260, 261]. In keeping with Gag-based VLPs 
generated by others [54], VLPs in the present study were spherical and relatively 
uniform with an average diameter of 159 nm (Fig. 30), which equates to a 
circumference of about 500 nm. A lipid-raft from which a VLP buds is estimated to 
be about 40-100 nm in width [262]. Thus, it might be expected that a lipid raft micro-
domain would likely not make up the entire membrane component of a VLP, but that 
other regions of the membrane would also co-exist. Based on this expectation, VLPs 
might mimic at least some other general properties of the plasma membrane and not 
exclusively that of lipid-rafts alone. Since there are no reports yet on the lipid 
membrane environment of VLPs, future studies should include lipidomic and 
proteomic analysis of VLPs. These studies might provide valuable insights to gain 
better understanding of the role of lipid-rafts and other non-raft regions, and 
structural proteins pertinent to various membrane domains on receptor functioning in 
VLPs.  
Whilst the precise organization of membrane lipids and proteins integral to VLPs is 
not yet well understood, it is generally recognized that VLPs contain plasma 
membrane proteins that remain in their native conformation [54, 263]. Indeed, the 
VLPs generated for the present study, bound insulin in a manner indistinguishable 
from their corresponding parental cell lines. The affinity of insulin for its receptor in 
the VLPs and their corresponding parental cells was not significantly different (Table 
7). Moreover, the decrease in insulin binding to its receptor in VLPs, in response to 
either cholesterol reduction (MBCD) or cholesterol enrichment (cMBCD) (Fig. 39), 
also mimicked the observations in their parental cell lines (Fig. 37) and also to the 
observation in context of membrane cholesterol reduction or enrichment in HepG2 
cells and differentiated myotubes (Fig. 7). This decrease in insulin binding in VLPs 
cannot be due to receptor internalization, since the VLPs lack the cytoplasmic 
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component of a cell. As discussed in section 4.1, changes related to the activity of 
transmembrane proteins such as PC-1 and caveolin-1 may influence insulin binding 
to its receptor. However, this postulate requires that such modulatory factors 
influence insulin access to the insulin receptor to explain the observation that the 
decreased binding is due to receptor availability to insulin or certain insulin receptor 
(α-subunit) antibodies. Understanding the changes in insulin receptor localization in 
various membrane micro-domains and its interaction with modulatory factor(s) in the 
membrane, will present a significant challenge for future research.  
It is interesting to note that the insulin receptor content of VLPs derived from CHO 
T10 (overexpressing) cells and CHO K1 cells were similar (Fig. 35), despite the 
marked difference in insulin receptor content observed between the parental cells 
(Fig. 34). Based on competitive binding analysis, almost all the insulin receptors 
expressed in the wild-type CHO K1 cells were incorporated into the VLPs generated 
from these cells (Table 7). However, by contrast, only 2% of the insulin receptors 
expressed in CHO T10 cells was recovered in the VLPs generated from these cells. 
Thus, the 98% of the insulin receptors expressed in CHO T10 cells were not 
recovered in VLPs, which preferentially egress from the lipid-raft regions in the 
membrane. This majority of insulin receptors in CHO T10 cells thereby reside 
outside the lipid-raft regions of the plasma membrane. As a consequence, the 
majority of the overexpressed insulin receptors may not function in a manner that 
fully mimics the insulin receptor in the wild-type cell line. Indeed, as discussed in 
section 4.1, there appears to be a clear disconnect between insulin binding and 
insulin signalling in the CHO T10 cells. This is an important observation that 
potentially impacts many cell models overexpressing growth factor receptors and 
other proteins that signal via specific membrane micro-domains such as the lipid-
rafts. Therefore, caution must be exercised when using cell models that overexpress 
proteins that are associated with lipid-rafts as cells may have a limited capacity to 
localize these proteins where they are needed to function normally. Also, future 
studies using more direct approaches such as flow cytometric analysis should be 
conducted to quantify insulin receptor content and other associated proteins that may 
influence insulin receptor function in VLPs. This approach was attempted in the 
present study but without success, with the smaller size of the VLPs being a 
limitation to the analysis by flow cytometry. Immunostaining the VLPs with 
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antibodies for the target protein and coupling them with aldehyde/sulfate latex beads 
may overcome this limitation [264].  
It is notable that insulin bound to the insulin receptors in CHO T10 cells or the VLPs 
generated from these cells, with approximately 5-fold lower affinity than to insulin 
receptors in CHO K1 cells or the VLPs generated from these wild-type CHO-K1 
cells. This decrease in the calculated affinity of insulin for its receptor in CHO T10 
cells or VLPs generated from these cells can be visibly verified by the rightward shift 
of the competitive binding plots (Fig. 33). This difference in affinity cannot be 
explained on the basis of the difference in insulin receptor isoforms expressed  in the 
wild-type CHO K1 cells and CHO T10 cells, since the A-isoform overexpressed in 
CHO T10 cells, is expected to have up to a 2-fold higher affinity for insulin than the 
B-isoform [36, 42, 265]; the latter is likely the predominant isoform in the CHO K1 
cells since they are epithelial cell lines derived from the ovary of the Chinese 
hamster [189]. Finally, the difference observed in affinity between CHO T10 and 
CHO K1 cells, and in the VLPs derived from these cells is unlikely to be due to any 
experimental artefact arising from inappropriate assumptions or errors in the 
competitive binding assays. Insulin binding to VLPs derived from both CHO K1 and 
CHO T10 cells were measured at the same time.  All assumptions inherent in 
competitive ligand binding assays were also carefully observed. Care was taken to 
ensure data was collected over the entire competitive binding curves and that the 
receptor concentrations in the assays were at least one tenth the value of the 
equilibrium dissociation constant calculated from the data. Furthermore, given that 
the recovery of insulin receptors in VLPs derived from either CHO K1 cells or CHO 
T10 cells was essentially indistinguishable, the concentrations of insulin receptors in 
the assays must have been very similar. Furthermore, the observations were highly 
reproducible in three independent experiments.  
The difference in apparent affinity observed between insulin binding to the CHO K1 
and CHO T10 cells appears genuine but is quite perplexing. Future research 
investigating the kinetics of binding might be informative, to either confirm or refute 
the interpretation of the equilibrium binding studies detailed in the present study, as 
inconsistencies between the equilibrium and kinetic evaluation of insulin binding 
between isoforms has been noted previously [266]. Application of real-time 
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technologies such as surface plasmon resonance and VLPs immobilized to sensor 
chips may provide powerful tools for such future research [53]. Indeed, VLPs were 
successfully immobilized to L1 sensor chips by the author and preliminary studies 
were conducted. However, choosing an appropriate reference or control VLPs that 
lack insulin receptors has been problematic as VLPs generated from CHO K1 cells 
also contain as many insulin receptors as VLPs derived from CHO T10 cells. It may 
be necessary in future to block insulin binding to the reference VLPs with an 
appropriate monoclonal antibody. It would not be possible to develop a CHO K1 
insulin receptor knockout as insulin is the only growth hormone for these cells, 
which remains in the G1 phase in its absence [267]. 
Much is still to be discovered before the utility of VLPs can be fully realised. A 
better understanding of the composition of VLPs describing the inherent lipid-rafts 
and other membrane micro-domains, and the proteins associated with these domains 
is needed. However, description of the proteome or array of integral membrane 
proteins in lipid-rafts is now emerging. Several thousand proteins, identified using 
iTRAQ/mass spectrometry in lipid-rafts isolated from different cells, form the basis 
of RaftProt database [268]. Likewise, the protein content of Gag-based VLPs and 
other virus-like particles are currently being studied with the help of mass 
spectrometry-based, label-free quantitative proteomics [264, 269]. These insights 
into the proteome of VLPs in their lipid-raft (and non-raft regions) will improve our 
understanding of protein localization and assembly within VLPs and membranes in 
general.  
Finally, VLPs present as an intriguing platform to study membrane protein functions, 
especially those that localize in and out of lipid-rafts, in response to changes in 
membrane cholesterol composition. The insulin receptor as detailed in this Thesis is 
one such example. It will be interesting to evaluate the VLP topology of the insulin 
receptors and its association with other membrane proteins within the VLP using 
electron microscopy. The influence of cholesterol depletion and enrichment on the 
localization of the insulin receptors within the lipid micro-domains constitutive to the 
VLPs will be intriguing. VLPs offer many advantages over whole cells; in the 
absence of the cell cytosol, VLPs could be largely free of proteases that can denature 
inherent proteins. In addition, processes involving receptor 
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downregulation/internalization, which can complicate ligand binding analyses, are 
also absent in the VLPs. VLPs can also be conveniently immobilized on sensor chips 
to enable ligand binding analysis using surface plasmon resonance (SPR). This 
approach will provide a powerful platform in the future to study the interaction of 
insulin with the insulin receptors, within its native membrane environment, in real-
time and without the need for the use of radioactive or fluorescent labels [53, 270]. 
Thus, in future, VLPs in conjunction with technologies such as SPR or micro-scale 
thermophoresis will enable the analysis of the insulin-insulin receptor interaction in 
greater detail compared to the conventional approaches currently used for binding 
analyses.  
5.0. CONCLUSIONS AND FUTURE DIRECTIONS  
The binding of insulin to the insulin receptor was markedly influenced by the 
cholesterol content of the plasma membrane. Indeed, there appears to be an optimal 
level of cholesterol that supports maximal insulin binding. Cholesterol within the 
plasma membrane influenced insulin binding by altering the apparent number of 
available or accessible insulin receptors in the plasma membrane for insulin or 
antibody binding. Altering cholesterol levels in the plasma membrane of cells likely 
impacts the location of integral membrane proteins such as the insulin receptors 
within various plasma membrane micro-domains. But how these postulated changes 
in the location of other membrane proteins could influence the accessibility of the 
insulin receptor to its ligand is unclear. It may affect the access of the insulin 
receptors to modulatory factors that impact ligand binding. This however does not 
explain the reduced accessibility of anti-insulin receptor monoclonal antibody (83-7) 
to the insulin receptors, which was also affected by changes in cholesterol content. 
One possible explanation for the decreased binding of insulin following membrane 
cholesterol alteration could be that insulin receptors may aggregate to form clusters 
in various membrane micro-domains that in turn, may affect their ability to bind 
insulin, or indeed the antibody used; this however needs further investigation.  
Cholesterol within the plasma membranes supports the formation of lipid-raft micro-
domains that harbour various tyrosine kinase based receptors, including the insulin 
receptor and the location of receptors within or outside these regions is believed to 
affect the functionality of these receptors. It is notable in this study that the full 
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complement of insulin receptors within the plasma membrane of wild-type CHO K1 
cells in culture appeared to be located in lipid-rafts since they were all recovered in 
the VLPs that egress from these raft regions of the plasma membrane. It is also 
notable that in the CHO T10 cells, which overexpress insulin receptors (~ 280-fold 
vs CHO K1 cells), only 2% of the total insulin receptors were recovered in the VLPs 
generated from this cell type. Thus, it appears that insulin receptor localization to 
lipid-rafts in CHO T10 cell membranes is substantially impaired. Also, there was an 
apparent disconnect between insulin binding and the availability or accessibility of 
the insulin receptor from downstream signalling events of the metabolic aspects of 
insulin action in CHO T10 cells. While this disconnect in CHO T10 cells could be 
more readily explained by the selective overexpression of the A-isoform of insulin 
receptors, which mediates the mitogenic aspect of insulin action; it could also be 
possible that there is not adequate and appropriate raft structures in the membrane of 
CHO T10 cells to accommodate the enormous number of overexpressed insulin 
receptors in the membrane. Therefore,  a cell’s capacity to localize receptor proteins 
to appropriate membrane micro-domains could be an important consideration whilst 
employing any overexpressing cell model for the study of receptor interactions or 
indeed, other membrane proteins.  
The effect of the high-fat diet in decreasing the cholesterol content of mouse liver 
plasma membrane and in decreasing insulin binding, and of atorvastatin treatment in 
ameliorating these changes are among the novel findings of this Thesis. The decrease 
or increase in plasma membrane cholesterol by the high-fat diet or atorvastatin 
treatment, respectively, was almost entirely accounted for by the changes in the 
cholesterol content of the microsomal fraction. Thus, future studies should explore 
the mechanisms underlying the relative distribution of cholesterol in the plasma 
membrane and the endoplasmic reticulum and in other organellar membranes, and its 
impact on other vital functions of liver such as the synthesis and release of bile acids. 
While the development and use of VLPs has previously been described in the context 
of the IGF receptor (IGFR) and IGF-IGFR interactions, the studies in this Thesis 
represents the first demonstration of the development and use insulin receptor 
bearing VLPs, as is the demonstration of their insulin binding characteristics, which 
were very similar to the distinct characteristics (e.g binding affinities) of their cells of 
origin (CHOK1 and CHOT10 cells). The studies on VLPs also added to the evidence 
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supporting the influence of plasma membrane cholesterol on insulin receptor binding 
observed in the cell culture and mouse studies. That the VLPs generated either from 
an over-expressing cell model (CHO T10) or a wild-type cell model (CHO K1), 
carried a similar number of insulin receptors is an unexpected and another novel 
finding of this Thesis. The lack of available membrane raft structures to 
accommodate the over-expressed insulin receptors in CHO T10 cells was considered 
to be a possible reason for this finding. In context of the physical properties of the 
VLPs, the stability of VLPs over a wide range of temperature and their longer shelf-
life period increases their ease of handling and suggests VLPs are a viable alternative 
model for study of insulin-insulin receptor interactions. Being highly uniform 
spherical particles, as estimated by dynamic light scattering analysis in this study, 
VLPs could be conveniently immobilized on sensor chips for interaction analysis by 
advanced analytic techniques such as surface plasmon resonance (SPR). The use of 
insulin receptor bearing VLPs in SPR would enable real-time analysis of the kinetics 
and equilibrium constants of the interaction of insulin with its receptor.  
In conclusion, the findings of this Thesis highlight the influence of plasma membrane 
cholesterol content on the binding of insulin to its receptor. This Thesis provides a 
basis for further investigation concerning the distribution of cholesterol and its role 
in various membrane domains and how this might be affected by dietary changes or 
by cholesterol-lowering medication such as the statins, and within the broader 
context of insulin resistance.  
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